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Kaitlyn E. Kortright 
2021 
 
Bacteriophages (phages) are prolific, ubiquitous viruses that infect bacterial cells. Phages have 
proven to be invaluable tools of the biological sciences enabling the discovery and description of 
some of the foundations of molecular biology and genetics; excellent systems for the study of 
evolutionary dynamics; and their seemingly limitless diversity promises to produce interesting 
new biology for many years to come. As natural predators of bacteria, phages might additionally 
be employed for phage therapy, the therapeutic use of phages to treat bacterial infections. Lytic 
phages impose strong selective pressure on bacteria to evolve resistance to phage infection. Under 
certain environmental conditions this selection pressure can result in the evolution of phage 
resistance at reduced fitness; this is an example evolutionary trade-off, or the evolution of a certain 
trait at the detriment of the fitness. In particular, it is possible that phage-imposed selection on 
bacterial surface expressed molecules may result in reduced antibiotic resistance and/or attenuated 
virulence of opportunistic bacterial pathogens. In this thesis, we will examine the idea of phage-
imposed trade-offs on opportunistic bacterial pathogens.   
A published review paper serves as the first chapter and an introduction to phage biology 
and phage therapy. We present the history of the discovery of phages as well as the early reports 
of phage therapy. We highlight recent animal studies, case reports and clinical trials that have 






well as identify interesting question and potential hurdles that will likely underscore a modern 
approach to phage therapy. 
In chapter 2, transposon insertion sequencing (INSeq) is used as a high-throughput method 
to identify phage receptors to find new phage that use antibiotic resistance or virulence factors as 
receptors. Preliminary experiments using characterized phages T2, T4, T6 and T7 demonstrate that 
the top results of INSeq screens with phage are involved in phage binding. These screens were 
extended to enable receptor identification for five newly isolated phages, R3, U115, EC35, EC14 
and 8S. Adsorption assays and efficiency of plaquing assays to demonstrate phage binding and 
infection are used to validate the results of the INSeq screens with uncharacterized phage. In 
summary, this chapter establishes the use of INSeq screens as a high-throughput method to 
determine phage receptors which should allow for identification of phage that target virulence 
factors or molecules contributing to antibiotic resistance. 
Evolutionary dynamics between Pseudomonas aeruginosa and a lytic phage, OMKO1 that 
selects against antibiotic resistance, are examined in a short-term coevolution experiment in 
chapter 3. Time shift assays showed that coevolution of the three treatment populations followed 
arms race dynamic. Interestingly, only one treatment population demonstrated the predicted trade-
off between phage resistance and antibiotic resistance. Sequencing of bacterial population allowed 
for identification of mutations underlying bacterial evolution and the trade-off. Results from this 
study demonstrate that evolution may not be as repeatable or predictable as previous experimental 
evolution studies have suggested.  
In chapter 4, we identify a new Shigella flexneri phage that selects for phage-resistant 
bacteria that are attenuated for virulence. We isolate and characterize a new Myoviridae phage, 






including, live-dead staining, minimum inhibitory concentrations to various antibiotics and 
measurements of total lipopolysaccharide (LPS) quantity demonstrated that phage A1-1 selects for 
two different phenotypes of resistant mutants: OmpA deficient and altered LPS. Whole genome 
sequencing revealed that the five phage-resistant mutants examined in this study have mutations 
either in ompA or in genes involved in LPS biosynthesis genes. Using bacterial plaque assays, we 
showed that all five resistant mutants are attenuated for intercellular spread, indicating that in the 
case of phage A1-1, phage resistance trades off with bacterial virulence. 
While the previous two chapter highlight phage selection resulting in a trade-off, the final 
chapter involves a system in which phage selection resulted in a trade-up with antibiotic resistance. 
Tsx is a nucleoside porin in Escherichia coli which also serves as a receptor for phage T6, phage 
U115 and albicidin, a DNA gyrase inhibitor. We showed that selection for resistance to any of 
these three antibacterials resulted in cross-resistance to the other two. Competition assays showed 
resistance to these antibacterials does not result in a fitness cost relative to wild-type. In all 29 of 
the resistant mutants observed in this study, mutations in tsx were found. The trade-up between 
phage resistance and antibiotic resistance in this study highlights the need for rigorous studies of 
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Phage therapy, long overshadowed by chemical antibiotics, is garnering renewed interest in 
Western medicine. This stems from the rise in frequency of multidrug resistant bacterial infections 
in humans. There also have been recent case reports of phage therapy demonstrating clinical utility 
in resolving these otherwise intractable infections. Nevertheless, bacteria can readily evolve phage 
resistance too, making it crucial for modern phage therapy to develop strategies to capitalize on 
this inevitability. Here, we review the history of phage therapy research. We compare and contrast 
phage therapy and chemical antibiotics, highlighting their potential synergies when used in 
combination. We also examine the use of animal models, case studies and results from clinical 
trials. Throughout, we explore how the modern scientific community works to improve the 
reliability and success of phage therapy in the clinic, and discuss how to properly evaluate the 








Soon after Alexander Fleming’s 1928 discovery of penicillin and Western medicine’s widespread 
use of antibiotics since the 1940’s, Fleming himself warned that misuses of these drugs could result 
in antibiotic resistant bacteria 1. As predicted, clinical reports of antibiotic resistance followed, 
such as the evolution of resistant Mycobacterium tuberculosis in early clinical trials for 
streptomycin efficacy in treating tuberculosis 2. Nevertheless, the discovery and development of 
novel antibiotics flourished for many decades 3. However, in the latter 20th century, antibiotic 
discovery slowed and the alarming increase in rates of antibiotic resistance signaled that the golden 
age of antibiotics had perhaps ended. Indeed, aside from three new antibiotic classes discovered 
between 2005 and 2018, no novel drug classes have been developed since the 1980s 4-6. Similar 
mechanism of action among these newer drugs has led to potential evolution of cross resistance in 
bacteria. While synthetic modifications to some pre-existing antibiotics have temporarily extended 
their clinical usefulness 7, this approach has also selected for broader resistance mechanisms such 
as extended spectrum beta lactamases 8, adaptive changes that are perhaps more easily evolved 
compared to de novo resistance mechanisms.   
In 2017, the World Health Organization (WHO) highlighted the particular threat of Gram-
negative pathogens resistant to multiple antibiotics 9. Discovery, design, and development of new 
and alternative antibacterial therapies are crucial. This review concerns the therapeutic use of 
bacteriophages (phages): viruses that exclusively infect bacteria and can act as bactericidal agents. 
This approach of ‘phage therapy’ is an old idea that is recently regaining popularity. Efforts are 
buoyed by development of easier methods for engineering phages for different purposes in 
biotechnology 10. Also, the extreme biodiversity of phages in nature 11, 12 can be leveraged for 






ideal for phage therapy use 13. Below we examine the past, present and future uses of phage 
therapy, especially addressing how this newly energized field may proceed with modern, rational 
therapeutic approaches. 
Phage Biology 
During a lytic infection cycle (Figure 1.1) a phage will: (1) attach to receptor(s) on the surface of 
a bacterium; (2) deliver the genomic content into the bacterium; (3) undergo viral replication in 
the cytosol via bacterial transcription, translation and replication; and (4) upon formation of new 
phage particles, escape the cytoplasm through lysis of the bacterium. This process is then repeated 
by the new phage particles as they infect additional susceptible cells. This highlights a long-
understood benefit of phage therapy: utilizing lytic viruses as self-amplifying ‘drugs’ that target 
and kill susceptible cells may be more efficient than applying antibiotics that are incapable of self-
amplification. 
Obligately lytic (or ‘virulent’) phages seem to be the best candidates for development of 
phage therapy (hereafter we refer to such phages simply as ‘lytic’). However, for completeness we 
briefly remind that lysogenic (or temperate) phages are also prevalent in nature. Lysogenic phages 
integrate into the host genome, and are inherited by daughter cells during binary fission; however, 
at a later time, under environmental perturbation or other physiological stressor, lysogenic phages 
excise from the bacterial genome and enter a lytic infection cycle. While lysogenic phages might 
be preferred in certain biotechnology applications, lytic phages are more akin to antibiotic drugs 
lethal to bacteria, which suggests an easier path to approval for treating bacterial infections. 
In the mid-20th century bacteria and lytic phages were used in classic experiments to 
elucidate fundamentals of biology and genetics, including demonstration of the spontaneous nature 






these studies, it is increasingly recognized that phage biodiversity is immense. Importantly, 
whereas some phages are highly specific to a single species or even genotypic strain of bacteria 17, 
other phages have naturally broad host ranges or can easily mutate to infect bacterial genotypes 
and species other than the typical host 18. The aforementioned first step of lytic phages infection is 
attachment to the receptor(s) on the cell surface. These receptor binding sites are most commonly 
proteins or sugar moieties on the bacterial cell, which are recognized by phage proteins that are 
effectively responsible for phage host specificity (Figure 1.2). There are many well characterized 
examples of phage binding, especially the morphological structures used for these purposes. For 
instance, phage T4 uses two sets of tail fibers, long and short, to bind to susceptible Escherichia 
coli bacteria 19; phage SPP1 uses a tail spike to attach to Bacillus subtilis hosts 20; the Siphoviridae 
family of phages generally use baseplate proteins to initiate infection of Lactococcus lactis bacteria 
21; and Cystoviridae phages such as phi-6 infect Pseudomonas syringae via attachment proteins 
embedded within an envelope that surrounds the nucleocapsid 22. However, the immensity of 
phage biodiversity suggests that the basic biology of phage binding to bacterial proteins remains a 
vastly untapped science, ripe for new discoveries. The presence of phage-binding sites and their 
possible structural variation should affect specialized versus generalized ability for phage 
attachment. Nevertheless, in the following sections we highlight that historical efforts in phage 
therapy have not always investigated and characterized the receptor binding site(s) used by phages 
to initiate infection. Clearly, current development of phage therapy candidates could include: an 
investigation of the receptor binding site(s) used by phages when infecting bacteria; whether 






evolution of bacterial resistance to therapeutic phages may affect bacterial fitness components, 
such as rates of cell division and expression of pathogenicity traits. 
Early Phage Therapy 
The discovery of phages is attributed to the independent work of two microbiologists: Frederik 
Twort in 1915 and Félix d’Hérelle in 1917. While Twort was the first to observe and describe the 
effects of a ‘transparent material’ that inhibited bacterial growth 23, it was not until 1917 when 
d’Hérelle isolated an anti-Shigella microbe, that the idea of an obligate parasite of bacteria was 
termed bacteriophage or “bacteria-eater” 24. Almost immediately after his discovery, d’Hérelle 
recognized the therapeutic potential of phages as a treatment for bacterial diseases. In 1919, he 
successfully used phages to treat chickens infected with Salmonella gallinarum 25, 26. This success 
in animals soon led d’Hérelle to attempt treating human infections with phages. In 1921, five 
patients with bacillary dysentery were successfully treated with a phage that infects Shigella 
dysenteriae 26, 27. In 1927, clinical trials treating cholera in India showed that mortality decreased 
from 62.8% in control groups to 8.1% in phage-treated groups 28. Furthermore, d’Hérelle noted 
that introducing anti-cholera phages into drinking wells of villages during an outbreak prevented 
additional infections from occurring 28. 
Early-identified challenges  
Soon after d’Hérelle’s initial successes, many other scientists recognized the therapeutic and 
prophylactic potential of phages and began to target other infections, though with varying success. 
Among criticisms surrounding the design and quality of early phage therapy trials, scientists 
started identifying some potential challenges of phage therapy. (1) The possible drawback of 
extreme phage specificity was recognized early on, indicating that a phage may not be useful 






Hauduroy used phages successfully to reduce bacterial load in the blood of patients with typhoid 
fever 29, whereas a year later Smith (1924) unsuccessfully used phages on a similar patient 
population; Hadley (1928) speculated Smith’s failure stemmed from unknowingly using phages 
with a narrow host-range. d’Hérelle himself acknowledged this weakness, attributing the success 
of his early trials to careful choice of phages capable of infecting the causative bacterial agent 26. 
(2) The early methods used to bulk-manufacture therapeutic phages were likely heavily 
contaminated with lysed bacteria. With limited and unreliable filtering and purification steps, the 
possible beneficial effects of phages were difficult to separate from the confounding effects of 
contaminating bacterial antigens 30. (3) Early pharmacokinetic experiments showed that phages 
were rapidly removed from the body via the spleen, calling into question the sustained efficacy of 
phages over time 31. (4) In 1943, Luria and Delbruck used selection by lytic phages to calculate 
spontaneous mutation rates of bacteria, and in doing so, demonstrated that bacteria are readily 
capable of evolving resistance to lytic phage attack 16. (5) Lastly, early studies showed that in vitro 
laboratory experiments with phages and bacteria did not always match with experimental 
outcomes observed in vivo 32-34. As these perceived problems were identified, in Western medicine, 
the interest in phage therapy waned relative to newly discovered chemotherapeutics, antibiotics, 
and the trend away from phage therapy in the West was firmly cemented through the 1970s. This 
sentiment was in stark contrast to vested interests of physicians and scientists in the then USSR, 
Poland and elsewhere who continued to develop phage therapy in earnest; the legacy continues to 
be evident in locales such as the G. Eliava Institute of Bacteriophages in Tbilisi, Georgia. This 
important work has been the focus of numerous prior reviews and will not be discussed 35. 






the incidence of antibiotic resistant infections increased globally, phage therapy was re-considered 
by the West.   
Smith and Huggins’ pioneering studies 
This interest was propelled forward in the 1980s with a series of well-designed experiments by 
Smith and Huggins. These experiments addressed many of the historic criticisms of phage therapy 
described above, while demonstrating safety and efficacy in animal models. Smith and Huggins 
began by showing that phage effectiveness in vitro could correlate with in vivo efficacy and 
ultimately chose phage R, which demonstrated the greatest in vitro virulence, for further 
characterization 36. Phage R appears limited in host range, only infecting K1+ E. coli and likely 
uses the K1 capsule as a receptor. Through a series of lethal bacterial challenges in mice, Smith 
and Huggins demonstrated that a single dose of phage R was as effective as eight doses of 
streptomycin 36. In the same experiment, they showed that bacterial lysate, free of phages, provided 
no therapeutic effect. After intramuscular inoculation of mice with no bacterial challenge, they 
observed that phages persisted in the inoculated muscle and spleen 28 days after the original 
inoculation while it was cleared relatively rapidly from the liver and blood at 16 and 20 hours post 
inoculation, respectively. Smith and Huggins noted that all phage-resistant mutants, observed at a 
frequency of ~0.01, were K1- variants that had been previously shown to be avirulent. In a single 
paper, Smith and Huggins were able to address many previous criticisms. Furthermore, they 
observed phage therapy to be potentially more effective than chemical antibiotics. 
Smith and Huggins further investigated factors that could influence the effectiveness of 
phage therapy in an E. coli diarrhea model in calves. They cleverly employed a rational multi-
phage approach to combat the emergence of resistant mutants 37. Specifically, after choosing lytic 






vitro. Subsequently, they chose a second phage B44/3 for its ability to infect bacteria that were 
resistant to the first phage B44/1, and additionally selected for B44/3-resistant mutants that were 
susceptible to phage B44/1 infection. By examining phage resistance prior to the therapeutic use 
of these phages, Smith and Huggins were able to anticipate the evolution of phage resistance and 
use a dual-phage approach that might limit the emergence of phage-resistant bacteria. In 1987, 
Smith and Huggins examined the stability of phages during orally administered therapy and 
observed that poor phage stability in the acidic environment of the stomach could be countered by 
administering calcium carbonate prior to phages 38. These revolutionary studies by Smith and 
Huggins determined that the many perceived criticisms of phage therapy were unfounded or less 
concerning than believed, paving the way for new and rational approaches to phage therapy. 
Other scientists have since re-examined and expanded on Smith and Huggins’ studies. 
Rapid clearance of phages in vivo was originally deemed a negative aspect of phage therapy, but 
Merril et al. (1996) demonstrated that it is possible to select for phage variants that are long 
circulating in blood 39. Following Smith and Huggins favorable results in phage treatment of mice 
infected with E. coli, Soothill et al. (1992) demonstrated efficacy of phage treatment in mice 
infected with either Pseudomonas aeruginosa or Acinetobacter baumanii 40. In 2002, Bull and 
Levin et al. revisited Smith and Huggins’ original experiments comparing the efficacy of K1 
antigen targeting phages versus a non-K1 targeting phages against E. coli in mice 41. The K1-
antigen targeting phage was observed to protect 100% of mice treated immediately, while the non-
K1 targeting phage resulted in 60% mortality. In a second experiment, phage therapy resulted in 
9% mortality compared to streptomycin which resulted in 54% mortality. These data confirm 
Smith and Huggins results that K1-capsule targeting phages are more effective in treatment than 






Phage Therapy: A Renewed Approach 
The ability to characterize and test phages as antibacterial therapies has advanced immensely. The 
current era offers inexpensive whole-genome sequencing, automated technology for measuring the 
growth of microbes, and efficient high-throughput methods for screening hundreds or even 
thousands of samples simultaneously. Meanwhile, it is increasingly recognized that modern 
clinical trials should be carefully designed to be safer, more inclusive, and (if possible) to generate 
valuable data, compared to earlier attempts. An appropriately conducted phage therapy trial should 
be double-blinded and placebo-controlled with large diverse cohorts, and perhaps designed to 
generate relevant longitudinal data from clinical isolates. For example, researchers could conduct 
follow-up lab studies and whole-genome sequencing of phages and/or bacteria taken during 
treatment, to test a myriad of basic and clinical microbiology as well as evolutionary hypotheses. 
Also, our increased understanding of the human microbiome and its interactions with human 
immunology warrant closer investigation of possible phage and immune system interactions in 
clearing infections.  
However, one obvious limitation to phage therapy is the inevitable evolution of phage 
resistance in bacteria 42. Modern approaches to phage therapy should both acknowledge and 
capitalize on this certainty. Evolutionary biology describes how genetic trade-offs should be 
widely observed in biological systems; organisms sometimes evolve one trait that improves fitness 
(a relative advantage in survival or reproduction), while simultaneously suffering reduced 
performance in another trait 43-48. Phage therapy would thus benefit from utilizing certain phages, 
which select for the target bacterial pathogen to suffer specific genetic trade-offs 49. In particular, 
if the proximate binding of a lytic phage is known to associate with a virulence factor or 






bacteria to mutate or down regulate the phage-binding target(s). This approach should be 
especially useful in the case of opportunistic bacterial pathogens, because the bacteria could evolve 
reduced virulence or antibiotic resistance and still thrive in a different ecological setting (e.g., soil) 
as opposed to ‘arms-race’ selection for escalating virulence in an obligate pathogen such as in 
response to vaccine pressure (e.g., Marek’s Disease virus in chickens 50). Thus, this approach to 
phage therapy should be doubly effective; success is achieved when phages lyse the target 
bacterium, but also when bacteria evolve phage resistance because they suffer reduced virulence 
or increased sensitivity to antibiotics. In the following sections we return to this paradigm of phage-
imposed genetic trade-offs.  
A phage that requires a virulence factor to attach to and infect a bacterium may select 
against the expression of that virulence factor (Figure 1.3). Selection against virulence factors 
could be multiply effective as some virulence factors such as capsules have been shown to hide 
antigenic sites 51, provide some degree of antibiotic resistance 52, and prevent phagocytosis by 
macrophages 51. Phages that use components of LPS as receptors select against the expression of 
these components typically resulting in ‘rough’ colony-forming mutants through phase variable 
expression of LPS, point mutations or even large chromosomal deletions in LPS biosynthesis 
genes 53-57. Bacterial mutants that evolve resistance to LPS targeting phages are typically have both 
reduced fitness and virulence 58. Selection against other virulence factors that can serve as phage 
receptors such as adhesins, pili or secretion systems could prevent bacterial attachment and 
invasion of epithelial cells 59-62.  
Similarly, phages that attach to an antibiotic efflux pump to infect may select against the 
expression of the efflux pump, rendering the bacteria more sensitive to antibiotics that were 






coli at a typical frequency of 10-5 to 10-6 63. The TLS-resistant mutants with altered TolC were 
hyper-sensitive to novobiocin. Additionally, when phage-resistant mutants were selected in the 
presence of novobiocin, the frequency of recovered mutants decreased 1000-fold. More recently, 
it was demonstrated that phage OMKO1 associates with the outer membrane protein M (OprM) of 
MexAB- and Mex-XY-OprM efflux pumps of the opportunistic pathogen P. aeruginosa 64. This 
interaction selects for phage-resistant mutants that are sensitive to antibiotics, as a ‘genetic trade-
off’. Chan et al. demonstrated that phage-resistant mutants, in both lab strains and clinical isolates 
of P. aeruginosa, were more sensitive to antibiotics including ceftazidime 64. This was likely due 
to mutations or deletions in the operon encoding for the multidrug efflux pump resulting in 
nonfunctional gene products. Hypothetically, this promising result might also occur in other 
bacterial pathogens with similar modes of achieving broad antibiotic resistance via homologous or 
convergent efflux pump mechanisms. Overall, thoughtful consideration of the inevitable evolution 
of phage resistance during treatment could greatly benefit phage therapy efforts. 
Animal Models for Efficacy  
Animal studies can help bridge the gap between in vitro studies and actual clinical application of 
phage therapy. Unfortunately, most animal models investigate acute infections, which may not be 
the ideal analog for phage therapy targeting chronic infections in humans. Many of these studies 
observe best results when phages are applied simultaneously with the bacterial challenge, which 
will not necessarily be applicable in the clinic. In many cases, no measures were taken to check 
for the in vivo evolution of phage resistance by bacteria. Also, the comparison of phage treatment 
to antibiotic treatment or even a combination of phage and antibiotic treatments are only beginning 






efficacy and safety of phage therapy in living hosts, and are crucial for further development of the 
approach.  
Systemic Infections 
Several studies have investigated the efficacy of phage therapy for treatment of systemic 
infections. In a gut-derived model of P. aeruginosa sepsis, Watanabe et al. (2007) observed 67% 
survival of infected mice when phage therapy was administered orally one day post infection 65. 
Capparelli et al. (2007) observed that successful protection of mice with a systemic 
Staphylococcus aureus infection depended on phage dose 66; Biswas et al. (2002) observed similar 
results of dose dependent success in a mouse model of vancomycin-resistant Enterococcus faecium 
bacteremia 67. In a systemic disease model of Vibrio vulnificus, successful control of disease was 
only achieved when bacterial infection and phage treatment were administered simultaneously 68. 
The determinants of success for phage therapy to treat systemic infections are likely dependent on 
multiple factors which need to be thoroughly examined prior to the widespread use of phages as a 
treatment for sepsis in humans. 
Local Infections 
Phage therapy for localized infections (e.g., otitis, urinary tract infections, infected burns) is 
recognized for its potential to entirely circumvent the use of chemical antibiotics.  Furthermore, 
use of chemical antibiotics for surgical and hospital acquired infections is limited as these often 
constitute the strains with greatest antibiotic resistance. Watanabe et al. (2007) observed 92% 
survival of mice with an intraperitoneal P. aeruginosa infection treated simultaneously with 
phages 65. A similar study of S. aureus abscesses in mice by Capparelli et al. (2007) enumerated 
the reduction in bacterial load resulting from phage therapy, and observed that phages applied 






after bacterial challenge, a single dose of phages resulted in a 100-fold reduction in bacterial load, 
whereas multiple doses of phages resulted in a 10,000-fold reduction 66. In a mouse model of P. 
aeruginosa infection of burn wounds, phage treatment improved survival rate from 6% in the 
untreated controls to 88% when phages were administered via intraperitoneal injection 72 hours 
post infection 69. In contrast, phage treatment only resulted in 22% or 28% survival when 
administered subcutaneously or intramuscularly. Further pharmacokinetic studies demonstrated 
that phages delivered intraperitoneally persisted at higher levels in the liver, spleen and blood than 
phages delivered intramuscularly or subcutaneously69. Finally, a murine model was used to 
investigate the ability of phages to treat an E. coli urinary tract infection 70. Phages administered 
intraperitoneally 24 hours after bacterial challenge resulted in a 100-fold reduction in bacterial 
load in the kidneys 48 hours after phage treatment. The same phages resulted in a significant 
reduction in bacterial load in an E. coli pneumonia model, but was ineffective in an E. coli model 
of sepsis.  
Gastrointestinal Infections  
Applying phage therapy to gastrointestinal bacterial infections could potentially reduce or prevent 
colonization of virulent bacteria without disrupting the natural gut flora. Galtier et al. (2017) 
observed that a preventative treatment of phages, four days after an adherent-invasive E. coli 
challenge, was able to reduce bacterial colonization in the gut of dextran sodium sulfate treated 
mice and prevented the progression of colitis symptoms 71. In an insect model of Clostridium 
difficile colonization, prophylactic treatment with phages two hours prior to bacterial challenge 
resulted in 100% survival, while simultaneous administration of phages and bacteria resulted in 
72% survival, and phage administration two hours post bacterial challenge resulted in 30% 






to reduce V. cholerae colonization in the small intestine of infant mice when phages were provided 
three and six hours prior to bacterial challenge 73. However, phage-resistant bacterial mutants were 
recovered after treatment, and effects of phage treatment were reduced when administered more 
than six hours before bacterial challenge and when mice were challenged with a higher dose of V. 
cholerae 73. While the result of prophylactic treatment of gastrointestinal infections with phages 
are generally favorable, more studies that provide treatment after bacterial challenge, such as 
Galtier et al. (2017), are needed as prophylactic treatment is not always possible in the clinic 71. 
Lung Infections 
Phage therapy for the treatment of lung infections, particularly chronic lung infections which are 
common in those with cystic fibrosis (CF), has seen renewed interest recently with the increase in 
MDR bacteria associated with the lung. Waters et al. (2017) observed complete eradication of a 
CF strain of P. aeruginosa in mice when two doses of phages were administered intranasally to 
infected mice 24/36 or 48/60 hours after infection74. Treatment at 144/156 hours post infection 
resulted in complete eradication of infection in 70% of mice and a significant reduction in the 
remaining 30%. In another CF lung infection model, phage treatment significantly improved the 
survival rate of mice when administered intranasally at two hours post infection 75. Interestingly, 
a high dose of phages administered 4 days prior to bacterial challenge provided complete 
protection to mice, indicating that prophylactic treatment with phages could prevent chronic 
infections. Semler et al. (2014) investigated different routes of administration of phages in a mouse 
model of Burkholderia cepacia complex respiratory infection 76. A 100-fold decrease in bacterial 
load was observed when phages were administered via nebulization while no decrease was 






prophylactic and curative treatment of lung infections with phages indicate that these types of 
infections may be a reliable target for effective phage therapy. 
Antibiotic and Phages in Combination 
While there have been many in vivo studies on the efficacy of phage therapy, not many recent 
studies have compared the in vivo efficacy of phage therapy to that of antibiotics or even combined 
phages and antibiotic treatment. Huff et al. (2004) investigated the efficacy of traditional 
antibiotics, phage treatment, or a combination of both in a head-to-head trial in an E. coli challenge 
in broiler chickens 77. The standard of care treatment, enrofloxacin (fluoroquinolone), reduced 
mortality from 68% in untreated birds to 3%, while phage treatment alone reduced mortality to 
15%. A combination therapy of phages and enrofloxacin resulted in no mortality 77. Similarly, 
Oechslin et al. (2016) observed that phages in combination with ciprofloxacin resulted in a 10,000-
fold greater reduction in bacterial load as compared to phages or ciprofloxacin treatment alone in 
rats with experimental endocarditis due to P. aeruginosa 78. Furthermore, they noted that this 
particular combination of phages and antibiotics resulted in synergistic killing of P. aeruginosa 
both in vitro and in vivo 78. As the future of phage therapy will likely be that of combined therapy 
with chemical antibiotics, additional studies examining potential synergy between phages and 
antibiotics both in vitro and in vivo are needed.  
Compared to phage therapy studies in vivo animal models, there have been relatively few 
reports on the clinical use of phages and even fewer controlled clinical trials. As summarized in 
Table 1.1, below we describe some notable case studies and clinical trials that have been 
performed; the lists are not exhaustive and other examples can be found in the literature 79, 80. 






Case 1: Pseudomonas Sepsis Case Report 
A child with DiGeorge syndrome and congenital heart disease presented with P. aeruginosa 
bacteremia following multiple surgeries that included insertion of a pacemaker 81. Anti-
pseudomonal antibiotics initially controlled the infection but ultimately failed. Adverse reactions 
to cephalosporins and fluoroquinolones further limited antibiotic options. Phages provided by the 
US Navy were screened for lytic activity against the infectious strain and a cocktail of two phages 
was created. After intravenous phage administration, blood cultures fluctuated between positive 
for P. aeruginosa and below the limit of detection for several days. Phage therapy was resumed 
on day 11, following a temporary cessation due to decompensation attributed to progressive heart 
failure, which coincided with four days of blood cultures negative for P. aeruginosa. In this case, 
phage therapy appeared to reduce the infection in the blood, though was apparently ineffective at 
source control as blood cultures reverted to positive upon termination of therapy. 
Case 2: Urinary Tract Infection Case Report 
Khawaldeh et al. (2011) reported treating a P. aeruginosa urinary tract infection associated with a 
bilateral ureteral stent 82. Following cessation of antibiotic therapy, the infection consistently 
recurred within a week. Libraries of phages from the Eliava Institute were screened against the 
bacterial isolate and a suitable commercial phage product identified. This phage cocktail contained 
phages with activity against Streptococcus pyogenes, S. aureus, E. coli, P. aeruginosa, Proteus 
vulgaris and Proteus mirabilis. On day six of the treatment, antibiotic therapy with meropenem 
and colistin was initiated. Khawaldeh et al. (2011) reported 10-fold reduction of bacteria in the 
urine after five days of phage treatment. Two days of subsequent antibiotic treatment resulted in 
apparent clearance of the infection at which point culturable P. aeruginosa was below the limit of 






and one was replaced. Urine samples remained sterile for one year after treatment, at which point 
observations were concluded. 
Case 3: Surgical Site Infection Case Report 
LaVergne et al. (2018) reported a postoperative A. baumanii infection in an individual following 
a craniectomy 83. Strains of A. baumannii isolated from the infection were resistant to almost all 
antibiotics and antibiotic combination therapy. Phages provided by the US Navy were screened 
for lytic activity against the infectious strain and a cocktail of five phages was chosen for 
therapeutic use. Five minutes after phage administration, the concentration of phages in blood was 
approximately 100 PFU/mL. This was approximately 100-fold lower than expected if the phages 
were simply diluted into an average human blood volume 10 minutes after administration, phages 
were undetectable. Despite initial improvements, the lack of significant improvement led to 
withdrawal of care. Unfortunately, bacterial load was not measured during the course of treatment 
and it is difficult to attribute any clinical improvement to the administration of phages. It appears 
that in this case, phages were actively removed from the blood, either through adsorption to 
bacteria in vivo, or active removal by the body. 
Case 4: Pancreatitis Case Report 
Phage therapy was utilized in a case of necrotizing pancreatitis complicated by an MDR A. 
baumannii infected pseudocyst 84. Phages from several institutions were screened against the 
isolated infectious strains and two cocktails each consisting of four different phages were 
formulated. The first cocktail was administered via lavage at the site of the pancreatic pseudocyst. 
The following day, the second cocktail was administered intravenously. Resistance emerged 
against all of the phages used in both cocktails by eight days after the first administration of phages, 






against the resistant strains and was again administered intravenously. Resistance to the original 
cocktails correlated with increased presence of encapsulated bacteria, further suggesting bacterial 
response to phage administration. Phage therapy was continued for approximately 12 weeks, over 
the course of which clinical improvement was observed and the infection was eventually resolved.  
Case 5: Aortic Graft Infection Case Report 
Surgical intervention to repair an aortic aneurysm with a Dacron graft resulted in a P. aeruginosa 
infection that was refractory to standard treatment 13. This chronic infection resulted in the 
formation of an aorto-cutaneous fistula with purulent discharge. Infection control was attempted 
with intravenous ceftazidime followed by oral ciprofloxacin. Resistance to ciprofloxacin evolved 
during the course of treatment, debridement and irrigation were unsuccessful in resolving the 
infection, and surgical replacement of the graft was not an option. After three years of suppressive 
chemical antibiotic therapy which failed to eradicate the infection other options for infection 
control were considered. A recent report of P. aeruginosa phage OMKO1 that had demonstrated 
synergy when used in combination with ceftazidime 64 was screened for lytic activity against the 
strain. Instillation of a single dose of phage OMKO1 and ceftazidime was applied topically at the 
site of fistular discharge while continuing the existing therapy of intravenous ceftazidime. Four 
weeks after the administration of phages, partial graft excision and replacement was required 
following bleeding from the fistula. Cultures taken at the time of surgery were negative for P. 
aeruginosa and the course of ceftazidime was discontinued. Two years after phage treatment, there 
was no recurrence of the infection in the absence of any antibiotic therapy. The favorable outcome 
of this case underscores the rational choice of phages and route of administration for this particular 






clinically relevant antibiotics applied in proximity to the source of infection undoubtedly 
contributed to the positive outcome. 
Clinical Trials of Phage Therapy 
Trial 1: Otitis Clinical Trial 
In 2009, a clinical trial was designed to investigate the safety and preliminary efficacy of phage 
therapy for treating chronic P. aeruginosa otitis 85.  Wright et al. (2009) utilized a cocktail of six 
phages with lytic activity against P. aeruginosa in individuals with chronic otitis 85. While the 
authors report a significant accumulated reduction of bacterial counts in the phage treatment group 
and no significant accumulated change of bacterial counts in the placebo group, three individuals 
from each group had undetectable levels of P. aeruginosa by day 42. Phages were isolated for an 
average of 23 days from individuals in the phage treatment group suggesting that phages were 
either cleared upon resolution of the infection, phages were unable to reach the site of infection, 
or the bacteria became phage-resistant. There were no serious adverse events reported in either 
group, indicating the safety of phage therapy for the treatment of otitis.  
Trial 2: Diarrheal-Disease Clinical Trial 
A clinical trial was conducted in Bangladesh to test safety and efficacy of two different phage 
cocktails that target pathogenic E. coli in diarrheal diseases 86. Individuals presenting with acute 
onset of dehydrating diarrhea were admitted to the study. Phage treatment consisted of oral 
administration of one of two different phage cocktails that had been previously characterized: a 
T4-like phage cocktail (T) containing 11 phages and a commercial phage cocktail (M) from Russia 
consisting of at least 17 different phages in oral rehydration solution. Standard treatment of oral 
rehydration solution was given to the placebo group. There were no adverse effects reported and 






phages were lytic against the specific E. coli strains causing disease and no actions were taken to 
buffer the stomach prior to the administration of phages.  It is possible, therefore, that significant 
numbers of phage particles were unable to survive the low-pH environment of the stomach, and 
that the surviving particles were unable to amplify due to the lack of an appropriate host 87.  
Trial 3: PhagoBurn Burn Wound Clinical Trial 
The most recent clinical trial to date, PhagoBurn, evaluated the safety and efficacy of phage 
therapy to treat P. aeruginosa infected burn wounds 88. A phage cocktail of 12 phages with lytic 
activity against P. aeruginosa were added to an alginate template that was applied directly to the 
wound. The control group received standard of care treatment which consisted of 1% sulfadiazine 
silver applied topically. The average time to sterilization for the phage treated group and control 
group was 144 hours and 47 hours, respectively. These unexpectedly poor results could be 
explained by administration of a lower phage dose than intended. The concentration of the phage 
cocktail had dropped over the course of the study and a dose of 200 to 2000 PFU was used instead 
of the expected 2 × 107 PFU dose. With concentrations of phages 4-5 orders of magnitude lower 
than expected it is possible, if not probable, that the lack of efficacy can be attributed to this 
unintended change in the treatment protocol. 
Perspectives and Future Directions 
Will Phages Ever Replace Antibiotics? 
A rational approach to phage therapy has many potential advantages over a traditional chemical 
antibiotic approach (Table 1.2). (1) The non-lethal nature of some bacteriostatic antibiotics may 
permit antibiotic resistance to evolve more easily, as well as accommodate the emergence of 
persistor cells that are genotypically equivalent to wild-type bacteria yet physiologically capable 






lysing cells at the completion of their replication cycle. Furthermore, phages (unlike antibiotics) 
hijack most essential cellular processes including DNA replication, transcription and translation 
upon infection and are perhaps harder targets for evolution of bacterial resistance 90. (2) The 
popular broad-spectrum antibiotics may disrupt the normal balance of the microbiome which 
might otherwise provide a protective effect by occupying niche sites that prevent or constrain 
bacterial pathogens from invading the body 91. (3) Phages can be specific to species and even single 
strains of bacteria, making them an ideal therapeutic to selectively target and kill pathogens 90. The 
clinical use of phages will likely require preliminary laboratory assays to identify sensitivity of 
strains to therapeutic phages. Phage sensitivity could be determined in parallel with antibiotic 
sensitivity to ensure a better match between the proposed drug (phage) and the target bacterial 
strain. Relatedly, this may explain why the above-described case reports have been generally more 
successful than clinical trials to date (see case studies and clinical trials summarized in Table 1.1). 
(4) In addition, while antibiotics must be continually dosed to clear infection, phages are able to 
amplify at the site of infection (suggesting fewer doses should be needed) and will be cleared from 
the body when the susceptible bacteria are gone. (5) Resistance to antimicrobials is inevitable 16. 
However, unlike antibiotic therapy, phage therapy can take advantage of this outcome via careful 
choice of therapeutic phages that select for resistant bacterial mutants with lower fitness, especially 
reduced virulence or impaired antibiotic efflux (see above section on Phage Therapy: A Renewed 
Approach). (6) Furthermore, as phages co-evolve with bacteria over time, it is possible that the 
administered phage population will evolve to infect the phage-resistant bacteria (an arms race), 
which is not possible for antibiotics. (7) Phage treatment of biofilms may prove more promising 
than antibiotic treatment of biofilms 13; however, this difference may depend on the target 






92. (8) Finally, while novel antibiotic discovery has stagnated in recent years, discovery of new 
phages has proven expeditious due to the vast biodiversity of phages in nature that have useful 
properties in biotechnology 7, 90.  
However, even with this more rational phage therapy approach, phages still have some 
limitations compared to traditional chemical antibiotics that need to be addressed before phage 
therapy can be fully accepted in modern clinical practice (Table 1.2). (1) Phages will likely not be 
an appropriate therapeutic for all infections. While some antibiotics are capable treating 
intracellular bacterial pathogens, phages do not have a reliable mechanism of entry into eukaryotic 
cells. (2) Also, there has been decades of research performed on antibiotics and their interactions 
with the immune system, whereas abundant analogous research with phages has yet to be 
completed 90, 93. (3) Since phages can be found everywhere, including within the human 
microbiome, neutralizing antibodies against certain phages typically associated with humans may 
be a general obstacle for phage therapy. (4) Because a phage population can undergo rapid 
exponential growth, widespread lysis of target bacteria can potentially release bacterial antigens 
that could be dangerous, particularly if the phages are administered internally; thus, endotoxin 
removal from preparations of phage lysates intended for therapy, as well as generation of 
endotoxins during therapy are valid concerns. (5) Finally, regulatory hurdles represent a significant 
barrier to the implementation of phage therapy in modern medicine; unlike the well-established 
path to approval of antibiotics, this path is currently being paved for phages and therefore very 
little useful precedence exists.   
Realistically, therapeutic use of phages may never completely replace administration of 
chemical antibiotics and may be inappropriate under some clinical conditions, suggesting that 






be an ideal combination that capitalizes on each treatment’s differing strengths (Table 1.2). Bedi 
et al. (2009) observed an additive effect when phages and antibiotics were used to treat a Klebsiella 
pneumoniae biofilm48. Knezevic et al. (2013) investigated the potential for phage-antibiotic 
synergism and observed synergy between P. aeruginosa phages and subinhibitory concentrations 
of ceftriaxone, but not with gentamicin, ciprofloxacin or polymyxin B 94. They proposed that the 
mechanism of action of the antibiotic must not interfere with critical processes in phage replication 
to see a synergistic effect. While not all phage and antibiotic combinations appear to be synergistic 
and the mechanisms behind synergism are still being explored, precision medicine is currently in 
vogue, and phage therapy shows promise as a ‘personalized’ approach for at least some infected 
individuals. As with any drug, the ideal circumstance is that phage therapy should be developed to 
reduce off-target effects and to minimize disruption of helpful microbiome communities to the 
extent possible. 
Other Considerations for Phage Therapy 
One method employed to expand phage host-range and subvert the criticism of narrow spectrum 
is to combine multiple phages to create phage cocktails. Traditionally, this has been perceived as 
a benefit, allowing the cocktail to be used against different strains or species of bacteria, and 
presumably decreasing the likelihood that mutations against all of the phages will simultaneously 
occur. Recent case studies show that in principle either a single phage or phage-cocktail approach 
might work (see Clinical Cases). However, a conceivable drawback of phage cocktails is their 
ability to select for “broad-spectrum” mechanisms of phage resistance, such as the production of 
a capsule that surrounds the cell, preventing phage binding. For these reasons, a rational approach 
to designing cocktails is warranted, involving consideration of: mechanism(s) whereby phage 






confirmation that the various phages in a cocktail do not compete with one another to reduce the 
overall efficacy. At the least, we see relevance for a more dedicated merger between phage-cocktail 
formulation and core principles and theories of evolution and ecological competition. 
A related subject is the mode of delivery for phages in therapy, and whether this choice 
would impact relative ratios of phages to bacteria at the site(s) of infection, and/or ratios among 
phages in a cocktail as they are administered versus the times when they actually encounter the 
infecting bacteria. The self-amplifying nature and lethality of lytic phages suggest that this therapy 
should often avoid the analogous consequence of bacterial evolution of resistance to chemical 
antibiotics delivered at too low of concentration. However, the density of phage particles relative 
to target bacterial cells may greatly impact timing and quality of the phage therapy outcome, and 
mode of delivery necessarily affects these key ratios. Therefore, the route of administration for 
phage therapy should consider the most likely method to deliver the highest concentration of phage 
particles to the site of infection, and therapeutic approaches might consider low initial doses of 
phages that are adjusted over time. Phage studies have not focused very closely on the therapy 
benefits versus costs of changes in the multiplicity of infection (ratio of phage particles to target 
susceptible bacterial cells) over time, either via administration or by estimating changes within the 
treated human or animal model; this seems like a relevant focus for phage therapy research moving 
forward. 
Summary 
Renewed interest in phage therapy in the West, and its continued development in countries such 
as Poland, Russia, and Georgia, mark a time for optimism for a viable alternative (or adjunct) to 
antibiotic therapy. Phage therapy like any medical treatment has benefits, costs and limitations in 






topics that should be addressed, especially as greater numbers of clinical trials on phage therapy 
are planned and executed. Is it possible to discover or engineer individual phage strains that 
broadly infect genotypes of a target pathogen, meriting their approval as standalone ‘drugs’? Or, 
would additional experiments on phage cocktails provide convincing evidence that phage mixtures 
should be the standard of care? Bioprospecting for phages is likely to continue yielding candidates 
with useful biologically properties, such as ability to select for reduced virulence and re-
sensitization of bacteria to antibiotics. But what is the probability that bacteria can evolve 
simultaneous resistance to both phages and antibiotics at no cost? How can the process of 
bioprospecting for phages be made more efficient? Could developing genomics and bioinformatics 
analyses as well as computer algorithms help identify potential phage candidates and predict 
phage-binding to cell receptors, strictly through high-throughput sequencing? Would reliable 
models such as non-pathogenic E. coli yield sufficiently useful data to predict utility of phage 
therapy in pathogens that are much harder to culture in the laboratory or where we lack animal 
models for acute and chronic bacterial diseases? How is phage therapy observed or theoretically 
predicted to interact with the immune system and human microbiomes 93, 96, 97, to either enhance 
or suppress this approach in resolving systemic and biofilm infections?  How would these 
interactions differ in sites as different as the respiratory and gastrointestinal systems? This non-
exhaustive list highlights many hypotheses regarding phage therapy that should be the focus of 
future basic research. Fortunately, this is an opportune time for basic researchers, clinicians, and 
physicians to work together to address open questions through rigorous experiments in the 
laboratory, in vivo models and clinical cases to reward phage therapy with the renewed interest 








Chapter 1 Figures 
Figure 1.1 Lytic phage infection cycle 
 
A cycle of lytic phage replication begins when the virus recognizes and irreversibly binds to a receptor (protein or 
sugar) on the surface of a bacterial cell. The phage delivers its genomic content into the cytoplasm of the bacterial 
cell. Typically, host resources, including proteins and genomes are repurposed to fuel phage replication. Replication, 
transcription and translation of the phage genome begins usually through redirecting host metabolism to the production 
of new phage particles. Upon assembly of new phage particles, lysis of the bacterial cell allows newly replicated phage 







Figure 1.2 Examples of bacterial receptors for phage binding 
 
Phage encode binding proteins that recognize and attach to sites on the surface of a bacterial cell. Many phage bind to 
protein structures on the bacteria such as pili (depicted in red) 22, flagella (yellow) 60, porins (blue) 19 or efflux pumps 







Figure 1.3 Phage selection against virulence or antibiotic resistance 
 
Certain lytic phage may be more effective in phage therapy, because they kill target bacteria while simultaneously 
imposing strong selection against bacterial virulence or antibiotic resistance when bacteria mutate to avoid phage 
attack. Phage that use antibiotic efflux pumps as receptors (red) can select for phage-resistant bacterial mutants with 
impaired efflux pumps; these phage-resistant bacterial mutants are more sensitive to antibiotics 23.  Phage that bind to 
structural virulence factors such as a capsular antigen (purple) can select for phage-resistant bacterial mutants that 
lack the capsule 38; these non-capsulated phage-resistant mutants are less virulent bacteria because they are more easily 







Table 1.1 Case Reports and Clinical Trials 
















and congenital heart 
disease with pace 
maker
MEM, TOB, 
ATM, PMB and 
CST
MEM, TOB, ATM, 
PMB, CST
3.5 × 105 PFU delivered 
intravenously every six hours
Initial PT for 36 
hours (6 doses 
total), PT resumed 
11 days later
Blood cultures negative 
after PT but reverted to 












bilateral ureteral stent 
placement
GEN, CAZ, CIP 
and MEM
None reported 2 × 107 PFU directly instilled 
into the bladder every 12 hours
10 days (MEM and 
CST treatment 
initiated on day 6)
Urine samples sterile 







Craniectomy Combination of 
CST, AZM and 
RIF
Intermediate 
sensitivity to CST 
with resistance to all 
other tested antibiotics
8.56 × 107 PFU delivered 
intravenously every two hours
8 days (98 doses 
total)
Initial improvements 













MEM, GEN, AMK, 
SXT, TET, CIP and 
CST
5 × 109 PFU delivered 
intravenously every six hours
84 days (336 doses 
total), MIN added 
on day 2
Clinical improvement 









CAZ and CIP CIP 1 × 108 PFU delivered 
topically on fistula
Single dose Cultures negative at four 
weeks post treatment
Infection Trial Treatment 
group












received single dose of 
glycerol-PBS buffer




Three patients from each group had 
undetectable levels of P. aeruginosa  at the 










coli  diarrheal 
diseases
Placebo-controlled, 











1.4 × 109 PFU cocktail M or 
3.6 × 108 PFU cocktail T 
delivered orally in oral 
rehydration solution 3 times 








blinded trial for safety 
and efficacy
12 individuals 
received a phage 
cocktail
13 individuals 
received standard of 
care 1% sulfadiazine 
silver
2 × 107 PFU (expected) 200-
2000 PFU (actual) applied 
topically 1 time per day for 7 
days (7 doses)
MEM, meropenem; TOB, tobramycin; ATM, aztreonam; PMB, polymyxin B; CST, colistin; GEN, gentamicin; CAZ, ceftazidime; AZM, azithromycin; RIF, rifampin; 
AMK, amikacin; MIN, minocycline; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; CIP, ciprofloxacin; PT, phage treatment
No significant difference between PT group 
and placebo group
Trial was stopped early due to insufficient 
efficacy of PT as compared to the standard of 
care (placebo) treatment. This was likely due 







Table 1.2 Comparing and contrasting antibiotics and phage  
 
A rational approach to phage therapy has many potential benefits that cannot be achieved with antibiotics alone. 
However, there are also limitations to phage therapy, in comparison to traditional antibiotics. While many of these 
differences historically have been considered limitations to using phage therapy, in some circumstances the perceived 
drawbacks may instead be leveraged as benefits. Both types of therapies historically have been administered alone; 
however, with many identified differences, a combination approach utilizing both therapies may prove to be the most 
efficacious in the long run  
Antibiotics Lytic (‘Virulent’) Phage
Bacteriostatic or bacteriacidal Bacteriacidal
Typically disrupts ONE bacterial process Disrupts MANY/ALL bacterial processes
Broad-spectrum more common than narrow-
spectrum 
High degree of species or strain specificity
Disruption of microbiome Only disrupts target bacteria
Not very effective against biofilms Penetration and destruction of biofilms
Minimal identification of bacteria Phage tested against target bacteria
Short time between diagnosis and treatment Longer time between diagnosis and 
treatment
Constant dosing to maintain inhibitory 
concentrations
Self-amplifying while target bacteria are 
present
Potential for immune recognition Potential for immune recognition
Widely accepted; used as treatment for 
infections
Push back on clinical application; only used 
on a compassionate care basis
Diffusion through membranes allows for 
treatment of intracellular bacteria
Unable to penetrate eukaryotic cells
Slow discovery process Rapid discovery process
Production methods in place to ensure safety 
of products
Steps must be taken to ensure removal of 
contaminating bacterial antigens generated 
during production
Regulations for production & manufacturing 
in place
Require new regulations for production & 
manufacturing
Resistance inevitable Resistance inevitable but phage can coevolve 
to infect resistant bacteria
Resistance frequently accompanied by 
compensatory mutations
Resistant mutants may result in lower 
fitness via reduced virulence or antibiotic 
sensitivity
Activity & Mechanism of Action
Clinical Use













Chapter 2: High-throughput discovery of phage receptors using transposon insertion 








Chapter 2 has been adapted from an article that is published: Kortright, K. E., Chan, B. K., & 
Turner, P. E. (2020). High-throughput discovery of phage receptors using transposon insertion 
sequencing of bacteria. Proceedings of the National Academy of Sciences, 117(31), 18670-18679. 
The study was designed by Kaitlyn Kortright, Dr. Paul Turner and Dr. Benjamin Chan. Kaitlyn 
Kortright preformed all experiments and analyzed data. The manuscript was prepared and edited 
by Kaitlyn Kortright, Dr. Paul Turner and Dr. Benjamin Chan. 
Raw sequencing is publicly available at NCBI Sequence Read Archive Project # 
PRJNA637562 and supplemental datasets have been deposited on Dryad 
(doi:10.5061/dryad.t76hdr7z3). We thank J. Wertz for strains; A. Goodman, B. Kazmierczak, S. 
Shames and D. Weinberger for valuable discussions regarding this study; and J. Bull and A. 






As the most abundant microbes on earth, novel bacteriophage (phage; bacteria-specific viruses) 
are readily isolated from environmental samples. However, it remains challenging to characterize 
phage-bacteria interactions, such as the host receptor(s) phage bind to initiate infection. Here, we 
tested whether transposon insertion sequencing, INSeq, could be used to identify bacterial genes 
involved in phage binding. As proof of concept, results showed that INSeq screens successfully 
identified genes encoding known receptors for previously characterized viruses of Escherichia coli 
(phage T6, T2, T4 and T7). INSeq screens were then used to identify genes involved during 
infection of six newly isolated coliphage. Results showed that candidate receptors could be 
successfully identified for the majority (five of six) of the phage; furthermore, genes encoding the 
phage receptor(s) were the top hit(s) in the analyses of the successful screens. INSeq screens 
provide a generally useful method for high-throughput discovery of phage receptors. We discuss 
limitations of our approach when examining uncharacterized phage, as well as usefulness of the 
method for exploring the evolution of broad versus narrow use of cellular receptors among phage 
in the biosphere. 
Chapter Introduction 
At an estimated 1031 particles, the number of bacteriophage (phage; bacteria-specific viruses) in 
the global biosphere comprises a vast and uninvestigated microbiological diversity 98. This largely 
untapped “bioprospecting” resource allows for newly discovered, naturally-occurring phage, to be 
developed for numerous applications. In stark contrast to this biodiversity are the relatively few 
phages that have been well-characterized (e.g., lambda, ΦX174, T4, T7, Φ6). These well-studied 
phages have been valuable for elucidating fundamental aspects of molecular biology and 




purposes, including alleviating current medical challenges posed by antibacterial resistance, 
exemplified by recent cases where phages were used to treat antibiotic-resistant bacterial infections 
in humans 13, 99. It is therefore crucial to design approaches whereby newly discovered phage are 
characterized prior to any intended applications.  
Isolating phage strains from environmental sources can be straightforward, though 
uncovering detailed characteristics of phage biology can be challenging. Sequencing approaches 
and molecular techniques are increasingly affordable, allowing for easier determination of genome 
size and nucleic acid content (DNA vs. RNA; single- vs. double-stranded) used to classify newly 
discovered phages into known or proposed virus families 100. Electron microscopy is typically 
sufficient to describe basics of phage morphology and capsid structure 101. Classic laboratory 
methods are useful for estimating host range (infectability across bacterial genotypes or species) 
and to determine whether a phage has a temperate versus strictly lytic replication cycle 100. 
However, other details of phage-bacteria interactions can be more difficult to ascertain. In 
particular, identifying the specific cell-surface receptor(s) that a phage uses in host binding, and 
the bacterial genes that are involved in resistance to phage infection are not as readily determined 
using the above methods.  
To initiate an infection, a phage particle must first recognize and bind one or more receptors 
on the surface of a susceptible bacterial cell. Many of the phage specific to Gram-positive bacteria 
use carbohydrate moieties of peptidoglycan or techoic acid as their receptors 102. Whereas others, 
such as phage g which infects Bacillus anthracis and phage SPP1 that infects Bacillus subtilis, use 
protein receptors GamR and YueB, respectively 61, 103.  Thus far, receptors used by phage of Gram-
negative bacterial hosts appear limited to specific proteins and/or lipopolysaccharide (LPS) 




conserved structures of bacteria, indicating that phage have been evolutionarily selected to exploit 
essential features of their hosts 112. In the simplest cases, a phage may use a single outer-membrane 
protein as a receptor, such as phage T6 attachment to the Tsx nucleoside channel of Escherichia 
coli 106. Other phage bind to a specific LPS motif, as seen in several members of the Podoviridae 
virus family 108. In further examples, phage use a primary receptor to facilitate attachment but 
require a secondary receptor to irreversibly bind to a host cell 110, 111. Finally, phage such as T2 
can use two or more receptors on the surface of a bacteria interchangeably to bind and initiate 
infection 104, 107.  
Elucidating molecular details of phage binding is fundamental to understanding phage 
biology because the receptors confer host-specificity of a virus, by allowing phage to differentiate 
between species or strains of bacteria. Nevertheless, it is challenging to determine phage receptors, 
especially when host bacteria themselves are not well characterized. Previously, knock-out 
libraries such as the Keio collection (single-gene deletion mutants of E. coli K-12) 113  have been 
utilized to identify specific bacterial genes involved in phage T7 infection 114, whereas similar 
resources do not exist for other non-model bacteria. Even in the case of E. coli, however, such 
methods can be laborious, involving the screening of individual phage samples on very large 
numbers of mutant bacterial strains if genes for phage receptors are unknown. Transposon mutant 
libraries have been used to identify bacterial mutants that are resistant to phage infection 115-117. 
While this method requires relatively less effort, it is limited by the number of transposon mutants 
chosen for follow-up study, making it potentially challenging to identify the receptor(s) used by a 
single phage. One other common method to identify possible phage receptors is to characterize 
spontaneous phage-resistant mutants of bacteria. However, this approach typically necessitates 




genome to identify candidate mutations, which are not guaranteed to be in genes encoding phage 
receptors. 
Advances in high-throughput sequencing have facilitated the development of new 
sequencing-based transposon mutant screens, which enable the rapid identification of genes that 
contribute to bacterial fitness in a particular selective environment 118, 119. This method makes use 
of a modified transposon to create a diverse transposon mutant library, where each bacterial 
genome contains a single randomly-incorporated insertion mutation. The sites of transposition in 
the mutant population can be easily identified by sequencing, and the relative abundances of 
specific insertions can be quantified. Comparison of the relative abundances of transposon mutants 
pre- and post- selection can be used to identify genes contributing to fitness (bacterial growth) 
under the selective environment of interest.   
Here, we describe a novel high-throughput method to identify phage receptors by querying 
the entire repertoire of bacterial genes that are critical for survival during selection by lytic phage 
(Figure 2.1A). The disruption of a gene involved in phage resistance would result in a fitness 
disadvantage under the selective pressure of phage; consequently, these mutants would be 
represented at a lower frequency in the output transposon mutant pool (TMP) (Figure 2.1B). 
Conversely, disrupting a bacterial gene required for phage infection and replication (e.g. genes 
encoding phage receptors), would provide a fitness advantage under the selective pressure of phage 
and these mutants should be enriched in the output TMP.  
We hypothesized that this approach could successfully identify bacterial genes responsible 
for receptor-binding in four well-characterized viruses capable of infecting E. coli K12: phages 
T2, T4, T6 and T7. Results of our high-throughput method agreed with the published literature in 




demonstrating that phages fail to attach to bacterial knockout mutants lacking the gene(s) encoding 
phage receptor(s). We then tested our second hypothesis that this method could be used to identify 
receptor-binding genes in each of six newly discovered and previously uncharacterized phage, 
similarly capable of infecting E. coli K12. Our approach, along with confirmatory adsorption 
assays, was successful in discovering the binding targets for five out of six of these viruses, 
demonstrating both the general utility of the method as well as the enduring challenge of 
developing an infallible technique for discerning phage receptors in bacteria.  
Results 
INSeq transposon mutant library covers 80% of non-essential genes 
The final pooled transposon mutant library contained 17,100 independent transposon insertions in 
3,253 bacterial genes. Visual inspection of results (Figure 2.2) showed genome coverage did not 
appear to be affected by the inherent GC bias of mariner transposons 120. However, there was an 
increased number of transposition events near the E. coli K12 origin of replication (Figure 2.2). 
This result likely was attributed to multiple copies of the origin present during DNA replication 
120.  While the final library was not completely saturated (i.e., not every non-essential gene was 
represented by a transposon mutant), approximately 80% of non-essential E. coli genes had at least 
one independent transposon insertion event in the final transposon mutant library. We used 
EcoCyc 121 to compile a list of 137 genes expressed at the cell outer membrane (Table 2.1); of 
these genes, 31 were not represented in the TMP used for our screens.  
The INSeq screen was initiated with a multiplicity of infection (MOI; ratio of phage to 
bacteria) roughly equaling 0.01 (see Methods). We noted that a lower MOI could allow for the 
occurrence of additional spontaneous (non-transposon-insertion) mutations that could experience 




allow the TMP to undergo multiple rounds of cell division under phage selection, which was 
necessary for transposon mutant enrichment in the designed INSeq screen (Figure 2.1). 
Furthermore, we reasoned that the reduced initial selective pressure at low MOI would allow us to 
observe transposon-disrupted genes with subtle (i.e., low to moderate) fitness effects 122. 
INSeq identifies receptors for phages T6, T2, T4 and T7 
As a proof of concept for our method, we tested whether an INSeq screen could accurately identify 
the bacterial receptors for four well-characterized phages: T6, T2, T4 and T7. Controls consisted 
of INSeq screens using ‘mock infections’ that were performed identically, but in the absence of 
test phage. Results (Figure 2.3 A-D) were plotted to depict all insertions in bacterial genes on a 
logarithmic scale, as the ratio of input normalized (to counts per million, CPM) reads to output 
normalized reads in CPM. As compared to the mock infected control (Supporting Information 
Appendix: Figure S2.1 A), each screen in the presence of a test phage resulted in an observed shift 
of the TMP with many transposon mutants becoming under-represented in the output population. 
This result was consistent with phage imposing strong selection pressure on the TMP. As the entire 
TMP shifts towards under-representation in the output population due to declining abundance of 
bacteria, it becomes difficult to distinguish truly significant hits that are at a fitness disadvantage 
in the presence of phage. However, this does not impair our ability to identify genes encoding 
phage receptors, as mutants in these genes should become over-represented in the output 
population. Therefore, candidate receptor hits were considered if they were statistically significant, 
had a positive log ratio, A, of output (AO) to input (AI) relative abundance (A = log[AO/AI]), and 
were genes encoding a membrane protein (Figure 2.3 E). 
The screen in the presence of phage T6 (Figure 2.3 A) yielded 144 significant hits (Chapter 




T6. The log ratio of output to input relative abundance (A) of a subset of the TMP, transposon 
mutants in genes encoding membrane proteins (Figure 2.3 E), were queried for candidate 
receptors. Transposon mutant tsx::Tn (A = 3.09), was the top hit of these screens. This result was 
consistent with previous observations of phage T6 using the Tsx nucleoside channel as a primary 
receptor 106. Eight other genes encoding membrane proteins were enriched in the output: lamB::Tn 
(A = 1.84), btuB::Tn  (A = 1.94), ompX::Tn  (A = 0.90), rhsD::Tn  (A = 0.55), ybgQ::Tn (A = 
0.36), ynfB::Tn (A = 0.22), ompW::Tn (A = 1.08), and pgaB::Tn (A = 0.68). However, A-values 
of these hits were far lower than that of tsx::Tn, indicating that in future screens, only the hits with 
the highest A-values should be considered as candidate receptors. Nonetheless, a subset of these 
other eight hits were assayed in further experiments to demonstrate that these genes were not 
involved in the binding of phage T6 (see below). 
The phage T2 screen (Figure 2.3 B) resulted in 143 significant hits, of which 86 (Chapter 
2 Appendix: Supplemental Data 1) were positively enriched in the presence of phage T2. 
Candidate receptors fadL::Tn (A = 2.60) and ompF::Tn (A = 2.53) were identified (Figure 2.3 E) 
as the top two hits of these screens. This was a key result, as it was unclear if our approach could 
successfully identify both receptors used by a phage when the presence of only one was necessary 
and sufficient for phage adsorption. Thus, these results were consistent with previous observations 
of OmpF and FadL as interchangeable receptors for phage T2 104, 107.  There were two other 
enriched hits in genes encoding membrane proteins: rhsD::Tn  (A = 1.00) and ynfB::Tn (A = 
0.55).These two hits also came up in the screen with phage T6, indicating that they might be 
commonly required for phage infection. However, as above, their A-values were far below those 




The phage T4 screen (Figure 2.3 C) resulted in 177 significant hits, of which only 20 
(Chapter 2 Appendix: Supplemental Data 1) were positively enriched in the presence of phage T4. 
The top hit (Figure 2.3 E) was ompC::Tn (A = 2.35); additionally envZ::Tn was significantly 
enriched in the output TMP (Figure 2.2 C). EnvZ is part of a two-component regulatory system 
that increases the expression of OmpC 123. Two other identified hits (Figure 2.3 E) were yjbF::Tn 
(A = 1.04) and yjbH::Tn (A = 0.34). Another gene in the same operon, yjbE::Tn (A=1.36), was 
significantly enriched in the output TMP. The Yjb operon is involved in production of extracellular 
polysaccharide and biofilm formation 124.  Previous literature suggests that phage T4 is not 
spatially inhibited by extracellular matrixes and is instead able to associate with the surface of 
biofilms 125. While it is interesting that multiple genes in this operon are significantly enriched in 
the output, further investigations of the importance of phage T4 with products of the Yjb operon 
is reserved for future studies, as previous results have demonstrated that phage T4 uses both OmpC 
and LPS as co-receptors 110. When OmpC is present, phage T4 can infect regardless of the terminal 
sugar residue of LPS; however, in the absence of OmpC, phage T4 is able to attach to LPS chains 
with an exposed, terminal glucose residue 110. Exposure of this terminal glucose residue in LPS is 
conferred by a deletion of waaU, a gene that was not included in the TMP. Validation assays, 
therefore, were conducted on the top hit from this screen, OmpC (see below). 
The phage T7 screen (Figure 2.3 D) resulted in 188 significant hits, of which 44 (Chapter 
2 Appendix: Supplemental Data 1) were enriched in the output TMP. A previous screen of the 
Keio collection identified 10 genes important for phage T7 infection; however, none of these 
single-gene deletions were sufficient to abolish infection 114. Phage T7 is predicted to use LPS, 
specifically lipid A or a keto-deoxyoctulosonate (KDO) sugar moiety, as a receptor 126; therefore, 




the genes involved in synthesis of the inner core regions of LPS are essential. Therefore, instead 
of querying the 44 significantly output-enriched hits from the INSeq screen for a specific gene, 
these hits were subjected to a gene ontology (GO) enrichment analysis 127. The results of GO Term 
analysis indicated that the significant, output-enriched transposon mutants from the phage T7 
screen were enriched for 22 genes involved in cellular biosynthetic processes (pyrI, yjbH, mutT, 
accA, uvrD, mmuP, yaeI, mmuM, hisA, metG, yegS, carB, sufS, opgH, waaF, gmhB, trpS, waaG, 
yebK, speB, hldD, and dnaQ). Upon closer inspection, approximately one third of these genes 
appeared to be involved in LPS metabolism: yaeI, waaF, gmhB, waaG, hldD, and yegS. 
Phosphodiesterase, YaeI, is annotated as a protein involved in lipid A biosynthesis and YegS is an 
annotated lipid kinase; while waaF, gmhB, waaG, and hldD are four out of five genes that make 
up Functional Gene Cluster 91 which consists of genes involved in synthesis and polymerization 
of the core heptose region of LPS. This result was encouraging, as it was unclear if our screen 
would be successful in identifying LPS as a receptor due to the complex nature of LPS biosynthesis 
and the essentiality of many of the genes involved. 
We note that false positives are expected to occur during our screen, especially since 
previous studies demonstrate that altering expression of one outer-membrane protein affects the 
expression of other outer-membrane proteins 128.  While we observed some false positives (e.g., 
see phage T6 results above), identification of phage receptors is still expected to succeed with this 
method in combination with confirmatory assays described below. In each of the screens 
conducted with phages T2, T4 and T6, the known receptors were all the top hit(s) from the short 
list of candidate receptors. The use of LPS as a receptor, as is the case for phage T7, is likely to be 




Efficiency of plating and adsorption assays confirm known receptors for characterized 
phages  
To verify that the top identified hits in the INSeq analyses were genes important for phage 
infection, we conducted efficiency of plating (EOP) assays to measure phage ability to 
productively infect bacterial strains lacking expression of the candidate gene 129 relative to 
productive growth on WT bacteria for a subset of the top hits. Since EOP does not directly measure 
phage attachment, adsorption assays were used to confirm that the putative genes were phage 
receptors for a subset of the top hits (Figure 2.4). We concluded that EOP and adsorption assays 
were successful in confirming that the top hit(s) from the screens with phage T6, T2, and T4 were 
the known receptor(s) (Chapter 2 Appendix: Supplemental Results). In addition, results from GO 
Term enrichment for phage T7 were confirmed by reduction in titers upon adsorption with LPS. 
INSeq identifies candidate receptors for newly isolated phage  
Next, uncharacterized phage were screened for receptors using our validated methods. Six phages 
(EC14, EC35, R3, P2, U115 and 8S) were chosen randomly from a large library of environmental 
phage isolates, and subjected to an INSeq screen for receptor identification. Prior to the current 
study, no traits for these phage strains were determined, other than their ability to infect E. coli 
K12. Screens with these six coliphage were performed as described above; hits that were 
statistically significant, had a positive log ratio of output to input relative abundance, and were in 
genes encoding membrane proteins were considered for further validation.  
The phage R3 screen resulted in 161 significant hits (Supplemental Figure S2.3 A), of 
which, 67 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage R3. 
Only two hits (Figure 2.5) were identified, ompA::Tn (A = 3.44) and rhsD::Tn (A = 0.96). As the 




The phage U115 screen resulted in 150 significant hits (Supplemental Figure S2.3 B), of 
which, 58 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage 
U115. The top hit (Figure 2.5) of these screens was tsx::Tn (A = 3.17). There were four other hits: 
lamB::Tn (A = 1.41), rhsD::Tn (A = 0.88), ompX::Tn (A = 0.45) and ybgQ::Tn (A = 0.06). The 
top two hits from these screens, Tsx and LamB, were considered candidate receptors for phage 
U115. 
The phage P2 screen resulted in 143 significant hits (Supplemental Figure S2.3 C), of 
which, 59 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage P2. 
Three hits (Figure 2.5) were slightly enriched: rhsD::Tn (A = 0.92), ynfB::Tn (A = 0.18), and 
yjbH::Tn (A = 0.84).  However, none of these hits were promising, as receptors for the well 
characterized phages T6, T2 and T4 were enriched to a log ratio greater than 1. Furthermore, all 
three of these transposon mutants were background hits in other screens. Therefore, it is likely that 
either phage P2 uses LPS as a receptor (as in phage T7), or that the receptor for phage P2 is one 
of the 31 membrane proteins not included in the TMP. 
The phage 8S screen resulted in 164 significant hits (Supplemental Figure S2.3 D), of 
which, 49 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage 8S. 
The top two hits (Figure 2.5) were ompC::Tn (A = 2.09) and lamB::Tn (A = 1.36). Other hits 
included rhsD::Tn (A = 0.64) and ynfB::Tn (A = 0.08). Additionally, OmpC regulators, envZ::Tn 
(A = 2.50) and ompR::Tn (A = 2.57), were enriched in the output TMP. The top two hits from this 
screen, OmpC and LamB, were considered candidate receptors for phage 8S infection. 
The phage EC35 screen resulted in 160 significant hits (Supplemental Figure S2.3 E), of 
which, 69 (Chapter 2 Appendix: Supplemental Data 1) were enriched in the presence of phage 




hits included rhsD::Tn (A = 0.50) and loiP::Tn (A = 2.42). Additionally, OmpC regulators, 
envZ::Tn (A = 2.38) and ompR::Tn (A = 3.03), as well as LamB regulators, malT::Tn (A = 2.61) 
and malK::Tn (A = 0.31), were enriched in the output TMP. The top three hits from this screen 
were LamB, OmpC and LoiP; however, loiP::Tn was only enriched in one out of three replicate 
screens. Therefore, LamB and OmpC were considered candidates for phage EC35 receptors. 
The phage EC14 screen resulted in 177 significant hits (Figure 2.5), of which, 32 (Chapter 
2 Appendix: Supplemental Data 1) were enriched in the presence of phage EC14. Similarly to 
phage EC35, the top two hits from the screen with phage EC14 were lamB::Tn (A = 2.47) and 
ompC::Tn (A = 2.33).  The other hit was rhsD::Tn (A = 0.48). Additionally, OmpC regulators 
envZ::Tn (A = 2.09) and ompR::Tn (A = 2.77), LamB regulator malT::Tn (A = 2.60), and malK::Tn 
(A = 0.003) were enriched in the output TMP. LamB and OmpC were considered candidates for 
phage EC14 infection. 
Receptors for five uncharacterized phages identified with EOP and adsorption assays 
EOP and adsorption assays were used to validate the candidate receptors for uncharacterized phage 
which were identified in each INSeq screen.  
Outer membrane protein OmpA was the candidate with the highest A-value in the screen 
with phage R3 (Figure 2.5), and was selected as the likely receptor for further analysis. In an EOP 
assay, phage R3 had an EOP (Figure 2.6 A) below the limit of detection on BW25113DompA. 
Plaquing was restored upon plasmid complementation of the ompA gene; however, plaquing was 
only restored to 46% of the phage growth on the parental strain. This result was likely due to 
differences in expression levels between chromosomally-encoded ompA and exogenous ompA. 
Furthermore, phage R3 did not adsorb (Figure 2.6 B) to strain BW25113DompA. Similar to 




and adsorption assays strongly indicated that OmpA was the primary receptor for the previously 
uncharacterized phage R3. 
The screen of phage U115 identified Tsx, a nucleoside transporter, as well as LamB as 
potential receptors for phage U115 (Figure 2.5). Phage U115 had an EOP (Figure 2.6 C) below 
the limit of detection on BW25113Dtsx and plaquing was restored to wild-type levels upon 
complementation with Tsx. Deletion of lamB had no significant effect on the EOP of phage U115. 
Phage U115 did not adsorb (Figure 2.6 D) to BW25113Dtsx or to the empty vector control, 
BW25113Dtsx. However, complementation with Tsx not only restored phage U115 adsorption, 
but allowed U115 to adsorb better than wild-type; 90% of phage U115 has adsorbed to 
BW25113Dtsx::pSF-tsx by 15 minutes while only 46.4% of phage U115 had adsorbed to WT by 
20 minutes. This result was likely due to the overexpression of exogenous tsx resulting in more 
Tsx on the outer membrane, relative to basal expression in WT bacteria. Phage U115 adsorbed to 
BW25113DlamB at levels comparable to wild-type. Results of both the EOP and adsorption assays 
indicated that phage U115 did not require LamB as a receptor to adsorb or infect E. coli, and that 
Tsx was the primary receptor for phage U115. 
The INSeq screen of phage 8S identified OmpC, an outer membrane porin, and LamB as 
potential receptors for the virus (Figure 2.5). EOP assays (Figure 2.6 E) revealed a 2.3-fold 
decrease in EOP of phage 8S on BW25113DompC and a 1455-fold decrease in EOP on 
BW25113DlamB. Phage 8S was unable to infect the double knockout, BW25113DompCDlamB, 
and infection was restored upon complementation with either ompC or lamB. Phage 8S appeared 
to adsorb (Figure 2.6 F) to BW25113DompC at levels similar to wild-type. However, phage 8S did 
not significantly adsorb to BW25113DlamB or to BW25113DompCDlamB. Adsorption was 




indicated that LamB was necessary for adsorption of phage 8S. However, since phage 8S was able 
to infect BW25113DlamB but unable to infect BW25113DompCDlamB, it likely used OmpC as a 
secondary receptor. Adsorption assays indicated that LamB was the primary receptor for phage 8S 
as it adsorbed well to BW25113DompCDlamB:pSF-lamB but did not adsorb appreciably to 
BW25113DompCDlamB complemented with ompC over the course of the assay. 
Similar to the screen for phage 8S, the screen for phage EC35 identified OmpC and LamB 
(Figure 2.5). There was a 1.7-fold decrease and a 6-fold decrease in EOP (Figure 2.6 G) of phage 
EC35 on BW25113DompC and BW25113DlamB, respectively. Phage EC35 was unable to infect 
BW25113DompCDlamB and infection was restored upon complementation with either ompC or 
lamB. Phage EC35 was unable to adsorb (Figure 2.6 H) to BW25113DlamB or 
BW25113DompCDlamB, but was able to adsorb to BW25113DompC and BW25113DompCDlamB 
upon complementation with lamB, and not with ompC. Again, these data indicated that phage 
EC35 used LamB as a primary receptor but likely required OmpC as a secondary receptor, as only 
deletion of both ompC and lamB abolished infection in an EOP assay. 
INSeq screens for a third phage, EC14, also identified OmpC and LamB as potential 
receptors (Figure 2.5). There was a 1.2-fold decrease and a 2.6-fold decrease in EOP (Figure 2.6 
I) of phage EC14 on BW25113DompC and BW25113DlamB, respectively. Phage EC35 was 
unable to infect BW25113DompCDlamB. Complementation with either ompC or lamB was 
sufficient to restore infection. Phage EC14 was unable to adsorb (Figure 2.6 J) to BW25113DlamB 
and BW25113DompCDlamB but was able to adsorb to BW25113DompC and 
BW25113DompCDlamB upon complementation with lamB or ompC. This result indicated that, 




Unlike the screens above, the screen with phage P2 resulted in no statistically significant 
hits (Figure 2.5) with a log ratio of output CPM to input CPM above 1.0 in genes expressed at the 
outer membrane; the top two hits were rhsD (A = 0.92) and yjbH (A = 0.84). Transposon mutant 
rhsD::Tn is likely background noise as it came up in every screen and follow up assays were not 
done. EOP and adsorption assays were performed with BW25113DyjbH. There is no decrease in 
EOP of phage P2 on BW25113DyjbH (Supplemental Figure S2.4 A). Phage P2 is able to adsorb 
to BW25113DyjbH (Supplemental Figure S2.4 B). It is possible that similar to phage T7, phage 
P2 uses LPS as a receptor. However, incubation with purified LPS did not result in a significant 
drop in titer (Supplemental Figure S4 C). Furthermore, GO term analysis did not uncover any 
significant enrichment for any biological processes. Another possibility is that similar to phage 
T2, phage P2 has multiple receptors. However, successful identification of both receptors of phage 
T2 indicates that our method should allow for the identification of multiple receptors. Therefore, 
it is likely that the receptor for phage P2 is one of the 31 outer membrane genes that was not 
represented in the original TMP; it is possible that a transposon mutant library with higher 
saturation would allow for the identification of the phage P2 receptor.  However, it is also possible 
that an essential gene encodes the receptor for phage P2 which would not be included in a 
transposon mutant library. 
In all screens performed, whether well-characterized phage or newly-isolated ones, lon::Tn 
was consistently the top hit (Figure 2.3 and Supplemental Figure S2.3). As lon encodes the Lon 
protease which functions in the cytoplasm, it was not considered a candidate receptor hit and no 
follow up was conducted. However, mutations in lon that disrupt the proteolytic function result in 
accumulation of rcsA, an activator of capsular polysaccharide biosynthesis 130. Therefore, it is 




Based on these screens, it is possible that mutations in lon result in a smaller fitness cost than 
mutations in genes that code for phage receptors. This result will be explored further in future 
studies.  
Discussion 
INSeq screens were successful in identifying candidate phage receptors for five out of six 
previously uncharacterized phage and further analysis of specific hits confirmed that the top hit(s) 
identified in the screens were the phage receptor(s). We note that our approach is designed to 
identify the receptor(s) used by a phage when interacting with the single bacterial strain. However, 
this method could be employed in multiple different strains of bacteria in order to identify receptors 
for different hosts a for phage that encode multiple tailspikes that permit infection across multiple 
bacterial hosts 131. 
Interestingly, each of the phage receptors identified in this study have been identified as 
receptors for other phage 132. With 137 annotated membrane proteins and a branching LPS chain 
consisting of 10 sugar monomers with various phosphate groups in E. coli BW25113, it is 
surprising that previous reviews on phage receptors reported that only ~10 membrane proteins and 
various sugar linkages were exploited as phage receptors 132, 133. Furthermore, three out of five 
phages chosen randomly from our coliphage library used OmpC as a receptor in some capacity. 
These observations are interesting because the vast biodiversity of lytic phage suggests that these 
viruses may have evolved to exploit most, if not all, possible receptors on the surface of bacteria, 
implicating selection by these ‘predatory’ phage as a possible key driver of genomic diversity in 
bacteria 134. However, this expectation assumes that all cell-surface structures are equally suitable 
to serve as phage receptors in the eyes of natural selection. Rather, selection for phage to use a 




molecule on the surface and whether the protein is well-conserved among bacterial genotypes. 
Both OmpA and OmpC are reported to be among the top 20 most highly expressed proteins in E. 
coli, with 207,618 and 163,538 molecules per cell respectively 135. On one hand, with so many 
potential binding sites on the surface (~1 OmpA or OmpC molecule per 30 nm2), a bacterium is 
extremely vulnerable to attack by phage that bind to either OmpA or OmpC, suggesting that phage 
should be strongly selected to target these structures 136. However, on the other hand this creates 
the possibility for intense competition among phage that use common binding sites such as OmpA 
or OmpC, which likely results in selection for phages to exploit a less common receptor to reduce 
competition for hosts. Previously, phage receptors have been vastly understudied, likely because 
of the large effort required to screen phage on individual bacterial mutants. Thus, the higher-
throughput INSeq screen presented here demonstrates a method to rapidly identify phage 
receptors, fostering a broader possibility to efficiently explore the evolution of phage binding sites 
and inter-phage competition to use these receptors. This could be a key first approach in the 
ultimate study of whether virus evolution has resulted in some binding targets to be over- versus 
under-exploited in the phage world. 
Around the time of submission, both a paper came out and a preprint was posted describing 
similar methods for identifying genes involved in phage infection in Enterococcus faecalis and E. 
coli respectively 137, 138. However, there were some differences in outcomes among these studies 
which may reflect differences in the efficacies of the approaches. It would be interesting to 
compare these various methods in future work. 
Conclusion 
Transposon insertion sequencing is a powerful technique that allows for identification of bacterial 




identify phage receptors for multiple E. coli phage. Proof of concept experiments validated this 
approach by confirming known phage receptors. In particular, this method was successful in 
confirming receptors for previously well-characterized phage that use a single protein receptor, 
dual-protein receptors, a primary LPS receptor and secondary protein receptor, and LPS as 
receptor. This method was then extended to identify receptors for five out of six previously 
uncharacterized randomly-chosen phage. We expect that a more saturated transposon mutant 
library would allow for identification of the receptor for newly-discovered phage P2. Our approach 
was particularly promising, because for each screen that resulted in the successful protein receptor 
identification, the genes encoding the receptors were among the top hits for each phage. 
In addition to identifying phage receptors, our screens could provide information about the 
fitness of other bacterial genes in the presence of phage, such as bacterial genes that were involved 
in phage replication or resistance to phage. Thus, our approach might allow for identification of a 
subset of bacterial genes that are universally important during phage infection or resistance.  
While this study focused on phage receptors for viruses that infect E. coli, transposon-
insertion sequencing provides information for any transposon mutant in the TMP, and has been 
employed in many different species of bacteria 129, 139-142. Our new method for the high-throughput 
identification of phage receptors should allow for rapid characterization of newly isolated phage 
that target various different species of bacteria. If enough phage receptors are identified for 
sequenced phage, bioinformatic approaches might be extended to allow for receptor identification 
based on the genomes of phage alone. Furthermore, in addition to using INSeq screens to identify 
phage receptors, our screens provide information about the fitness of other bacterial genes in the 
presence of phage, potentially allowing for the identification of a subset of bacterial genes that are 




throughput identification of phage receptors, INSeq screens may provide insight into generalized 
mechanisms of phage resistance. 
Materials and Methods 
Bacterial strains, plasmids and phage 
Bacteria used in this study were obtained from the Coli Genetic Stock Center at Yale University, 
and phages T2, T4, T6 and T7 were kindly provided by J. Wertz (Yale U). The six uncharacterized 
phages in the study were isolated from sewage or environmental water samples. All bacteria, 
plasmid and phage strains are listed in Supplemental Table S2.1 of the Chapter 2 Appendix. 
Bacteria were cultured at 37oC with shaking (200 rpm) in Luria Broth (LB) and on LB agar (15%) 
plates, where dilutions in LB followed by plating were used to estimate bacterial densities as 
colony-forming units (CFU) per mL. Carbenicillin (Cb; 100µg/mL), gentamicin (Gm; 10 µg/mL), 
kanamycin (Km; 50 µg/mL), arabinose (0.1%) and isopropyl  b-D-1-thiogalactopyranoside (IPTG; 
1mM) were added when appropriate. Phage strains were amplified in shaking liquid culture 
overnight on the amplification host, BW25113DicdC (hereafter referred to as wild-type, WT), and 
filter sterilized with a 0.22µm filter to obtain a cell-free lysate. Titers were estimated as plaque-
forming units (PFU) per mL, and determined by plaques formed via dilution plating in ‘soft’ agar 
(7.5%) overlays on lawns of WT grown on agar plates, unless otherwise noted. 
INSeq transposon mutant library preparation 
The insertion-sequence (INSeq) transposon mutant library was made via conjugation. Donor 
bacterial strain S17 l pir 118 containing plasmid pSAM_PA 142 was conjugated with recipient strain 
WT on plates containing arabinose, at a ratio of 1:1 donor to recipient. After 3 hours incubation at 
37oC, conjugation mixtures were plated for single colonies on plates with Gm and Km to isolate 




37oC, colonies were scraped into LB medium using a sterile spatula and stored in 20% glycerol at 
-80°C. 
INSeq screen 
Aliquots of the library were thawed on ice, washed once in LB and resuspended to a concentration 
of approximately 107 CFU/mL in LB and incubated at 37oC for 1 hour, with shaking. A sample of 
test phage was added, in triplicate, to a final concentration of approximately 105 PFU/mL, for 
MOI» 0.01. Following overnight incubation, cultures were harvested and genomic DNA was 
extracted and prepared for sequencing 141. DNA libraries were pooled and sequenced at the Yale 
Center for Genome Analysis via the Illumina HiSeq2500 system. Sequences were analyzed using 
scripts modified from Goodman et al (2009). Briefly, using Python scripts adapted from analysis 
packages previously described 141, sequencing reads were indexed by barcode, and transposon 
sequence was trimmed leaving 16 base pairs of adjacent genomic DNA. These 16 base pair 
sequences were aligned to the reference genome (Genbank accession # CP009273.1) using 
Bowtie2, by counting the number of reads for each insertion site, normalizing to counts per million 
reads and binning by gene143. Transposon insertions mapping to the distal 5% ends of any coding 
region as well as transposon insertions mapping to intergenic regions were filtered out during 
analysis. A Z-test was performed using the log ratio of normalized output count to normalized 
input count, and Q-values from false discovery rate (FDR) correction of < 0.05 were considered 
significant for further analysis.  
Efficiency of plating, and adsorption assays 
Efficiency of plating (EOP) was measured as the ratio of the test phage titer on the experimental 
strain to its titer on the WT strain. Phage binding to cells (adsorption) was measured over a 20 










Chapter 2 Figures & Tables 
 
Figure 2.1 Design of INSeq screen 
 
Design of INSeq screen. A Experimental setup for selection of pooled transposon mutant library (TMP) with phage 






Figure 2.2 Genome plot of E. coli strain BW25113 
 
 
Genome plot of E. coli strain BW25113. Track 1 (inside) is a heat map of GC content, where red represents high GC 
content and blue represents low GC content. Track 2 plots the abundance of transposon insertions in a coding region 






Figure 2.3 Results of INSeq screen with well-characterized phage. 
 
Results of INSeq screen with well-characterized phage. Each point represents the normalized relative abundance of 
all transposon mutants in a specific gene. All statistically significant transposon mutants are grey (P < 0.05). Certain 
hits are colored; other mutants in regulatory genes are unfilled circles in the same color as the gene. A Results of a 
screen with phage T6. Significantly over-represented hits tsx::Tn, btuB::Tn, lamB::Tn, and ompX::Tn are in blue, 
orange, red and yellow respectively. B Results of a screen with phage T2. Significantly over-represented hits ompF::Tn 
and fadL::Tn in green and blue respectively. C Results of a screen with phage T4. Significantly over-represented hit 
ompC::Tn is in purple. D Results of screen with phage T7. E Log ratio (A) of relative abundance of 106 transposon 




Figure 2.4 Assays validating phage receptors of well-characterized phage 
 
Assays validating phage receptors of well-characterized phage. A Efficiency of plating (EOP) assays for phage T6 on 
various E. coli strains. EOP was calculated as a ratio of titer on test strain to the titer on WT (BW25113 DicdC). EOPs 
are plotted as mean and standard deviation of three independent experiments. Significance was calculated using T-test 
as significantly different from 1. “<200” indicates that the titer on the test strain was below the limit of detection for 
this assay which was 200 PFU/mL. B Adsorption assays of phage T6 on various E. coli strains plotted as a log of the 
percent of free phage. Dashed lines indicate stains with an empty vector (pSF) or a complement vector (pSF-tsx) 
grown in the presence of 100 mg/L carbenicillin with induction by 1mM IPTG. Percent free phage was determined as 
a ratio of free phage at the time point divided by total phage added at the beginning of the assay and is plotted as a 
mean and standard deviation of three independent experiments. Linear regression was performed for each strain. 
Regression lines with a significantly non-zero slope indicate that the particular strain is able to support phage T2 
adsorption. C EOP assays for phage T2 on various E. coli strains. D Adsorption assays of phage T2 on various E. coli 
strains.  E EOP assays for phage T4 on various E. coli strains. F Adsorption assays of phage T4 on various E. coli 
strains. G LPS phage inactivation assays for phage T2, T4 and T7. Titers for each phage was determined after a 20 




three independent experiments. A T-test was used to determine significant differences between the mock condition or 






Figure 2.5 Results of INSeq screen with uncharacterized phage. 
 
Results of INSeq screen with uncharacterized phage. Log ratio (A) of relative abundance of 106 transposon mutants 
in genes encoding membrane proteins for each screen with uncharacterized phage. Grey represents statistically 
significant hits, other top hits ompA::Tn, tsx::Tn, ompC::Tn, and lamB::Tn are in green, blue, purple and red 





Figure 2.6 Assays validating phage receptors of newly isolated phage 
 
Assays validating phage receptors of newly isolated phage. A Efficiency of plating (EOP) assays for phage R3 on 
various E. coli strains. B Adsorption assays of phage R3 on various E. coli strains plotted as a log of the percent of 




E. coli strains. E Efficiency of plating (EOP) assays for phage 8S on various E. coli strains. F Adsorption assays of 
phage 8S on various E. coli strains plotted as a log of the percent of free phage. G EOP assays for phage EC35 on 
various E. coli strains. H Adsorption assays of phage EC35 on various E. coli strains. I EOP assays for phage EC145 
on various E. coli strains. J Adsorption assays of phage EC14 on various E. coli strains. (* indicates p < 0.05, ** 





Table 2.1 List of genes encoding membrane proteins 
 
List of genes encoding membrane proteins. Bolded genes are not included in the TMP. A * indicates essential genes 
  
acrZ envY mdtQ pgaA yaiW ynfB
amiD fadL mepS pgaB ybgQ ypjA
appX fecA mipA pgpB ybhC ypjB
bamA* fepA mlaA phoE yceK yqhH
bamB fhuA mliC pldA ychO yraJ
bamC fhuE mltA ppk yddB yraP
bamD* fimD mltB pqiC yddL* yzcX
bamE fiu mltC qseG ydeT
bcsC flgG mltD rcsF ydiY
bglH flgH mltF rhsB yehB
bhsA flu nanC rhsD yfaL
blc gfcD nfrA rlpA yfaZ
borD gfcE nlpD rsxG yfcU
btuB gspD nlpE rzoD yfeN
chiP hofQ nlpI rzoR yfgH
cirA htrE ompA sfmD yfiB
csgB lamB ompC skp yghG
csgE loiP ompF slp ygiB
csgF lolB ompL slyB yhcD
csgG lpoA ompG tamA yiaD*
cusC lpp ompN tamB yiaT
ecnA mdtP ompT tolC yjbF
ecnB lpoB ompW tsx yjbH
ecpC lptA* ompX uidC yjgL
elfC lptD* pagP wza yliI




Chapter 2 Appendix 
Supplemental Results 
Efficiency of plating and adsorption assays confirm known receptors for characterized 
phages  
Plaques of phage T6 were below the limit of detection (200 PFU/mL) on bacterial strain 
BW25113Dtsx and complementation with plasmid pSF-tsx restored plaquing to similar levels as 
on WT (Figure 2.4 A). Phage T6 did not adsorb to BW25113Dtsx, however adsorption was restored 
upon complementation (Figure 2.4 B). While these results, along with previous literature, 
demonstrate the ability of phage T6 to use Tsx as a receptor, EOP and adsorption assays were run 
on the other enriched membrane genes from the screen. As expected, phage T6 had an EOP similar 
to WT and adsorbed to BW25113DompX, BW25113DlamB and TA563btuB::Tn (Figure S2.2 
A,B), indicating that these genes were not involved in phage binding. 
Both BW25113DompF and BW25113DfadL were able to support phage T2 infection and 
replication at a similar level as WT (Figure 2.4 C). However, on a double knockout 
(BW25113DompFDfadL), phage T2 plaques were below the limit of detection, indicating that host 
bacteria lacking both ompF and fadL genes were unable to support phage infection and replication. 
Infection of phage T2 was restored through complementation of either OmpF or FadL in 
BW25113DompFDfadL (Figure 2.4 C). Phage T2 did not adsorb to BW25113DompFDfadL 
(Figure 2.3 D) in the time allowed in the assay. In contrast, adsorption was restored upon 
complementation with either OmpF or FadL (Figure 2.4 D). These results, combined with the 
aforementioned inability to detect phage T2 plaques on strain BW25113DompFDfadL, strongly 





We similarly analyzed whether our approach accurately identified known binding 
mechanisms for phage T4. Results for phage T4 (Figure 2.4 E) showed virus infection of 
BW25113DompC was below an EOP of 1.0, but was not significantly different from the 
complemented strain or the complemented control. Adsorption of phage T4 (Figure 2.4 F) to strain 
BW25113DompC was diminished and could be rescued upon exogenous expression of OmpC. 
However, phage T4 could use LPS as a co-receptor and therefore could still infect 
BW25113DompC as seen in the EOP assay. The results of the EOP and adsorption assays 
corresponded with previous observations in the literature that phage T4 uses OmpC to reversibly 
bind cells and increase efficiency of adsorption while irreversibly binding LPS a co-receptors110, 
130. 
Last, we conducted experiments to verify that our method produced results consistent with 
known receptor usage of phage T7. Instead of traditional EOP or adsorption assays with isogenic 
strains of E. coli, purified LPS was used to determine if LPS was a receptor for phage T7. 
Incubation of phage T7 with 80 ng/mL of LPS resulted in observed reduction in phage titer (Figure 
2.4 G) as compared to incubation of phage with no LPS, which indicated that phage T7 could use 
LPS alone as a receptor. Interestingly, there was no observed drop in titer when phage T4 was 
incubated with LPS even though phage T4 could infect cells in the absence of OmpC (Figure 2.4 
G). The results of the adsorption assay indicated that phage T4 did not appreciably adsorb to 
BW25113DompC over a 20 minute period. Therefore, perhaps longer incubation of phage T4 with 





Supplemental Data 1 can be found on Dryad (doi:10.5061/dryad.t76hdr7z3). Statistically 
significant hits for each phage screen with the Q- value, log ratio of output to input counts (A), 
Gene ID, and gene name. X indicates that the hit was either enriched in the output or in a gene 





Supplemental Figure S2.1 Results of a control INSeq screen 
 
Results of a control INSeq screen. Each point represents the normalized relative abundance of all transposon mutants 





Supplemental Figure S2.2 Additional assays validating phage T6 receptor 
 
Additional assays validating phage T6 receptor A Efficiency of plating (EOP) assays for phage T6 on various E. coli 
strains. B Adsorption assays of phage T6 on various E. coli strains plotted as a log of the percent of free phage. (* 





Supplemental Figure S2.3 Results of INSeq screen uncharacterized phage 
 
Results of INSeq screen uncharacterized phage. Each point represents the normalized relative abundance of all 
transposon mutants in a specific gene. All statically significant transposon mutants are grey (P < 0.05). Certain hits 
are colored; other mutants in regulatory genes are triangles in the same color as the gene they regulate. A Results of a 
screen with phage R3. Significantly over-represented hit ompA::Tn is in green. B Results of a screen with phage U115. 
Significantly over-represented hits tsx::Tn and lamB::Tn in blue and red respectively. C Results of a screen with phage 
P2. D Results of screen with phage 8S. Significantly over-represented hits ompC::Tn and lamB::Tn in blue and red 
respectively. E Results of screen with phage EC35. Significantly over-represented hits ompC::Tn and lamB::Tn in 
blue and red respectively.  F Results of screen with phage EC14. Significantly over-represented hits ompC::Tn and 




Supplemental Figure S2.4 Assays examining phage receptors of newly isolated phage 
 
Assays examining phage receptors of newly isolated phage. A Efficiency of plating (EOP) assays for phage P2 on 
various E. coli strains. B Adsorption assays of phage P2 on various E. coli strains plotted as a log of the percent of 
free phage. C LPS phage inactivation assays for phage R3, U115, P2, 8S, EC35 and EC14. Titers are plotted as means 
with standard deviation from three independent experiments. A T-test was used to determine significant differences 





Supplemental Table S2.1 Bacterial strains, plasmids and phage used in this chapter 
  





TMP GmR, KmR This study
BW25113DompA KmR CGSC
BW25113DompA ::pSF_empty KmR, CbR This study
BW25113DompA ::pSF_ompA KmR, CbR This study
BW25113DompF KmR CGSC
BW25113∆fadL KmR CGSC
BW25113DompF∆fadL KmR This study
BW25113DompF∆fadL ::pSF_empty KmR, CbR This study
BW25113DompF∆fadL ::pSF_ompF KmR, CbR This study
BW25113DompF∆fadL ::pSF_fadL KmR, CbR This study
BW25113DompC KmR CGSC
BW25113DompC ::pSF_empty KmR, CbR This study
BW25113DompC ::pSF_ompC KmR, CbR This study
BW25113DlamB KmR CGSC
BW25113DlamB ::pSF_empty KmR, CbR This study
BW25113DlamB ::pSF_lamB KmR, CbR This study
BW25113DompC∆lamB KmR This study
BW25113∆ompC∆lamB ::pSF_empty KmR, CbR This study
BW25113∆ompC∆lamB ::pSF_ompC KmR, CbR This study
BW25113∆ompC∆lamB ::pSF_lamB KmR, CbR This study
BW25113Dtsx KmR CGSC
BW25113Dtsx::pSF_empty KmR, CbR This study
BW25113Dtsx::pSF_tsx KmR, CbR This study
BW25113DompX KmR CGSC
TA563(btuB ::Tn) TetR CGSC
Plasmid Antibiotic Resistance Source
pSF_empty AmpR Oxford Genetics (OGS634)
pSF_ompA AmpR This study
pSF_ompC AmpR This study
pSF_ompF AmpR This study
pSF_fadL AmpR This study
pSF_lamB AmpR This study
pSF_tsx AmpR This study
Phage Source
T2 J. Wertz (Yale U)
T4 J. Wertz (Yale U)
T6 J. Wertz (Yale U)







GmR, gentamicin resistant; KmR, kanamycin resistant; CbR, carbenicillin resistant; TetR, tetracycline 










Chapter 3: Phenotypic variation among Pseudomonas aeruginosa populations when 







Chapter 3 has been adapted from a manuscript that is intended for submission to Journal of 
Evolutionary Biology in Summer, 2021. 
This study was designed by Kaitlyn Kortright and Dr. Benjamin Chan. Kaitlyn Kortright 
and Dr. Benjamin Chan preformed experiments. Kaitlyn Kortright analyzed data. The manuscript 
was prepared and edited by Kaitlyn Kortright, Dr. Benjamin Chan and Dr. Paul Turner. Raw 
sequencing will be publicly available at NCBI Sequence Read Archive Project # PRJNA713810. 
This project was supported by an award from Cystic Fibrosis Foundation, and a portion of the 






Experimental evolution studies have long been used to examine coevolutionary dynamics between 
phages and bacteria; however, here we extend traditional coevolution studies to examine 
both coevolutionary dynamics of phage OMKO1 and Pseudomonas aeruginosa and the evolution 
of an anticipated trade-off between phage resistance and antibiotic resistance in the bacteria. We 
observed that lytic phage OMKO1 and P. aeruginosa are able to coexist over a 10-passage 
evolution experiment, and ‘time-shift’ assays revealed that coevolutionary dynamics of the two 
microbes followed an arms-race pattern of coevolution with slight differences in dynamics across 
all three experimental populations. Measurements of antibiotic resistance at both clonal and 
population levels demonstrated that one experimental population evolved phage resistance at the 
expense of decreased resistance to tetracycline and erythromycin antibiotics (evolutionary trade-
off), whereas the other two P. aeruginosa treatment populations did not suffer the predicted trade-
off. Whole genome sequencing of bacterial populations revealed that treatment populations 
accrued greater mutational differences relative to the wild-type ancestor, compared to a control 
where bacteria evolved in absence of phage selection. In each treatment population, mutations 
were found in genes involved in biosynthesis of flagella, type-IV pilus and lipopolysaccharide; no 
mutations in these genes were observed in the control. In the bacterial population that showed a 
trade-off, results indicated three mutations in fleQ, wzz1 and wzz2, that swept to fixation at the 
same passage when the phage-resistance/antibiotic-resistance trade-off was observed. Results of 
this coevolution experiment remind that predicted evolutionary trade-offs may not always occur, 
and that in-vitro experimental studies of phage-bacteria interactions are valuable for elucidating 






It is estimated that Earth contains a staggering 1030 bacterial cells, and these are even outnumbered 
roughly tenfold by bacteriophages (phages; viruses of bacteria) that specifically infect them 145. 
Although these ubiquitous microbes form the bases of ecosystems, details of their coexistence and 
antagonistic coevolutionary interactions remain understudied. Nevertheless, the limited studies 
demonstrate that phage-bacteria associations have significant and widespread implications, 
including biogeochemical cycling of carbon, nitrogen, and phosphorus in oceans; regulating 
primary production in ecosystems; dictating flamingo population crashes 146; and developing 
antibacterial therapies. Phage therapy, the therapeutic use of phages to treat bacterial infections, is 
increasingly being considered as an adjunctive approach to treat multi-drug resistant bacterial 
infections. However, without rigorous studies of the coevolutionary details of phage-bacteria 
interactions, such treatments may yield unanticipated outcomes. Experimental evolution studies 
could benefit the re-emerging field of phage therapy, by describing the evolutionary dynamics that 
occur when bacteria are subjected to phage selection pressures. Additionally, experimental 
evolution studies might inform both the repeatability and predictability of the outcomes of these 
treatments. If phage therapy is to be used successfully, it is crucial to better understand the 
dynamics of phage-bacteria coevolution. 
Lytic phages exert selection pressure on bacteria to evolve resistance; in response, resistant 
bacteria select for phages to evolve improved infectivity. This reciprocal selection can produce 
two types of antagonistic coevolution: arms race dynamics (ARD) versus fluctuating selection 
dynamics (FSD). ARD follows a classic ‘gene-for-gene’ model where one bacterial genotype has 
a broad resistance (and one phage genotype has very broad infectivity), meaning that the bacteria 




the phage-bacteria relationship 147. In contrast, coevolution via cyclical fluctuations in allele 
frequencies is the basis of FSD, which follow matching-allele models of coevolution 148, 149. Here, 
phage infectivity (or bacterial resistance) requires a specific match between the bacterial and phage 
genotypes, and polymorphism is maintained by negative frequency-dependent selection. Theory 
predicts that environments with weaker costs of resistance/infectivity should produce ARD, 
whereas those with stronger costs should foster FSD; ARD are seen in many phage-bacteria 
coevolution studies 150-153 with fewer showing FSD 154, 155 suggesting that the cost of evolution of 
phage resistance tends to be weak under laboratory conditions. However, if a trade-off exists 
between phage resistance and another phenotypic trait, there might be a greater cost to phage 
resistance than previously observed.  
Phage OMKO1 is a ‘jumbo phage’ of Pseudomonas aeruginosa that selects for phage 
resistant bacteria with increased sensitivity to traditional antibiotics 64. This observed trade-off 
between phage resistance and antibiotic resistance may be explained by the binding of phage 
OMKO1 to the surface exposed outer membrane component, OprM, of one of the multi drug efflux 
pump systems (MexAB-OprM) in P. aeruginosa. However, recent evidence suggests that OMKO1 
is either plastic or highly evolvable in its binding, perhaps using the type-IV pilus or flagellum as 
a receptor instead of OprM (unpublished data). Here, we conducted a short-term (10 passage) 
laboratory coevolution experiment with replicate communities of phage OMKO1 and P. 
aeruginosa strain PA01, to determine (1) if phage OMKO1 and the host bacteria can coexist over  
approximately 100 bacterial generations, (2) whether ARD or FSD govern the coevolutionary 
trajectories, (3) if a trade-off between phage resistance and antibiotic resistance occurs, and (4) 





Bacteria and lytic phages coexist for the duration of a short-term coevolution experiment  
A short-term (10-passage) serial-transfer experiment (as described in the Methods) was conducted 
with P. aeruginosa strain PA01 and lytic phage OMKO1, to test whether the microbes could 
coexist and to look for evidence that coevolution occurred (Figure 3.1). All three treatment 
communities (bacteria plus phages) presented generally lower bacterial densities in the first half 
of the study (days 1 to 5), compared with maximum densities achieved by bacteria in the one 
control containing bacteria alone, which was numerically stable throughout (Figure 3.2A). 
Furthermore, all of the treatments experienced decreases in bacterial density that were not evident 
in the control; the bacteria fell to a low density in all treatments at passage 2; in treatments 1 and 
2 at passage 5; and in treatment 3 at passage 6. Interestingly, the lower bacterial densities in 
treatment 1 at passages 2 and 5 correlate with higher phage titers at these same time points (Figure 
3.2B), with phage titer becoming stable around 109 PFU/mL for the remainder of the study. The 
phage titers of the other two treatments tracked with each other; after a large increase in titer at 
passage 1, phage titers in treatments 2 and 3 steadily decreased until passage 9, such that all three 
treatments ended with 109 PFU/mL (Figure 3.2B). We concluded that PA01 bacteria and phage 
OMKO1 were capable of coexisting throughout the 10-passage study, indicating that reciprocal 
coevolution was at least possible during the short-term experiment. 
Coevolutionary timeline of PA01 and OMKO1 occurs differently in three populations 
To determine if bacteria in experimental treatments were evolving to resist phages, the fitness 
(fitness = OD600challenge / OD600LB) of 96 randomly-sampled bacterial clones was assayed as 
described in the Methods. As expected, bacterial clones from the control showed lower fitness in 
the phage challenge than bacterial clones from the treatments, which were subjected to phage 




passages of each treatment population were less-fit in the phage challenge, than bacterial clones 
from the same treatment isolated during later passages (Figure 3.3A-C). Fitness of bacterial clones 
from treatment 1 and 2 increased markedly from passages 2 to 3 (Figure 3.3A,B). While the fitness 
of bacterial clones from treatment 1 remained stable for the rest of the experiment, the fitness of 
bacterial clones from treatment 2 seemed to decrease slightly in the later passages (Figure 3.3A,B). 
The fitness of bacterial clones from treatment 3 increased gradually over the 10 passages, without 
the dramatic ‘jump’ upwards in fitness observed in treatments 1 and 2 (Figure 3.3C). We concluded 
that fitness of treatment bacteria in a phage challenge increased over time, indicating evolution of 
phage resistance in P. aeruginosa tended to occur in the presence of phage OMKO1 selection. 
To examine whether phages in the treatments changed in terms of their host range, phages 
at each passage were assayed for their ability to infect the ancestral PA01 used to initiate the 
experiment. Impact of phages on the growth curves measured for test bacteria were used to 
examine whether viruses changed in their killing efficiency. Results showed that phages in the 
earlier passages were better able to suppress (negatively-impact) bacterial growth, compared to 
those isolated in later passages (Figure3.4A-C). The maximum OD600 value of the test bacteria 
was extracted from each growth-curve dataset, to better-visualize the reduced fitness of passaged 
phages when allowed to infect the ancestral bacteria. Phages from passage 1 of treatment 1 
suppressed bacterial growth (OD600 of ~0.5), while later-passage phages allowed the ancestral 
bacteria to achieve OD600 of approximately 0.9 (Figure 3.4D). Phages from treatments 2 and 3 
caused less-dramatic fitness reductions on ancestral bacteria, with earlier passages (1 through 4) 
suppressing bacterial growth at OD600 of approximately 0.35, and later passages (5 through 10) 




fitness, as measured by the ability to infect ancestral PA01, decreased over time in all treatments, 
indicating that phage evolution had occurred. 
Coevolutionary dynamics were investigated using time shift assays, where the bacteria 
obtained at each passage were cross-streaked against the phages from each passage to ascertain 
bacterial resistance and phage infectivity. In general, bacteria from each treatment were more 
resistant to phages of the past, and more sensitive to phages from future passages (Figure 3.5A). 
Correspondingly, phages were more infective on bacteria of the past, and less infective on bacteria 
of the future (Figure 3.5B). Some bacteria from treatments 2 and 3 were sensitive to phages from 
the past, specifically 6, 7 or 8 passages prior to the contemporary phages; whereas, in treatment 1 
some bacteria were resistant to phages of the future (Figure 3.5A). Time-shift assays for each of 
the treatments were consistent with expectations of ARD coevolution. 
Trade-off between phage resistance and antibiotic resistance occurs in one population 
To determine if the evolution of phage resistance resulted in a trade-off with resistance to 
antibiotics, the 96 bacterial clones from each passage that were assayed for fitness in the presence 
of contemporary phages (Figure 3.3) were similarly assayed for fitness in 3mg/L of tetracycline. 
Over the course of ten passages, fitness in tetracycline of treatment 2, treatment 3 and the control 
either didn’t change or increased slightly as seen by a positive slope of the regression line (Figure 
3.6B-D). However, fitness of treatment 1 in the presence of tetracycline appeared to decrease over 
the ten passages; more specifically, bacterial clones taken from passages 8, 9 and 10 have a lower 
fitness than clones taken from earlier passages (Figure 3.6A). These results were confirmed using 
both Etest strips and two-fold dilutions to measure the minimum inhibitory concentrations (MIC’s) 
of various antibiotics for bacteria taken from each passage. MIC measurements made using Etest 




lower MIC to tetracycline and erythromycin (Supplemental Figure S3.2A,B) but remain resistant 
to ampicillin (Supplemental Figure S3.2C). Additionally, to determine the MIC needed to kill 90% 
of bacteria (MIC90), bacterial from each treatment were plated on a range of two-fold dilutions of 
tetracycline (4 and 8 mg/L), erythromycin (64, 128 and 256 mg/L), meropenem (0.25 and 0.5 
mg/L) and gentamicin (0.5, 1 and 2 mg/L). MIC90 of gentamicin and meropenem (Supplemental 
Table S3.1) remain unchanged over the 10 days of passages, however, MIC90 of tetracycline and 
erythromycin (Supplemental Table S3.1) trend down for treatment 1 at the latter passages (days 7-
10) as compared to the control. Taken together, these results show preliminary evidence that a 
trade-off between phage resistance and antibiotic resistance may have occurred for treatment 1 but 
not for treatment 2 or 3. 
Genomics reveals likely loci undergoing change 
Deep sequencing (DS) of bacterial populations from each passage was used to examine the 
genetics underlying the observed ARD coevolution. Frequencies of high-quality variants in coding 
regions that differed from the common ancestor’s genome were plotted as heat maps for each of 
the treatments and control (Supplemental Figure S3.3). Treatment 1 showed the greatest number 
of alleles that differed from the ancestor (n=288); furthermore, the number of mutations was 
elevated at passages 1 and 2 (n=84 and 87, respectively), while the number of such mutations 
decreased in future passages (Supplemental Figure S3.3A). Treatments 2 and 3 had fewer sites that 
changed (n=125 and n=163 respectively) and the number of mutations did not deviate throughout 
the experiment (Supplemental Figure S3.3B,C). As expected, the control had the fewest number 
of allele changes (n=115) and the number of mutations did not vary across passages (Supplemental 
Figure S3.3D). The majority of the mutations observed in each treatment and the control were 




and 2 did not have any fixed synonymous mutations (Ds) while treatment 3 and the control had 2 
Ds mutations each (Table 3.1). Treatment 1 and 3 had 9 mutations each that were fixed and non-
synonymous (Dn) while treatment 2 and the control had 7 Dn mutations each (Table 3.1). 
Additionally, DS and analysis was used to identify a subset of the genetic variations, 
specifically variants in genes common to the treatments but not observed in the control. Treatments 
1 and 2 had mutations in genes involved in type-IV pilus biogenesis; these bacterial populations 
shared 4 point mutations (three of which were non-synonymous) in pilB that were low frequency 
variants at passages 1 and 2 (Figure 3.7A,B and Supplemental Table S3.2). Treatment 2 had an 
additional two non-synonymous point mutations in fimU that fixed at passage 3 and 4, but were 
subsequently lost from the population (Figure 3.7B and Supplemental Table S3.2). No mutations 
in type-IV pilus biogenesis genes were observed in treatment 3 or control bacteria (Figure 3.7C 
and Supplemental Table S3.3).  
All three treatments showed bacteria with mutations in flagellar biosynthesis genes. 
Treatment 1 had two non-synonymous mutations in fleQ, three indels in fleS, and two point 
mutations in fliI (Figure 3.7A and Supplemental Table S3.2). Treatment 2 bacteria had a single 
point mutation in fleQ that fixed at passage 3 and remained at high frequency until passage 8 
(Figure 3.7B and Supplemental Table S3.2). Bacteria from treatment 3 had two mutations in fleQ 
and an insertion in fleR, all three of which rose independently to high frequency for a single passage 
(Figure 3.7C and Supplemental Table S3.2). No mutations in flagella biosynthesis genes were 
observed in the control.  
Finally, each treatment population showed mutations in multiple genes involved in both 
A-band and B-band lipopolysaccharide (LPS) biosynthesis. Treatment 1 bacteria had a high 




and low frequency mutations in wbpX and wbpZ towards the end of the experimental evolution 
(Figure 3.7A and Supplemental Table S3.2). Treatment 2 had mutations in wbpX and gmd that 
were observed during passages 6 and 7-8 respectively (Figure 3.7B and Supplemental Table S3.2). 
Treatment 3 bacteria had mutations in wbpY (passage 6) and wzt (passage 9-10) (Figure 3.7C and 
Supplemental Table S3.2). All three treatments had bacteria with multiple non-synonymous wzz1 
and wzz2 mutations that occurred over the course of the experiment. No mutations were observed 
in any genes involved in LPS synthesis in the control (Supplemental Dataset S1). A complete list 
of mutational variants observed in each population can be found in Supplemental Dataset S1. 
Discussion 
Bacterial densities and phage titers (Figure 3.2) showed that it was possible for lytic phage 
OMKO1 and P. aeruginosa host bacteria to coexist for the entirety of a short-term experiment. 
Fitness challenges in the presence of phages (Figure 3.3) showed that bacteria from treatment 
populations were able to evolve resistance (achieve high fitness) to contemporary phages, while 
bacteria from the control remained highly susceptible (low fitness) to phage infection. 
Furthermore, decreases in phage titers (Figure 3.2B) for each treatment population seemed to 
correlate temporally with the evolution of phage resistance in each bacterial population (Figure 
3.3). These population dynamics are most clearly seen in treatment 1; phages from treatment 1 
monotonically decreased from passages 1 to 4 (Figure 3.2B, blue) while bacteria from treatment 1 
shift from phage-susceptible at passages 1 and 2 to phage-resistant at passages 3 and 4 (Figure 
3.3A). However, the titer of treatment 1 phages rebounded after passage 4, likely indicating that 
the phage population had evolved to infect the phage-resistant bacteria. Taken together, these 
results indicated that bacteria from the treatments containing phages evolved resistance to phages. 




phages were evolving in response to bacterial evolution, or that bacteria had not evolved complete 
phage resistance. Results (Figure 3.4) seemed to indicate that phages had evolved decreased 
infectivity on ancestral PA01 bacteria. This was likely due to phage evolution of increased 
infectivity on coevolving bacterial populations (phages were evolving to infect bacteria that were 
evolving to resist phages). Time shift assays (Figure 3.5) helped illuminate the dynamics of the 
coevolution that appears to have occurred in the experimental treatments; bacteria were more 
resistant to phages of the past and more sensitive to future phages (Figure 3.5A); and phages were 
more infective to past bacteria and less infective to those of the future (Figure 3.5B). These results 
were consistent with predictions of ARD. However, there were some instances in treatment 1 
where bacteria were resistant to future phages, and in treatments 2 and 3 there were phages that 
could successfully infect future bacteria. While the coevolutionary dynamics seemed to follow 
patterns generally indicative of ARD, during some passages, FSD may have occurred instead. 
All three treatments contained bacterial populations that became resistance to phages; 
however, the previously observed trade-off between phage-resistance and antibiotic-resistance was 
only observed in treatment 1 (Figure 3.6, Supplemental Figure S3.2 and Supplemental Table S3.1). 
This result is curious as each population originated from the same ancestral bacterial clone, 
experienced the same selection pressures, and evolved phage-resistant bacteria over time. 
Previously, reduced MIC was observed for individual clones of bacteria that evolved resistance to 
phage OMKO1, originating both from phage selection on standing genetic variation in the bacteria 
and when P. aeruginosa was subjected to short-term experimental evolution 64, 156. This offers two 
possible explanations for the non-observed trade-off in treatments 2 and 3. In this study, instead 
of measuring MIC using individual clones, MIC was measured at the population level. It is possible 




making measurements at the population level. Additionally, during the short-term coevolution 
study, individual bacterial clones in each experimental population experienced selection by co-
evolving phages, but also contended with other bacterial competitors in the population. Different 
bacterial genotypes present in the population likely had differing relative finesses to each other. 
Perhaps the trade-off is less likely to occur when bacteria are forced to contend with multiple 
selection pressures, due to differences in relative fitness of individual bacterial clones. 
Genomics may also help explain why the trade-off was only observed in one bacterial 
population. Results showed that there was more genetic variance in the treatment populations than 
in the control. Furthermore, bacteria in treatment 1, the only population where the trade-off was 
observed, had the most variants, particularly at passages 1 and 2 prior to the evolution of phage 
resistance in that treatment (Figure 3.3A). This greater genetic variation likely contributed to a 
higher likelihood of mutations present that increased individual fitness in the local environment; 
it is possible that this greater genetic variation, early in the experiment for treatment 1, contributed 
to the evolution of the observed trade-off between phage resistance and antibiotic resistance.  
The observed changes in allele frequency over the course of the experiment demonstrated 
that all three treatment populations, as well as the control, underwent microevolution. A higher 
ratio of Dn/Ds than Pn/Ps for each treatment as well as the control indicated that these populations 
were likely undergoing positive selection 157. During positive selection, also known as Darwinian 
selection, certain genotypes are beneficially advantaged and can sweep to fixation, as opposed to 
negatively selected (i.e., purifying selection) where deleterious genotypes removed from the 
population. In the context of coevolution, positive selection is indicative of ARD while negative 
section is indicative of FSD. This supports the conclusions made from the time-shift assays (Figure 




Additionally, bacterial genomics revealed the loci that changed and likely contributed to 
phage resistance and to the trade-off observed in treatment 1. The treatment populations showed 
variants in genes involved in the biosynthesis of type-IV pilus, flagella and LPS, while the control 
presented no variants in these genes (Figure 3.7, Supplemental Table S3.2 and Supplemental 
Dataset S1). The treatment populations did not have any high frequency variants in multi-drug 
efflux genes such as oprM, the predicted receptor for phage OMKO1. Unpublished data suggests 
that unselected variants of phage OMKO1 use the type-IV pilus or the flagella of PA01 as 
receptors. This is interesting considering the convergence of variants with type IV pilus and 
flagella changes observed multiple times in the treatments. Transcriptional activator FleQ 
regulates FleRS a two-component regulatory system that controls flagellar biosynthesis; each 
population has a mutation in at least one of these genes that is fixed for one or more passages at 
some point over the course of the experiment 158-160. Treatments 1 and 2 had low frequency variants 
in pilB, mutants of which are defective in pili biogenesis, at early passages 161. Treatment 2 had an 
additional mutation in fimU, part of the prepilin operon, which was fixed at passage 3 and 4 162. 
Together, these mutations indicate that perhaps more variants in the phage population were using 
pili or flagella as receptors instead of the expected receptor, OprM. Further sequencing and 
analysis of phage genomes could uncover tail-fiber mutations that confirm this hypothesis. All 
three treatment populations had many mutations in various genes involved in LPS biosynthesis, 
particularly in genes involved in both A-band and B-band O-antigen synthesis and chain length 
regulation (wzz1, wzz2, wzy, wbpX, wbpY, wbpL and wbpZ) 163-167. While phage OMKO1 is not 
expected to use LPS as a receptor, defects in LPS have been shown to result in a loss of both 




Many of the mutations discussed above were observed transiently in treatments 2 and 3. 
However, treatment 1 had three mutations (A1188191G, G3546149A, and C1028191CG in fleQ, 
wzz1, and wzz2 respectively) that rose to high frequency or fixed in passages 7 through 10 (Figure 
3.7A), making it possible that these mutations are linked together on a single genotype that is at 
high frequency in the population. Furthermore, the timing of these mutations corresponds with the 
observation of the trade-off between phage resistance and resistance to tetracycline and 
erythromycin (Figure 3.5A), indicating that these mutations might be responsible for the trade-off 
in treatment 1. Loss of the O-antigen has been previously implicated in alteration of membrane 
permeability, due to the hydrophilic nature of the O-antigen 168. Therefore, it is possible that the 
mutations in wzz1 and wzz2 are contributing to the trade-off observed between phage resistance and 
sensitivity to erythromycin, a hydrophobic antibiotic. This is in contrast to gentamicin where loss 
of the O-antigen has been shown to increase resistance to gentamicin; however, no change in 
resistance to gentamicin was observed in this study 169. It is not surprising that the trade-off was 
not observed for ampicillin, as resistance is usually driven by beta-lactamases present in the 
cytoplasm of the bacteria 170 and we did not expect phage selection to affect the expression of these 
enzymes. Resistance to meropenem and tetracycline is usually conveyed by the upregulation of 
multi-drug efflux pumps 170; as no efflux mutations were observed in treatment 1 at passages 7 
through 10, it is unsurprising we see no trade-off between phage resistance and meropenem 
resistance. However, resistance to tetracycline has also been reported to change with alterations in 
membrane permeability; therefore, it is possible that the same high-frequency mutations in wzz1 
and wzz2 are contributing both to the trade-off between phage resistance and erythromycin 




Further experiments, using genotyped clones from later passages of treatment 1, could confirm 
this observation and will be the goal of future studies. 
While the experimental evolution study presented here demonstrates that bacteria and lytic 
phages can both coexist and coevolve over a short time period, it also shows that there is more 
work to be done if we are to predict the outcomes of such interactions. Each treatment was initiated 
using identical starting material: media was taken from the same bottle, bacteria were taken from 
the same culture, and phages were taken from the same stock. We see the bacterial evolution of 
phage resistance, and convergence on a similar set of variants at the population level in the 
treatment populations. However, the bacterial phenotypes at the end of the 10-day passaging are 
not the same for each treatment population. Based on prior knowledge of phage OMKO1 selection 
resulting in a trade-off between phage resistance and antibiotic resistance, we expected to see this 
trade-off evolve in each treatment population 64. Instead, we observe this trade-off occurring only 
in bacteria from treatment 1. Although it is possible that the trade-off would have occurred in each 
treatment population if we had let the coevolution experiment play out for longer, the evolutionary 
dynamics occurring in treatments 2 and 3 seem to be occurring at a different pace than in treatment 
1, demonstrating that experimental evolution may not be as repeatable as previously thought 172. 
The population level approach combined with the high temporal and genomic resolution used in 
this study likely contributed to the observations that highlighted the irreproducibility of evolution 
seen between the three experimental populations 172, 173. This underscores the complexities 
involved in predicting evolutionary outcomes; even though the evolution that occurred in this study 
was repeatable to some extent, the predicted outcome of the evolution of phage resistance, namely 
the trade-off between phage resistance and antibiotic resistance, did not always occur. Clearly there 




Materials and Methods 
Strains and Culture Conditions 
P. aeruginosa strain PA01 and phage OMKO1 were the only microbes used in this study. All 
bacteria and phages were grown in Lysogeny Broth (LB) medium (10g tryptone, 5g yeast extract, 
10g NaCl per L). Bacteria were grown on 1.5% LB agar plates and phages were grown with 
bacterial lawns in 0.75% LB top agar.  
Experimental Evolution Design 
Three treatments (PA01 bacteria plus phage OMKO1) were established. At the start of the 
experiment, phages and bacteria were mixed together in a sterile flask at multiplicity of infection 
(MOI; ratio of phage particles to bacterial cells) of ~0.0001 initial concentration (i.e., 104 plaque-
forming units [PFU] of phage OMKO1 and 108 colony forming units [CFU] of PA01 bacteria per 
mL), in a final volume of 10 mL LB medium. One control (bacteria alone) was similarly 
established, without input phages. After overnight incubation at 37°C with 200 rpm shaking, each 
treatment and control was passaged 1:100 into a new sterile flask with 9.9mL fresh LB medium. 
This process of 1:100 serial transfer was repeated for a total of 10 experimental passages. 
Bacterial Phenotypic-Challenge Assays 
At each passage of the experimental evolution study, a sample from each overnight treatment and 
control was diluted and plated on LB agar; after overnight incubation at 37°C visible colonies 
formed. At random, 96 individual colonies were picked from each plate and resuspended in 200µL 
LB medium. The goal was to compare how 96 randomly-isolated colonies (clones) from each 
treatment and control grew across three different challenge environments, throughout the 
experiment; 3840 clones total were examined (96 clones from 4 treatments/control over 10 




well in each of three 96-well plates, which contained either LB medium, LB plus phage OMKO1 
at MOI greater than 10, or LB with 3mg/L tetracycline. The 96-well plates were then placed in a 
static 37°C incubator. After 18 hours, plates were removed from incubation and optical density at 
wavelength 600 nm (OD600) was measured for the bacteria in each well, using a spectrophotometer 
(Tecan Infinite F500 microplate reader). Fitness of a bacterial clone in the challenge environment 
(phage OMKO1; tetracycline) was defined as the observed OD600 in that environment divided by 
observed OD600 in the control environment (LB medium). Ratio estimates greater, equivalent and 
less than 1.0 indicated that the clone was more fit, equally fit or less fit in the challenge 
environment, respectively. 
Antibiotic Resistance Measurements 
The minimum inhibitory concentrations (MIC) of tetracycline, erythromycin and ampicillin 
antibiotics that were effective in impacting growth of a bacterial strain/population were determined 
using Etest strips (Biomerieux). Briefly, an overnight culture of bacteria was diluted to a 
McFarland standard of 0.5 and spread on Mueller-Hinton agar plates Agar (2g beef extract, 17.5g 
casein hydrolysate, 1.5g starch, 17.0g agar per L). The bacterial lawn was allowed to dry and an 
Etest strip containing was placed on top of the lawn. After overnight incubation at 37°C the plate 
was scored by recording the lowest concentration of antibiotic that inhibited growth (zone of 
clearing) of the bacterial lawn.  
The MIC necessary to inhibit the growth of 90% of a bacterial population (MIC90) was 
determined for tetracycline, erythromycin, gentamicin and meropenem using a direct plating 
method. Briefly, serial dilutions of a test bacterial culture were plated on LB plates and on LB 
plates containing a range of two-fold dilutions of each antibiotic (tetracycline: 4 and 8 mg/L; 




0.5 mg/L). After overnight incubation at 37°C, CFU were counted for each plate and MIC90 was 
recorded as the antibiotic concentration that reduced the number of CFUs to 10% or less of the 
CFU observed on LB without antibiotics. 
Sequencing and Variant Calling 
Bacterial genomes were extracted using a previously described protocol 141 and sequencing 
libraries were made using Nextera XT library preparation kits (FC-131-1096, Illumina). Paired-
end 150 base pair reads were generated on an Illumina HiSeq 2500 rapid run. High-quality reads 
were aligned to the PA01 reference genome (Genbank Accession # AE004091.2) using Bowtie2 
143. Variants were called using GATK 174. Only high-quality variants (GATK quality score > 200) 






Chapter 3 Figures & Tables 
Figure 3.1 Experimental setup of short-term coevolution experiment 
 
Experimental setup of short-term coevolution experiment. All populations were started from a clonal PA01 culture. 
Three treatment populations of phages and bacteria (blue, purple and green) were initiated at an MOI of ~0.0001. One 
control of bacteria only (grey) was started at the same time. All populations were passaged 1:100 every 24 hours into 




Figure 3.2 Bacterial density and phage titer 
 
Bacterial density and phage titer A Bacterial density measured as OD600 at the time of each passage for 10 days for 
treatment 1 (blue), treatment 2 (purple), treatment 3 (green) and the control (grey). B Phage titers of OMKO1 from 




Figure 3.3 Bacterial fitness in the presence of contemporary phages 
 
Bacterial fitness in the presence of contemporary phages for approximately 96 randomly selected bacterial clones from 
A treatment 1, B treatment 2 and C treatment 3. Bacterial clones from D the control were challenged to grow in the 
presence of contemporary phages from treatment 1. Here fitness is defined as the ratio of bacterial density in the phage 
challenge to the bacterial density in media. For each population, a linear regression was preformed to determine the 




Figure 3.4 Impact of phage populations on ancestral bacteria 
 
Impact of phage populations on ancestral bacteria. A-C Bacterial growth curve of ancestral PA01 alone (grey dotted 
line) or in the presence of phage populations at each passage from treatment 1, treatment 2, and treatment 3 
respectively. Each growth line represents the average of three technical replicates. D The first maximum OD600 
measurement for ancestral PA01 grown in the presence of phage populations at each passage from treatment 1 (blue), 




Figure 3.5 Coevolutionary dynamics 
 
Coevolutionary dynamics A Time shift assays to determine the proportion of phage resistant bacterial populations. 
The dashed line at 0 are assays of bacterial populations with contemporary phage populations. Negative numbers 
along the x-axis represent assays of bacterial populations with past phage populations. Positive numbers along the x-
axis represent assays of bacterial populations with future phage populations. B Time shift assays to determine the 






Figure 3.6 Bacterial fitness in the presence of 3mg/L of tetracycline 
 
Bacterial fitness in the presence of 3mg/L of tetracycline for approximately 96 randomly selected bacterial clones 
from A treatment 1, B treatment 2, C treatment 3 and D the control. Here fitness is defined as the ratio of bacterial 
density in the tetracycline challenge to the bacterial density in media. For each population, a linear regression was 





Figure 3.7 Frequencies of new alleles 
 
Frequencies of new alleles of genes involved in type IV pilus biogenesis 104, flagellar synthesis (grey), and LPS 
biosynthesis (B-band genes in solid line and A-band genes in dotted line) of A treatment 1 (blue), B treatment 2 





Table 3.1 Types of mutations 
 
The total number of synonymous & fixed (Ds), non-synonymous & fixed (Dn), synonymous & polymorphic (Ps) and 
non-synonymous & polymorphic (Pn) mutations in coding regions for treatments 1, 2 and 3 and the control. 
  
1 2 3 Control
Ds 0 0 2 2
Dn 9 7 9 7
Ps 82 28 43 39
Pn 191 89 109 67





Chapter 3 Appendix 
Supplemental Figure S3.1 Fitness in the presence of contemporary phages 
 
Fitness in the presence of contemporary phages for approximately 96 randomly selected bacterial clones from the 
control challenged to grow in the presence of contemporary phages from A treatment 2 or B treatment 3. Here fitness 
is defined as the ratio of bacterial density in the phage challenge to the bacterial density in media. A linear regression 





Supplemental Figure S3.2 Minimum inhibitory concentrations of each population 
 
Minimum inhibitory concentration for each passage of treatment 1 (blue), treatment 2 (purple), treatment 3 (green) 
and the control (grey) of A tetracycline, B erythromycin, and C ampicillin. Measurements were made at the population 




Supplemental Figure S3.3 Heat maps of new allele frequencies 
 






Supplemental Table S3.1 MIC90 of tetracycline, erythromycin, meropenem and gentamicin 
 
Minimum inhibitory concentration to kill 90% of bacteria (MIC90) of tetracycline, erythromycin, meropenem and 
gentamicin made in duplicate for each passage of treatment 1, treatment 2 treatment 3, and the control. (> indicates 
the MIC90 was higher than the range of concentrations examined and ≤ indicates the lowest concentration examined 
was sufficient to kill 90% of the colony forming units, but the actual MIC90 could be lower)
Tetracycline Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10
> 8 ≤ 4 > 8 ≤ 4 8 > 8 ≤ 4 ≤ 4 ≤ 4 ≤ 4
> 8 > 8 8 8 > 8 > 8 ≤ 4 ≤ 4 ≤ 4 ≤ 4
> 8 8 8 8 > 8 8 8 8 8 > 8
8 > 8 > 8 > 8 > 8 > 8 > 8 > 8 > 8 > 8
> 8 8 8 8 > 8 8 ≤ 4 ≤ 4 ≤ 4 8
> 8 > 8 > 8 > 8 > 8 > 8 > 8 ≤ 4 8 8
8 8 8 > 8 > 8 > 8 > 8 > 8 > 8 > 8
≤ 4 > 8 > 8 > 8 > 8 > 8 > 8 > 8 > 8 > 8
Erythromicin Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10
>256 128 > 256 ≤ 64 256 256 ≤ 64 ≤ 64 ≤ 64 ≤ 64
256 256 256 ≤ 64 128 > 256 128 128 128 128
> 256 256 256 256 256 256 256 256 256 > 256
> 256 256 256 > 256 256 > 256 256 > 256 > 256 > 256
256 256 256 256 > 256 256 128 128 256 128
> 256 256 256 > 256 256 > 256 256 128 128 128
256 256 256 256 >256 >256 256 >256 >256 256
≤ 64 256 256 256 > 256 256 256 256 > 256 > 256
Meropenem Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10
> 0.5 > 0.5 > 0.5 ≤ 0.25 > 0.5 > 0.5 0.5 0.5 0.5 0.5
> 0.5 > 0.5 > 0.5 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5
> 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5
> 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
> 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5
> 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5
≤ 0.25 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 > 0.5 < 0.25 > 0.5 > 0.5
Gentamicin Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10
> 2 > 2 > 2 1 > 2 > 2 > 2 > 2 > 2 > 2
> 2 > 2 > 2 ≤ 0.5 ≤ 0.5 > 2 > 2 > 2 > 2 > 2
> 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2
> 2 > 2 > 2 > 2 2 > 2 > 2 > 2 > 2 > 2
> 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2
> 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2
> 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2 > 2




















Supplemental Table S3.2 Location, mutation and frequencies of new alleles 
 
 





















5070994 pilB non-synonymous Q411L 0 0.1935 0 0 0 0 0 0 0 0 0
5071004 pilB synonymous H414H 0 0.1935 0 0 0 0 0 0 0 0 0
5071005 pilB non-synonymous M415L 0 0.1818 0 0 0 0 0 0 0 0 0
5071011 pilB non-synonymous M417L 0 0.1935 0 0 0 0 0 0 0 0 0
1188191 fleQ non-synonymous N202S 0 0 0 0 0 0 0 1 0.9348 1 1
1188291 fleQ 12 bp deletion 0 0 0 0.625 1 0 0 0 0 0 0
1190231 fleS 3 bpdeletion 0 0 0.25 0 0 0 0 0 0 0 0
1190236 fleS 1 bp insertion 0 0 0.25 0 0 0 0 0 0 0 0
1190324 fleS 1 bp deletion 0 0 0.9 0 0 0 0 0 0 0 0
1196848 fliI synonymous E276E 0 0 0 0 0 0 0 0 0 0 0.16
1196853 fliI non-synonymous A278G 0 0 0 0 0 0 0 0 0 0 0.1538
3546149 wzz1 non-synonymous A260V 0 0 0 0 0 0.5676 0 0.9863 0.9912 0.9394 1
3546461 wzz1 non-synonymous P156L 0 0 0 0 0 0.575 0 0 0 0 0
1028191 wzz2 1 bp insertion 0 0 0 0 0 0.5172 0 1 0.9623 1 0.9
3537986 wzy non-synonymous N381S 0 0 0.88235 0 0 0 0 0 0 0 0
6139402 wbpX 24 bp deletion 0 0 0 0 0 0 0 0 0 0.31818 0.22581
6136624 wbpZ non-synonymous T164P 0 0 0 0 0 0 0 0 0.35417 0 0.33333
3529218 wbpL 1 bp deletion 0 0 0 0.91667 0.88235 0 0 0 0 0 0





















5070994 pilB non-synonymous Q411L 0 0 0.2222 0 0 0 0 0 0 0 0
5071004 pilB synonymous H414H 0 0 0.2222 0 0 0 0 0 0 0 0
5071005 pilB non-synonymous M415L 0 0 0.2222 0 0 0 0 0 0 0 0
5071011 pilB non-synonymous M417L 0 0 0.1667 0 0 0 0 0 0 0 0
5098645 fimU non-synonymous R145L 0 0 0 1 1 0 0 0 0 0 0
5098648 fimU non-synonymous V146L 0 0 0 0 1 0 0 0 0 0 0
1188304 fleQ non-synonymous G240C 0 0 0.6364 1 1 0.9167 1 1 1 0 0
1028719 wzz2 non-synonymous A183V 0 0 0.3571 0.4074 0 0 0 0 0 0 0
1029022 wzz2 non-synonymous V284E 0 0 0 0 0.9565 0.875 0.95 1 0 0 0
6139316 wbpX 5 bp deletion 0 0 0 0 0 0 0.3103 0 0 0 0
6143588 gmd non-synonymous R164S 0 0 0 0 0 0 0 0.6364 0.875 0 0
Frequency of Alternate Allele






Supplemental Table S3.3 cont. Location, mutation and frequencies of new alleles 
  
Location, gene, mutation type and frequencies of new alleles found in treatment 1, treatment 2 and treatment 3 plotted in Figure 3.7.





















1188203 fleQ non-synonymous I206S 0 0 0 0 0.9286 0 0 0 0 0 0
1188291 fleQ 12 bp deletion 0 0 0 0 0 0 1 0 0 0 0
1191793 fleR 1 bp insertion 0 0 0 0 0 0 0 1 0 0 0
3546149 wzz1 non-synonymous A260V 0 0 0 0 0 0 0 0 0 0.8462 0.7778
3546176 wzz1 non-synonymous Y251C 0 0 0 0 0.7143 0 0 0 0 0 0
3546471 wzz1 non-synonymous Q153Stop 0 0 0 0 0 0 1 0 0.9167 0.4 0
3546595 wzz1 1 bp deletion 0 0 0 0.2222 0 0 0 0 0 0 0
1028365 wzz2 non-synonymous A65V 0 0 0.6667 0.5714 0.8462 0 0 0 0 0 0
1028961 wzz2 non-synonymous T264P 0 0 0 0 0 0 1 0 0 0 0
1029022 wzz2 non-synonymous V284E 0 0 0 0 0 0 0 0.5455 0 1 0
6137773 wbpY 21 bp deletion 0 0 0 0 0 0 0.4167 0 0 0 0
6139973 wzt 6 bp deletion 0 0 0 0 0 0 0 0 0 0.4444 0.7





Supplemental Dataset 1 can be found on Dryad (doi: 10.5061/dryad.1g1jwstvp). This is a table of 
the location, mutation, and frequencies of all high quality (Q>200) found in treatment 1, treatment 
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There has recently been an increasing interest in phage therapy as an alternative option for 
infection management, especially when phages have been shown to cause an evolutionary trade-
off between phage resistance and bacterial fitness traits such as virulence. A vast repertoire of 
virulence factors allows Shigella flexneri to invade gut epithelial cells, replicate intracellularly, 
and evade the immune system through intercellular spread. In particular, the intercellular spread 
stage of S. flexneri infection causes tissue damage, contributing to mortality. It has previously been 
shown that the porin OmpA is necessary for the polar localization of virulence factor IcsA, which 
polymerizes host actin and allows the bacterium to be motile inside host cells. We hypothesize that 
a phage which uses OmpA as a receptor to recognize, bind and infect S. flexneri, will select for 
phage-resistant bacteria that are attenuated for intercellular spread.  Here we show that a naturally 
isolated Myoviridae phage, A1-1, requires OmpA as a receptor. Using phenotypic traits observed 
from efficiency of plaquing assays, membrane integrity assays, total LPS measurements, MIC 
measurements as well as phage cross resistance profiles, five A1-1 resistant S. flexneri mutants 
can be placed into two phenotypic groups. R1 and R2 phenotypically resemble ompA knockouts 
and R3, R4 and R5 phenotypically resemble LPS-deficient strains. Whole genome sequencing 
confirms that R1 and R2 have mutations in ompA, while R3, R4 and R5 have a mutation in gmhA, 
a mutation in gmhC and a 30,000 base pair deletion spanning gmhA, respectively. Bacterial plaque 
assays confirm that all five phage-resistant mutants are unable to spread intercellularly. Thus, 







As a facultative, intracellular pathogen and a causative agent of bacillary dysentery, Shigella 
flexneri is a Gram-negative bacterium of medical importance. Fecal-oral transmission of these 
bacteria is common and usually occurs via contaminated drinking water 175. Bacteria rapidly 
traverse the gastrointestinal tract to invade colonic epithelial cells. Upon invasion, both 
chromosomally-encoded and plasmid-encoded virulence factors enable S. flexneri to overcome 
host immune responses, replicate intracellularly, and spread to neighboring epithelial cells 176. In 
particular, intercellular spread of S. flexneri is a virulence trait that damages colonic epithelial 
cells, destroying barrier function and resulting in severe shigellosis and dysentery. 
Shigellosis is a major public health problem in low-income countries that lack dependable 
water sanitation, and this disease contributes to approximately 1.3 million deaths annually 177. 
Children under the age of five account for almost 70% of the total mortality, primarily for cases in 
sub-Saharan Africa and southern Asia 178. Antibiotic treatment for shigellosis can rapidly improve 
patient outcomes 178. However, many of the recommended antibiotics are expensive and 
increasingly ineffective due to bacterial resistance to antibiotics, making them difficult to 
implement with limited health services 178. Thus, shigellosis remains a persistent cause of 
mortality, particularly for young children, with insufficient practical options for disease 
management. Therefore, alternatives to expensive and logistically challenging antibiotic 
treatments for shigellosis could valuably reduce disease burden, especially in children.  
As the rates of antibiotic resistance in bacteria continue to increase alarmingly, 
complementary treatments to control bacterial infections are quickly being considered. One such 
treatment is phage therapy, the clinical use of bacteriophages (phages), viruses that specifically 




candidates for phage therapy due to their predator-like effect on susceptible host bacteria. The 
lifecycle of a lytic phage involves attachment to one or more receptors on the surface of a 
bacterium, introduction of genomic material to the cytoplasm, intracellular replication, 
transcription and translation of phage genes, assembly of new phage particles, and lysis of the 
bacterial host to repeat the cycle 179. There are recent reports of implementation of phage therapy 
to treat refractory bacterial infections, particularly those that are resistant to multiple antibiotics 13, 
83, 180. While phage therapy has demonstrated potential and promise as a complementary therapy 
to antibiotics, it is expected that these viruses should select for evolution of phage-resistance in 
target bacteria. Therefore, it is crucial to design rational phage treatments, so that evolution of 
phage resistance is leveraged as a possible benefit, rather than necessarily constituting a barrier to 
effective treatment.  
The concept of evolutionary trade-offs permeates evolutionary biology. Trade-offs occur 
when an organism evolves a new phenotype that improves fitness in a certain environment at the 
cost of decreased fitness in another environment 47. In the context of phage therapy, it should be 
possible to identify phages that direct the evolution of their host bacteria, such that evolution of 
phage resistance, on average, results in a clinically-useful fitness trade-off. In particular, by 
choosing a lytic phage that exerts selection pressure on an antibiotic-resistance and/or virulence 
mechanism, the phage-susceptible bacteria are killed while the remaining population is enriched 
for phage-resistant variants with reduced drug resistance and/or virulence 49. In either case, the 
phage treatment would cause evolution of phage resistance to be a benefit, rather than a liability. 
To implement a rationally designed phage treatment that selects for a virulence trade-off 
in bacteria, a surface-expressed virulence factor must be identified that the phage uses for binding. 




symptoms, while providing the bacteria refuge from immune system detection and from antibiotics 
that poorly transit across eukaryotic cell membranes. One of the plasmid-encoded virulence factors 
of S. flexneri, IcsA, recruits and polymerizes host cell actin on one end of the bacterium to create 
actin tails 181. These actin tails move the bacterium around the host cytoplasm, occasionally 
propelling the bacterium into the membrane, causing protrusions which can lead to spread of the 
bacterium to a neighboring host cell 182. IcsA is both surface-expressed and essential for S. flexneri 
virulence, suggesting its potential usefulness as a binding receptor for a phage therapy candidate. 
However, IcsA is plasmid-encoded 183, indicating that this virulence factor might be spontaneously 
lost from target bacteria during cell division, and may be capable of horizontally transferring into 
cells of non-target bacteria. For this reason, a better strategy would be to discover a phage that 
interacts with a known chromosomally-encoded virulence factor of S. flexneri bacteria, rather than 
targeting a genetic element that could be more easily gained or lost. Recent reports have implicated 
other outer membrane proteins 184, 185 as necessary for intercellular spread of S. flexneri, including 
OmpA, a highly conserved outer-membrane porin: a pore or channel in Gram-negative bacteria 
that translocates small molecules across the membrane. In S. flexneri, OmpA is surface-expressed, 
required for virulence, and chromosomally encoded; these three properties make it an attractive 
target for testing our hypothesis due to its potential as a phage receptor 186 that could be leveraged 
to select against virulence in this pathogen.   
In this study, we describe the recently-isolated lytic phage A1-1, a dsDNA virus discovered 
in a waste water sample obtained in Cuatro Cienegas, Mexico, a geographic region renowned for 
its extreme microbial diversity 187. Characterization of phage A1-1 revealed that it was a member 
of the Myoviridae family, and that the virus naturally used OmpA as a binding receptor to infect 




while selecting for evolution of resistance in the bacterial population, to cause a trade-off in 
decreased virulence (i.e., reduced capacity for phage-resistant mutants to undergo intercellular 
spread). We randomly isolated five spontaneous phage-resistant mutants, and results of our 
phenotypic and genotypic characterizations revealed that these strains could be placed generally 
into two different groups. Nevertheless, our data confirmed that all isolated mutants suffered the 
predicted trade-off: these bacteria could invade and replicate in mammalian-derived cells in a 
tissue culture model of S. flexneri infection, but the evolved phage resistance was always 
associated with attenuated virulence because the mutants were incapable of intercellular spread. 
Results 
Novel lytic phage A1-1 is a Myoviridae virus that binds to OmpA of Shigella flexneri  
We predicted that naturally-occurring lytic phages of S. flexneri have evolved to exploit OmpA as 
a receptor. We sought to isolate such a phage from water samples, assuming that these contained 
high levels of microbial biodiversity.  From waste water obtained in Cuatro Cienegas, Mexico, 
phage A1-1 was purified on S. flexneri strain PE577 using classical phage-isolation techniques, 
and was then grown using S. flexneri strain M90T as a host in the below experiments.  
We used SPAdes 188 for de novo assembly of the phage A1-1 genome, and results showed 
a tentative genome size of 104,552 base pairs. Phage A1-1 was observed to have a GC content of 
35.89%, whereas the host bacteria had a GC content of 50.9%. Preliminary annotation of phage 
genes using PHASTER 189 revealed 139 coding regions (Figure 4.1A) with no indication that genes 
for lysogeny (temperate phage life cycle) were present. Sequence alignment suggested that phage 
A1-1 was similar to myoviruses known to infect Escherichia coli. Transmission electron 




morphology is consistent with the typical structure of virus particles of the Myoviridae family of 
dsDNA viruses.  
We then conducted phage growth curves, in triplicate, that estimated key features of the 
phage A1-1 lytic reproductive cycle, and tested its ability versus inability to infect wild-type and 
OmpA knockout strains of S. flexneri, respectively. Results showed that phage A1-1 had a latent 
and eclipse period of approximately 30 minutes, and a burst size of roughly 12 phage particles per 
lysed bacterial cell (Supplemental Figure S4.1A). Furthermore, these data confirmed that phage 
A1-1 was able to grow on M90T bacteria, but was unable to infect M90TDompA lacking the 
putative OmpA binding site.  
To determine conclusively whether phage A1-1 required OmpA to bind and infect S. 
flexneri cells, we performed adsorption assays to measure cell binding, and efficiency of plaquing 
(EOP) assays to measure infectivity of phage A1-1.  Results of replicated (n = 3) adsorption assays 
showed that phage A1-1 was unable to adsorb to both M90TDompA and M90TDompA:pSF-vector 
(empty vector control); in both cases, the slope of the linear regression for observed plaque forming 
units (PFU) over time was not statistically significantly different than zero. However, we observed 
that phage A1-1 was able to adsorb to wild-type M90T as well as M90TDompA:pSF-ompA, (Figure 
4.1C). Similarly, EOP assays performed in triplicate (Supplemental Figure S4.1B) showed that 
phage A1-1 was able to infect M90TDompA:pSF-ompA with an EOP of 0.365±0.15 (mean ± sem), 
but unable to infect M90TDompA or M90TDompA:pSF-vector with EOPs below the limit of 
detection (200 PFU/mL) on both strains. Finally, we examined growth kinetics of S. flexneri in the 
presence of phage A1-1 using bacterial growth curves. As expected, growth of the susceptible 
wild-type strain, M90T, was completely suppressed in the presence of phage over the 15-hour 




vector strains were both unimpacted by phage A1-1 (Supplemental Figure S4.1C).  While growth 
of M90TDompA:pSF-ompA was suppressed by phage presence, the reduced growth was less severe 
compared to the M90T wild-type, likely due to differences in chromosomal versus exogeneous 
expression of OmpA (Supplemental Figure S4.1C). Taken together, the above results showed that 
phage A1-1 was a naturally-occurring virus that could be isolated and characterized as requiring 
OmpA to bind and initiate infection of S. flexneri host bacteria. 
Phage A1-1 selects for two different phenotypes of phage-resistant mutants 
Since the above results showed phage A1-1 used OmpA to infect S. flexneri, we hypothesized that 
phage resistance would involve modification of the phage receptor and that phage-resistant 
mutants would be phenotypically similar to M90TDompA. Fluctuation assays revealed that phage 
A1-1 selected for phage-resistant mutants of M90T at a frequency of 4.18·10-7±1.22·10-7 (mean ± 
sd). Five spontaneous phage-resistant mutants (hereafter, R1, R2, R3, R4 and R5) were 
independently isolated and randomly chosen for further characterization. 
Using similar assays as above, we sought to confirm that all five mutants showed traits 
associated with phage resistance. As expected, phage A1-1 had an EOP below the limit of detection 
(200 PFU/mL) on each resistant mutant (Figure 4.2A).  Similar to data for M90TDompA presented 
above, all five resistant mutants did not support phage adsorption, indicated by the slopes of linear 
regressions that were not statistically significantly different than zero (Figure 4.2B). Also, growth 
of the phage-resistant mutants was not visibly altered by the presence of phage A1-1, while growth 
of wild-type M90T was completely suppressed by phage A1-1 (Figure 4.2C). We noted that 
mutants R1 and R2 grew to final densities similar to the M90T ancestor, but mutants R3, R4 and 
R5 reached final densities that were roughly two-fold less than the wild-type (Figure 4.2C). 




R5 grew as ‘rough’ colonies on agar, indicating that the latter mutants were potentially altered for 
lipopolysaccharide (LPS) production. In summary, these results confirmed that all of the mutants 
had phenotypic traits consistent with resistance to phage A1-1 infection, but the strains could be 
separated into two groups (R1 and R2; R3, R4 and R5).  
To further characterize the five phage-resistant mutants, we used assays that investigated 
membrane permeability, LPS quantity per cell and resistance to several antibiotics, because 
changes (relative to wild-type) in these traits were anticipated if phage resistance was conferred 
by altering OmpA and/or LPS. Using membrane-integrity assays as proxies for cell permeability, 
results showed that permeability of resistant mutants R1, R3 and R5 was statistically significantly 
lower than that of the M90T wild-type (Figure 4.3A). Total LPS measurements revealed that while 
R1 and R2 had similar amounts of LPS per colony forming unit (CFU) compared to M90T and 
M90TDompA, R3, R4 and R5 showed almost an order of magnitude more LPS per CFU (Figure 
4.3B). It was expected that alterations to OmpA and LPS would result in changes in minimum 
inhibitory concentration (MIC) for certain antibiotics. Mutants R3, R4 and R5 showed a significant 
decrease in mean fold change (as compared to wild-type) in MIC of erythromycin (R3: 
0.042±0.015 sem; R4: 0.056±0.009 sem; R5: 0.071±0.012 sem) (Figure 4.3C). Mutant R5 
presented a significantly decreased fold change in ciprofloxacin MIC, 0.667±0.083 sem (Figure 
4.3D). Mutant R1 showed a significantly decreased fold change in vancomycin MIC, 0.438±0.188 
sem, while mutants R3 – R5 had significantly increased fold changes in vancomycin MICs (R3: 
2.33±0.417 sem; R4: 2.25±0.334 sem; R5: 2.25±0.334 sem) (Figure 4.3E). Fold change in MIC of 
tetracycline was not different from wild-type for all five mutants (Figure 4.3F). We further 
concluded that phage A1-1 tended to select for phage-resistant mutants in two groups; R1 and R2 




To further investigate the potential role for LPS in phage resistance, EOPs were measured 
on E. coli knockout strains 113 for genes involved in LPS biosynthesis 190. The EOP of phage A1-
1 was below the limit of detection when the following fifteen E. coli genes were knocked out: 
ompA,  galU, waaC, gmhA, gmhB, gmhC, gmhD, waaF, waaQ, waaP, waaY, waaG, waaO, waaJ, 
and waaB (Supplemental Figure S4.2). EOP measurements for phage A1-1 on BW25113DicdC 
and BW25113DompC controls, as well as on BW25113DwaaS and BW25113DwaaL knockouts, 
were not statistically different from phage ability to grow on wild-type BW25113 (Supplemental 
Figure S4.2). In contrast, the EOP of phage A1-1 on BW25113DwaaZ was slightly improved, 
compared to wild-type BW25113 (Supplemental Figure S4.2). These results suggested that LPS 
biosynthesis genes waaS, waaL, and waaZ were not determinants of phage A1-1 growth. From 
these results, we concluded that portions of S. flexneri LPS were required somehow for phage A1-
1 infection. 
Since our earlier results showed that phage A1-1 used OmpA to bind and initiate infection 
of S. flexneri, we anticipated that the genetics underlying phage resistance should be governed by 
alterations of OmpA, and not by changes in LPS. While results above (Figure 4.1) hinted that 
OmpA might be the only receptor for phage A1-1, EOP data from the E. coli LPS knockout strains 
implied that further tests were needed to examine whether LPS also served as a receptor. To that 
end, we tested whether resistance to phage A1-1 additionally altered susceptibilities of the resistant 
mutants to previously-characterized phages 60B and T7. Phage 60B putatively requires OmpC as 
a receptor. Our results showed that wild-type M90T, and mutants R1 and R2 were susceptible to 
phage 60B infection, indicating that this constituted the ancestral phenotype, whereas our data 
found that mutants R3, R4 and R5 displayed resistance to phage 60B (Supplemental Table S4.1). 




R1 and R2 were resistant to phage T7, indicating this was the ancestral phenotype; while R3, R4 
and R5 were susceptible to phage T7 (Supplemental Table S4.1). Differences in phage T7 
resistance again suggested that there were putative LPS changes conferring phage A1-1 resistance 
in mutants R3, R4, and R5. Moreover, the differences in phage 60B resistance for these strains 
compared to wild-type suggested that LPS changes may be broadly affecting the structure of 
different outer membrane porins. Therefore, we hypothesized that while LPS might be necessary 
for A1-1 infection, it was not serving as a receptor; rather, LPS could serve to maintain the 
appropriate structure of the phage A1-1 binding receptor OmpA. 
Western blots were used to determine whether the five resistant mutants expressed OmpA.  
Blots for OmpA of whole cell lysates showed that resistant mutants R1 and R2 did not express 
OmpA; however, R3, R4 and R5 expressed OmpA to a similar degree as the wild-type control 
(Figure 4.4A). Furthermore, western blots of fractioned cell lysates revealed that R3, R4 and R5 
expressed OmpA at the membrane (Figure 4.4B). These results supported our hypothesis that LPS 
was likely not a receptor for phage A1-1, but instead was maintaining a conformation of OmpA 
that was required for phage A1-1 binding. 
Based on differing results of observed colony morphologies, MICs of various antibiotics, 
phage A1-1 infection ability on LPS mutants of E. coli, and western blots for OmpA, we concluded 
that phage-resistant mutants R1 and R2 phenotypically resembled the M90TDompA knockout and 
did not express this OmpA, while R3, R4 and R5 appeared to be phage A1-1 resistant due to LPS 
deficiencies. 
Whole genome sequencing reveals underlying mutations conferring resistance 
Whole genome sequencing was used to determine whether the genotypes of the resistant mutants 




mutants were sequenced, aligned to the reference genome for the wild-type M90T ancestor 
(GenBank # CM001474.1), and GATK was used to identify variants. Results showed that both R1 
and R2 had a nonsense mutation in ompA, resulting in a premature stop codon after amino acid 
172 (Figure 4.5). R3 had a nonsense mutation in gmhA that resulted in a premature stop codon 
after amino acid 176 (Figure 4.5). R4 had a transversion at base pair 787 of gmhC. Finally, R5 had 
a 29,645 base pair deletion between two insertion sequence 1 (IS1) elements at positions 303,277 
and 332,873; this deletion included 27 genes, one of which was gmhA (Figure 4.5). The EOP of 
phage A1-1 was restored to levels observed on wild-type S. flexneri, when R1 and R2 were 
complemented with plasmid pSF-ompA, R3 and R5 harbored plasmid pSF-gmhA, and R4 
contained plasmid pSF-gmhC (Figure 4.2A). Altogether, whole genome sequencing and EOP 
assays confirmed that R1 and R2 were ompA mutants, while R3, R4 and R5 were LPS-deficient 
mutants. 
Phage-resistant mutants are attenuated for intercellular spread 
We originally sought to test the prediction that a phage requiring OmpA to bind and infect S. 
flexneri would select for phage-resistant mutants that were attenuated for intercellular spread. 
Virulence of phage-resistant mutants was assayed using intracellular replication assays and plaque 
assays in primate-derived Vero cells grown in laboratory tissue culture. As expected, M90T and 
M90TDompA bacteria were capable of invading and replicating in Vero cells, while the negative 
control, M90TDmxiH, a knockout for the type III secretion system needle, was unable to invade 
(Figure 4.6A). All five of the phage-resistant mutants were able to invade and replicate 
intracellularly; R1, R2, R3 and R5 replicated to levels similar to M90T at the 7-hour timepoint 
while R4 replicated 10-fold less than M90T by this time (Figure 4.6A). Plaque assays revealed 




nor M90TDmxiH (Figure 4.6B,C) could spread intercellularly, and none of the phage-resistant 
mutants (Figure 4.6D-I) could spread between cells. Therefore, although all five resistant mutants 
were able to invade and replicate intracellularly, as predicted they were unable to spread 
intercellularly, indicating that resistance to phage A1-1 led to evolution of reduced virulence in S. 
flexneri. 
Discussion 
Classical phage biology assays, including adsorption assays, EOPs and growth curves suggest that 
phage A1-1 uses OmpA as a receptor. A1-1 selected for two different phenotypes of phage-
resistant mutants. R1 and R2 formed smooth colonies, exhibited decreased membrane permeability 
as compared to wild-type, and were more sensitive than wild-type to vancomycin; R3, R4 and R5 
formed rough colonies, exhibited decreased membrane permeability as compared to wild-type, 
were more sensitive than wild-type to erythromycin, were more resistant than wild-type to 
vancomycin, had greater total LPS per CFU than wild-type, and showed altered phage resistance 
profiles to phages 60B and T7. Whole genome sequencing revealed that A1-1 selected for resistant 
mutants with mutations in ompA (R1 and R2). However, A1-1 also selected for resistant mutants 
in gmhA (R3 and R5) and gmhC (R4), two genes involved in the biosynthesis of the heptose sugars 
that make up the inner core of LPS 121. Resistant mutants R3, R4 and R5 all express OmpA on the 
membrane and phage A1-1 fails to adsorb to these resistant mutants. This leads to two possibilities: 
phage A1-1 both OmpA and LPS as co-receptors, or phage A1-1 uses OmpA as a receptor and 
LPS is somehow required for binding but is not a receptor.  
While the first possibility cannot be ruled out in this study, it is worth noting that plaques 
of A1-1 were never observed on M90TDompA even when high titers of A1-1 were plated. If both 




genetic variation would likely lead to variants of phage A1-1 that could plaque on M90TDompA, 
using only LPS as a receptor. This was not observed; instead, it seems likely that A1-1 uses OmpA 
as a primary receptor and that LPS is required for binding either as a secondary receptor or to 
maintain the proper conformation of OmpA for A1-1 binding. Since resistant mutants R3, R4 and 
R5 all express OmpA and no phage adsorption to these resistant mutants was observed, it seems 
unlikely that LPS is being used as a secondary receptor by phage A1-1. Therefore, perhaps LPS is 
involved in maintaining a particular conformation of OmpA that is necessary for phage binding. 
Indeed, it has been previously observed that complex interactions between LPS and outer 
membrane proteins (OMPs) are involved in both OMP biogenesis and stabilization of particular 
conformations of various OMPs 191-193.  Three different conformations of E. coli OmpA have been 
proposed: a monomeric narrow pore conformation with two domains (an eight stranded β-barrel 
and a periplasmic domain), a monomeric large pore conformation with a single domain (sixteen 
stranded β-barrel), and a dimer of the two-domain narrow pore structure 194-196. OmpA in M90T 
appears to be localized to both the periplasm and membrane fractions (Figure 4.3B), indicating 
that perhaps the two-domain narrow pore structure with the periplasmic domain is the main 
conformation of OmpA in S. flexneri. Interestingly, OmpA in resistant mutants R3, R4 and R5 is 
localized more in the membrane fraction than in the periplasmic fraction (Figure 4.3B), possibly 
indicating that the single domain large pore structure dominates the conformation state of OmpA 
in these LPS-deficient mutants. Indeed, it has been previously suggested that core LPS plays a role 
in maintaining the conformation of OmpA. Experiments in the current study seem to support this 
hypothesis. 
When S. flexneri invades and replicates within human host cells, it is known to spread 




unipolar IcsA on the bacteria. It is previously demonstrated that O-antigen null mutants (i.e., those 
with truncated LPS) are attenuated for intercellular spread 197. Therefore, it is perhaps unsurprising 
that the phage-resistant LPS mutants R3, R4 and R5 are capable of intracellular invasion and 
replication but not intercellular spread. However, the mechanism behind why O-antigen confers 
the ability for S. flexneri to spread intercellularly has not been fully elucidated. Furthermore, prior 
work shows that OmpA is required for intercellular spread 184; as expected, our isolated phage-
resistant mutants with OmpA changes, R1 and R2, are similarly defective for this virulence trait. 
Interestingly, the shared ompA mutation that likely confers phage resistance in R1 and R2 is in the 
region that likely composes the final predicted extracellular loop of the eight-stranded β-barrel 
conformation and truncates OmpA at position 174. It is observed that OmpA residues 188-190 
interact with a periplasmic protein, PhoN2, to maintain polarity of IcsA 198. Therefore, if these two 
resistant mutants express a partial peptide of OmpA, where residues 1-169 are wild-type and 170-
173 are frameshifted, this partial protein likely is neither suitable for phage A1-1 adsorption nor 
has the region predicted to interact with PhoN2 to maintain polarity of IcsA. This perhaps explains 
the observed defect in intercellular spread observed for phage-resistant mutants R1 and R2. 
It is unsurprising that ompA mutants and rough mutants of S. flexneri in the current study 
are attenuated for intercellular spread based on the previous literature, but it is noteworthy that 
these mutants were obtained strictly via selection for resistance to phage A1-1. In all five 
randomly-chosen mutants, phage resistance led to attenuation for intercellular spread; thus, 
selection for resistance to phage A1-1 in S. flexneri consistently traded off with maintenance of a 
key virulence factor in this biomedically-important pathogen. While this interesting result yields 
insights into possible S. flexneri interactions with lytic phages, expectations for phage-bacteria 




The epidemiology of S. flexneri typically involves colonization of an index human case 
(presumably via consumption of contaminated food or water) which then can be fecal-orally 
transmitted to household members and other nearby individuals. As a facultative intracellular 
pathogen, S. flexneri is capable of growth inside of human host cells, but can also exist as “free-
living” bacteria in the natural environment. During clinical infections, bacteria are presumably 
protected from phage attack while replicating inside colonic epithelial cells; however, during fecal-
oral transmission, bacteria are free-living and once again vulnerable to phage. This is an example 
of an alternating environment with intermittently-changing selection pressures experienced by the 
bacteria. That is, aside from other possible selection pressures such as escape from host immunity, 
a population of S. flexneri may sometimes experience selection to avoid phage infection, and at 
other times can experience absence of this selection if intracellular invasion provides a refuge from 
phage exposure. Under such complex conditions, selection would positively favor evolution of 
phage resistance in free-living bacteria; in this ecology, the mutations underlying phage resistance 
would be beneficial and positively selected. However, inside intestinal epithelial cells, the ecology 
presents a different target for selection; here, the mutations for phage resistance observed in this 
study would be deleterious because of the trade-off we observed between phage resistance and 
intercellular spread.  
This scenario stimulates two predictions: (1) evolution of phage resistance (i.e., positive 
vs. negative selection for this trait) should occur differently for facultative intracellular pathogens 
such as S. flexneri, depending whether the bacterial population is growing inside versus outside of 
the human host; and (2) the particular phage-resistant mutants in the current study should 
experience a net fitness cost if the frequency of environmental fluctuations necessitate intracellular 




ongoing studies in our laboratory to examine spontaneous phage-resistant mutants of S. flexneri 
selected under simultaneous selection pressures of phage A1-1 and intracellular growth constraints 
in Vero cells. The second prediction can be examined by subjecting the phage-resistant mutants in 
the current study to experimental evolution that toggles between batch culture and tissue culture 
environments. Here, the outcome can be informed by previous studies of microbial evolution in 
fluctuating environments. For example, it is observed that phages subjected to elevated-
temperature selection (i.e., heat shocks) outside of bacterial cells results in evolution of greater 
thermotolerance (increased particle stability) to withstand degradation in elevated temperatures, 
despite the deleterious nature of these mutations for phage reproduction in benign temperature 
environments 199. Thus, antagonistically-pleiotropic mutations can evolve in microbes, even 
though these changes confer high fitness in only a portion of the selective environment.  We might 
expect that a fluctuating environment would cause the particular phage-resistant mutants in our 
study to undergo further evolution, such as compensation for their complete inability to spread 
intercellularly, to perhaps maintain some degree of phage resistance while also achieving minimal 
intercellular spread (a compromise). In contrast, our study may reveal that evolution of phage 
resistance creates a strong evolutionary constraint, whereby acquisition of phage A1-1 resistance 
prevents S. flexneri from readily undergoing compensatory evolution, thus effectively confining 
the bacteria to the free-living ‘ecology’ when faced with selection to avoid phage attack. If this 
result holds true for the system presented in the current study, it might be possible to select for 
long-lasting phage-resistant S. flexneri strains that are attenuated for virulence, an important step 





Phage A1-1 is a newly isolated Myoviridae phage that uses OmpA as a receptor to infect S. flexneri. 
Mutants resistant to phage A1-1 have altered membrane permeability, changes in antibiotic 
resistance profiles, and do not support adsorption of phage A1-1. A combination of whole genome 
sequencing and targeted Sanger sequencing reveal that two of these resistant mutants have a 
mutation in ompA, two resistant mutants have mutations in gmhA and one has a mutation in gmhC. 
EOP assays with complemented strains confirm that these mutations confer resistance to phage 
A1-1. While phage A1-1 does not appear to use LPS as a receptor, we hypothesize that interactions 
between OmpA and LPS are required to maintain a particular confirmation of OmpA to allow for 
phage attachment and will investigate this further in future studies. Finally, all five phage-resistant 
mutants tested in this study are attenuated for virulence; while they can still invade and replicate 
intracellularly, they are unable to spread intercellularly in a tissue culture model of infection. This 
study demonstrates that it is possible to find phage that select for a trade-off between phage 
resistance and virulence in bacteria. 
Materials and Methods 
Strains and culture conditions 
Bacteria, phage and plasmid strains used in this study are listed in Supplemental Table S4.2. S. 
flexneri was grown in 0.1% congo-red tryptic soy (CR-TS) medium (10g tryptone, 5g soytone, 
10g NaCl, 0.1g congo red dye per L) unless otherwise noted. E. coli was grown in Lysogeny Broth 
(LB) medium (10g tryptone, 5g yeast extract, 10g NaCl per L). Phage A1-1 was amplified to high 
titer on M90T unless otherwise noted. Bacteria were grown on 1.5% agar plates and phages were 
grown on plates in 0.75% agar top layer. Plasmids were maintained using 100ug/mL of 
carbenicillin and expression was induced with 1mM IPTG. Lambda-red recombination 200 was 




was used to remove the Kanr cassette from each of these strains to create strains M90TDompA and 
M90TDmxiH.  
Assays to characterize phage  
Adsorption assays to estimate phage cell-binding ability were performed as described by Kropinski 
(2009) 144. Efficiency-of-plating assays to estimate phage infectability on challenge bacteria 
relative to that on a permissive host strain, and phage growth curves to estimate virus traits (i.e., 
latent period, exponential growth rate, burst size) were performed as previously described 100. 
Bacterial growth curves were performed at multiplicity of infection (MOI; ratio of phage particles 
to bacterial cells) of approximately 100. Transmission electron microscopy (TEM) was performed 
using uranyl acetate-stained phages on 300 mesh carbon film copper grids, and phage particles 
were visualized on a FEI Tecnai Biotwin microscope. 
LPS extractions 
Lipopolysaccharide (LPS) was extracted from bacteria using an LPS extraction kit (Abcam 
ab239718) and LPS was quantified using a carbohydrate quantification assay (Abcam ab155891). 
LPS was extracted following the instructions provided in the kit. Briefly, bacteria were grown 
overnight on LB agar, scraped into PBS, centrifuged for 5 min at 5,000g at 4°C, resuspended in 
extraction buffer, sonicated and incubated on ice for 10 minutes to allow for full lysis. Any unlysed 
cells were removed via centrifugation (5 min at 5,000g at 4°C) and the supernatant was treated 
with proteinase K at 60°C for one hour. Any remaining debris was removed via centrifugation (5 
min at 5,000g at 4°C). Total carbohydrate content (grams/CFU) in the supernatant was quantified 





Minimum inhibitory concentration (MIC) was measured using Etest strips (Biomerieux). Briefly, 
overnight cultures of bacteria were spread on Mueller Hinton Agar (MHA, 2g beef extract, 17.5g 
casein hydrolysate, 1.5g starch, 17.0g agar per L) plates and test strips were plated. After overnight 
incubation, MIC values were determined by the lowest concentration at which the bacterial growth 
was inhibited. These measurements were conducted with three-fold replication. 
Membrane permeability assay 
Membrane permeability of cells grown in LB was assayed using the Live/Dead BacLight kit 
(ThermoFisher L34856) using a microplate reader (Tecan Infinite F500) following the 
manufacturer instructions. 
Cell fractionation, protein gels and western blots 
Whole cell lysates were made by centrifuging cells (5 minutes at 5,000g), resuspending in 1x 
Laemmli buffer (Biorad) and boiling at 100°C for 15 minutes. Cell fractions were made following 
the previously published protocols 201. Briefly, late log cultures were centrifuged at 5,000g for 5 
minutes and gently resuspended in 200 µL of TES buffer (200mM Tris-HCl pH 8.0, 0.5mM 
EDTA, 0.5M sucrose). Lysozyme (10 µg/mL final) was added to the resuspended cells followed 
by 720 µL of TES buffer that had been diluted 1:1 in water. The lysate was incubated for 30 
minutes on ice with gentle inversion to mix and then centrifuged at 5,000g for 5 minutes at 4°C. 
The supernatant was saved as the periplasmic fraction. The spheroplast fraction, the pellet, was 
resuspended in TES buffer diluted 1:1 in water containing 2mM phenylmethylsulfonyl fluoride 
(PMSF), 2mM MgCl2 and 10 µg/mL of DNAseI and lysed via four cycles of freeze thaws from -
273°C to 37°C. Unlysed spheroplasts were removed via centrifugation at 2,000g for 5 minutes at 




supernatant was saved as the cytoplasmic fraction, and the pellet was resuspended in TES buffer 
diluted 1:1 in water and saved as the membrane fraction. Whole cell lysates and fractions were run 
at 200V for 45 minutes on a 10% Tris-Glycine polyacrylamide gel and transferred to a PVDF 
membrane (90V for 60 minutes) and blotted with an anti-OmpA antibody (Biorbyt orb241331). 
Sequencing and analysis 
Genomes were extracted as previously described 141. Sequencing libraries were made using 
NexteraXT library preparation kits (FC-131-1096, Illumina). Samples were run paired-end 150bp 
reads on the Illumina HiSeq 2500 platform. Reads were aligned to reference genomes for M90T 
(Genbank Accession # CM001474.1) and the virulence plasmid, pWR501 (Genbank Accession # 
NC_002698.1) using Bowtie2 143  and variants were called using GATK 174.  
Bacteria intracellular growth curves 
Intracellular growth curves of S. flexneri were performed as described by Hale and Formal (1981) 
with some modifications 202. Briefly, 24 hours prior to assay, Vero cells were plated in Dulbecco’s 
Modified Eagle Medium (DMEM) with 5% fetal bovine serum (FBS) to 90% confluency in a 24-
well dish. On the day of the assay, overnight bacterial cultures were diluted 1:100 and grown to 
mid-late log. Cultures were centrifuged (5 minutes at 5,000g) and resuspended in DMEM with 5% 
FBS. Vero cells were washed once with PBS prior to infection. Bacteria were added to each well 
to an MOI of 10 and the plate was centrifuged at 200 rpm for 5 minutes. Plates were incubated for 
30 minutes at 37°C and 5% CO2. Wells were washed three times with PBS, DMEM with 5% FBS 
and 100 µg/ml gentamicin was added to each well, and plates were incubated at 37°C and 5% CO2 
for the duration of the assay. At five time points (0, 1, 3, 5 and 7 hours), plates were destructively 




with sterile, deionized water and gentle pipetting, and bacterial CFU was enumerated via plating 
on CR-TS agar plates. 
Bacterial plaque assays  
Plaque assays were performed as described by Oakes et al. (1985) with some modifications 203. 
Briefly, 24 hours prior to infection, Vero cells were plated to 90% confluency in a 6-well dish in 
DMEM with 5% FBS. On the day of the assay, overnight bacterial cultures were diluted 1:100 and 
grown to mid-late log. Cultures were centrifuged (5 minutes at 8,000g) and resuspended in DMEM 
with 5% FBS to achieve a range of MOI’s between 100 and 0.1. Vero cells were washed once with 
PBS. Bacterial suspensions were plated on Vero cells and allowed to attach and invade for one 
hour at 37°C and 5% CO2 with gentle rocking every 15 minutes. After the incubation, 2x Minimum 
Essential Media (MEM) complete (10X MEM, 100X L-Glutamine, 100xVitamins, 100X NEAA, 
7.5% sodium-bicarbonate added to sterile distilled water to a final concentration of 2x with 200 
µg/ml gentamicin) was mixed with an equal volume of molten 1% agarose in water and FBS to 
5%, added to each well, and allowed to solidify. Plates were incubated for 48 hours at 37°C and 
5% CO2. An additional top layer of 2% neutral red stain (MilliporeSigma N2889) in PBS with 







Chapter 4 Figures & Tables 
Figure 4.1 Basic characterization of newly-discovered lytic phage A1-1 
 
Basic characterization of newly-discovered lytic phage A1-1 on host, Shigella flexneri. A. Genome annotation of 
phage A1-1 using PHASTER. Plate proteins are shown in purple, fiber proteins shown in yellow, coat proteins shown 
in blue, phage-like proteins shown in red and hypothetical proteins are shown in grey.  B. TEM image of phage A1-1 
(200 nm scale bar). C. Adsorption assay of phage A1-1 on bacterial hosts: M90T (purple), M90TDompA (yellow), 
M90TDompA:pSF_vector (grey) and M90TDompA:pSF_ompA (black). Error bars show standard deviations of the 
mean of three biological replicates. Significance determined by testing whether slope of the linear regression line 





Figure 4.2 Characterization of phage resistance 
 
Characterization of phage resistance A. Efficiency of plaquing (EOP) assay of phage A1-1 on various strains. Dashed 
line at 1 indicates EOP on M90T. DL indicates the EOP was below the limit of detection (~10-9). B. Adsorption assay 
of phage A1-1 on bacterial hosts: M90T (purple), R1 (yellow), R2 (grey), R3 (black), R4 (blue) and R5 (red). Error 
bars show standard deviations of the mean of three biological replicates. Significance determined by testing whether 
slope of the linear regression line deviates from zero. C. Growth curves of M90T (purple), R1 (yellow), R2 (grey), R3 
(black) R4 (blue), and R5 (red). Solid lines indicate bacteria growing in absence of phage; dashed lines indicate phage 





Figure 4.3 Phenotypic characterization of five spontaneous phage-resistant mutants 
 
Phenotypic characterization of five spontaneous phage-resistant mutants of S. flexneri. A. Membrane permeability 
measured as a linear regression of the ratio of green to red fluorescence of different suspensions of live and dead cells 
stained with SYTO 9 dye and propidium iodide. Error bars show standard deviations of the mean of three biological 
replicates. Significance determined using a student’s t-test comparing the slopes of the linear regressions to that of 
wild-type bacteria. B. Total LPS measured as µg per CFU. Error bars show standard deviations of the mean of three 
biological replicates. C-F. Fold change in MIC compared to MIC of wild-type M90T for erythromycin, ciprofloxacin, 
vancomycin (shaded region indicates limit of detection) and tetracycline. Error bars show standard errors of the 
average of three biological replicates. Unless otherwise noted significance determined using a student t-test.  (* 





Figure 4.4 OmpA expression in phage-resistant mutants 
 
OmpA expression in phage-resistant mutants of S. flexneri, compared to controls. A. Western blot for OmpA of whole 
bacterial cell extract of M90T, M90TDompA, R1, R2, R3, R4 and R5. B. Western blot for OmpA of cytoplasmic (C), 





Figure 4.5 Diagram of mutations 
 
Diagram of mutations identified via whole-genome sequencing. The chromosome of wild-type M90T is 4,580,866 
base pairs. Mutations were identified in all five phage-resistant mutants. R1 and R2 have identical single base pair 
insertions at position 507 in ompA (yellow). R3 has a single base pair insertion in gmhA (blue) at position 400. R4 has 
a transversion at position 787 of gmhC (red). R5 has a 29,645 base pair deletion spanning 27 genes, including gmhA 





Figure 4.6 Virulence of phage-resistant mutants 
 
Virulence of phage-resistant mutants, relative to controls, in a tissue-culture model of S. flexneri pathogenicity A. 
Representative intracellular growth curves of wild-type M90T (purple), M90TDompA (yellow), M90TDmxiH (red), 
R1 (black circle), R2 (black square), R3 (black triangle), R4 (black inverted triangle), and R5 (black diamond) bacteria. 
Error bars show standard deviations of the mean of three technical replicates.  B-I. Representative plaque assays of 
wild-type M90T, M90TDompA, M90TDmxiH, R1, R2, R3, R4 and R5, respectively, on monolayers of Vero cells at 




Chapter 4 Appendix  
Supplemental Figure S4.1 Further characterization of newly-discovered lytic phage A1-1 
 
Further characterization of newly-discovered lytic phage A1-1 on host, Shigella flexneri.  A. Phage growth curve of 
A1-1 on M90T (purple) and M90TDompA (yellow). Titers of filtered and chloroformed conditions are indicated with 
solid and dashed lines respectively. Error bars show standard deviation of three biological replicates. B. Efficiency of 
plaquing (EOP) assay of phage A1-1 on various strains. Dashed line at 1 indicates EOP on M90T. DL indicates that 
the EOP was below the limit of detection (~10-9). C. Bacterial growth curves of M90T (purple), M90TDompA 
(yellow), M90TDompA:pSF_vector (grey), M90TDompA:pSF_ompA (black) and M90TDompA:pSF_ompA171 (blue). 





Supplemental Figure S4.2 EOP of phage A1-1 on LPS knockouts 
 
Efficiency of plaquing of phage A1-1 on LPS knockouts. A. EOP assay of A1-1 on various strains. Dashed line at 1 
indicates EOP on M90T. Yellow shaded knockouts are genes involved in synthesis of KDO sugars. Red shaded 
knockouts are genes involved in synthesis of the inner core LPS. Purple shaded knockouts are genes involved in 
synthesis of outer core LPS and O-antigen. DL indicates that the EOP was below the limit of detection (~10-9). 
Significance determined using a student t-test between B25113 and test strains.  (* indicates p < 0.05, ** indicates p 
< 0.01, *** indicates p < 0.001) B. Diagram of M90T LPS with lipidA (grey), KDO region (yellow), inner core LPS 
(red) and outer core LPS (purple). Abbreviations as follows phosphoryl group (P), N-acetylglucosamine (GlcN), KDO 





Supplemental Table S4.1 Phage resistance profile of various strains to phages 60B and T7  
 
  



















PE577 S. flexneri - 186
M90T S. flexneri SmR ATCC BAA-2402
M90T∆ompA KanR S. flexneri SmR, KanR This study
M90T∆ompA S. flexneri SmR This study
M90T∆mxiH KanR S. flexneri SmR, KanR This study
M90T∆mxiH S. flexneri SmR This study
BW25113 E. coli - 113; CGSC
BW25113 ∆icdC E. coli KanR 113; CGSC
BW25113 ∆ompA E. coli KanR 113; CGSC
BW25113 ∆ompC E. coli KanR 113; CGSC
BW25113 ∆galU E. coli KanR 113; CGSC
BW25113 ∆waaC E. coli KanR 113; CGSC
BW25113 ∆gmhA E. coli KanR 113; CGSC
BW25113 ∆gmhB E. coli KanR 113; CGSC
BW25113 ∆gmhC E. coli KanR 113; CGSC
BW25113 ∆gmhD E. coli KanR 113; CGSC
BW25113 ∆waaF E. coli KanR 113; CGSC
BW25113 ∆waaQ E. coli KanR 113; CGSC
BW25113 ∆waaP E. coli KanR 113; CGSC
BW25113 ∆waaY E. coli KanR 113; CGSC
BW25113 ∆waaG E. coli KanR 113; CGSC
BW25113 ∆waaO E. coli KanR 113; CGSC
BW25113 ∆waaJ E. coli KanR 113; CGSC
BW25113 ∆waaB E. coli KanR 113; CGSC
BW25113 ∆waaS E. coli KanR 113; CGSC




A1-1 S. flexneri This study
60B S. flexneri This study




pSF-vector AmpR Oxford Genetics (OGS634)
pSF-ompA AmpR
KanR, Kanamycin resistance; SmR, Streptomycin resistance; AmpR, Ampicillin 
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Due to concerns over the global increase of antibiotic-resistant bacteria, alternative antibacterial 
strategies, such as phage therapy, are increasingly being considered. However, evolution of 
bacterial resistance to new therapeutics is almost a certainty; indeed, it is possible that resistance 
to alternative treatments might result in an evolved trade-up such as enhanced antibiotic resistance. 
Here, we hypothesize that selection for Escherichia coli bacteria to resist phage T6, phage U115, 
or albicidin will result in a pleiotropic trade-up in the form of cross-resistance, because all three 
antibacterial agents interact with the Tsx porin. Selection imposed by any one of the antibacterials 
resulted in cross-resistance to all three of them, in 29 spontaneous bacterial mutants examined in 
this study. Furthermore, cross-resistance did not cause measurable fitness deficiencies under 
normal growth conditions for any of the bacterial mutants. A combination of whole-genome and 
targeted sequencing confirmed that mutants differed from wild-type E. coli via change(s) in the 
tsx gene. Our results indicate that evolution of cross-resistance occurs frequently in E. coli 
subjected to independent selection by phage T6, phage U115 or albicidin. This study cautions that 
deployment of new antibacterial therapies such as phage therapy, should be preceded by a thorough 







As global concerns grow over the widespread emergence of antibiotic-resistant bacteria, attention 
has increasingly turned to antibiotic alternatives such as phage therapy: the use of bacteria-specific 
viruses, bacteriophages (phages), to treat bacterial infections. Although phage therapy is frequently 
seen as a novel medical technology, the approach originated in the early 20th century soon after 
phages were discovered24, 28. Less than a decade after the discovery of phages, penicillin was 
discovered and focus shifted to research and deployment of new antibiotics 204. Recently, interest 
in phage therapy has resurged as a tool for treating antibiotic resistant infections 179; however, just 
as antibiotics select for the evolution of antibiotic resistance, phages select for the evolution of 
phage resistance 16, 205. To avoid the historical mistakes that resulted in multi- and even pan-drug 
resistant strains, the evolutionary consequences of phage therapy need to be considered and 
investigated prior to its widespread use 206. 
While the evolution of phage resistance in bacteria is perhaps inevitable, phage therapy 
strategies can be devised to leverage the evolution of phage resistance as an asset, rather than a 
limitation 179. In particular, by using lytic phages that interact with bacterial mechanisms of 
virulence and antibiotic resistance, these phages should kill bacteria while selecting for phage 
resistance that may compromise – or pleiotropically “trade-off” with – virulence or antibiotic-
resistance traits 179. Theory, experiments and emergency patient treatment provide evidence that 
certain phages can direct favorable “trade-off” outcomes, where the therapy kills the target 
pathogen while selecting for reduced virulence or increased antibiotic sensitivity in the remaining 
bacterial population 13, 207, 208. This approach exemplifies one goal of evolutionary medicine: 




However, not all bacterial mutations underlying the evolution of phage resistance result in 
genetic changes with extreme fitness costs that result in a trade-off 211. Instead, the opposite may 
happen whereby evolution of phage resistance results in an additional fitness gain, also known as 
a “trade-up”. Indeed, it is possible that the fitness effects of evolved phage resistance might 
pleiotropically trade-up with virulence or antibiotic resistance 212, 213. To examine this possibility, 
here we studied the interactions of Escherichia coli with two lytic phages and an antibiotic that all 
require the Tsx porin to enter the cell. Tsx is a substrate-specific outer-membrane porin, which 
uptakes nucleosides and deoxynucleotides into the periplasmic space 214. Phages T6 and U115 are 
shown to use the Tsx porin as a receptor for binding to E. coli 215. Additionally, the Tsx porin 
uptakes the antibiotic albicidin, a phytotoxic DNA-gyrase inhibitor produced by Xanthomonas 
albilineans, an agriculturally important pathogen that causes leaf scald in sugar cane grasses 216-
219. We hypothesized that selection for E. coli resistance to phage T6, phage U115, or albicidin 
should tend to produce cross-resistance to the other antibacterial agents, due to converging 
selection at the tsx locus. 
Our results confirmed that the predicted pleiotropic trade-ups evolved frequently; selection 
exerted by any one of the antibacterials led to perfect (100%) cross-resistance of E. coli mutants 
to all three antibacterials. Moreover, we observed that cross-resistance was generally “cost-free”, 
evidenced by equivalent growth of bacterial mutants relative to their wild-type ancestor in the 
absence of the phages and albicidin. In addition, we used sequence analysis to show that a wide 
variety of mutations at the tsx locus of E. coli may govern cross-resistance. Our study suggests that 
prior characterization of evolutionary consequences of antibacterial treatments, particularly the 
mechanistic interactions of lytic phages and antibiotics with target bacteria, can be used to inform 





Phages T6 and U115 each select for cross-resistance to the other phage and to albicidin  
Because phages T6 and U115 both rely on the Tsx porin for cell-binding, we predicted that 
evolution of resistance to one phage should often lead to cross-resistance against the other phage. 
To test this idea, we used a classic fluctuation analysis (see Methods) to obtain a collection of 
spontaneous mutants of E. coli that were resistant to each phage individually. We used a paired 
approach, where each of 10 independently-grown bacterial cultures were used to isolate one T6-
resistant and one U115-resistant strain (20 mutants total). Results for efficiency of plaquing (EOP) 
assays (see Methods) confirmed that growth of phage T6 on each of the 10 T6-resistant mutants 
(T6R1 through T6R10) was below the limit of detection, compared to normal infectivity of the 
phage on wild-type bacteria (Supplemental Table S5.1). Similarly, EOP experiments showed that 
phage U115 was unable to grow on each of the 10 U115-resistant mutants (U115R1 through 
U115R10), relative to expected infectivity on the wild-type (Supplemental Table S5.1). 
Furthermore, we found positive support for our hypothesis; in all 20 cases, evolved bacterial 
resistance to phage T6 provided cross-resistance to phage U115 using EOP assays, and vice versa 
(Supplemental Table S5.1). We concluded that independent selection for E. coli resistance to one 
phage provided cross-resistance to the other phage.  
We then used antibiotic-resistance assays (see Methods) to test the prediction that evolution 
of phage resistance would lead to cross-resistance to the antibiotic albicidin. We first used E. coli 
strains BW25113 and BW25113∆icdC as two positive controls, to confirm that these albicidin-
sensitive bacteria fail to form confluent lawns (i.e., they show zones of inhibited growth) when 
exposed to albicidin-producing X. albilineans strain XA23, but grow normally on X. albilineans 




behaved as expected, with zones of growth inhibition around XA23 indicating sensitivity of both 
bacterial strains to albicidin. We estimated that wild-type BW25113 had a mean clearing ratio (a 
ratio of the zone of clearing divided by the area of the X. albilineans spot) of 4.88 ± 0.47 s.d. in 
the presence of XA23 albicidin-producing bacteria, and that BW25113∆icdC bacteria showed a 
mean clearing ratio of 5.094 ± 0.524 s.d. (Supplemental Figure S5.1 A). As a negative control, the 
Tsx knockout, BW25113∆tsx, had no zone of inhibited growth on either XA23 or LS126 (Figure 
5.1); in both cases the mean clearing ratio of BW25113∆tsx was 1.0 ± 0.0 s.d. (Supplemental 
Figure S5.1 A). A test of the hypothesis confirmed our prediction was correct; all 20 phage-
resistant mutants showed no zones of growth inhibition around XA23 or LS126 (Figure 5.1 and 
Supplemental Figure S5.1 B) and presented mean clearing ratios of 1.0 ± 0.0 s.d. on XA23 and 
LS126 (Supplemental Figure S5.1 A), indicating that all the phage-resistant mutants were 
completely resistant to albicidin as well. 
Selection for albicidin resistance confers cross-resistance to phages T6 and U115 
We used albicidin selection (see Chapter 5 Methods) to isolate 9 independent spontaneous 
mutants of E. coli (albR1 through albR9). Using the above-described growth challenges on X. 
albilineans strains XA23 and LS126, our results confirmed that each mutant was albicidin resistant 
(Figure 5.1 and Supplemental Figures S5.1 A,B). We then tested whether the albicidin-resistant 
mutants were cross-resistant to infection with phage T6 and phage U115. Results showed that in 
all 9 strains tested, acquisition of albicidin resistance conferred cross-resistance to both phages T6 
and U115 (Supplemental Table S5.1). We concluded that the evolution of cross-resistance was 
absolute in this study system, such that evolution of resistance to one of the three antibacterials 




Cross-resistance to albicidin and phages T6 and U115 is cost-free for E. coli 
To further examine the evolution of antibacterial cross-resistance, bacterial growth assays (see 
Methods) were performed with replication (n = 3) in LB medium. Controls confirmed that wild-
type E. coli strain BW25113 showed no discernable growth in the presence of either phage T6 or 
U115 (Figure 5.2 A), and that growth of the tsx-knockout strain, BW25113∆tsx, was similar in the 
presence and absence of each phage (Figure 5.2 B). In contrast, all 10 of the T6-resistant mutants 
grew normally in the presence and absence of phage T6 (representative data shown in Figure 5.2 
C,D; see Supplemental Figure S5.2 B-I for all results). Similarly, growth of all 10 U115-resistant 
mutants was unaffected by presence or absence of phage U115 (representative data in Figure 5.2 
E,F; see Supplemental Figure S5.2 J-Q for all results). Lastly, the 9 albicidin-resistant mutants 
were capable of approximately equivalent growth in the presence and absence of either phage T6 
or U115 (representative data in Figure 5.2 G,H; see Supplemental Figure S5.2 R-X for all results).  
A visual comparison of the growth-curve results suggested that all the resistant mutants 
grew similarly to wild-type strain BW25113 in the absence of each phage (Figure 5.2 and 
Supplemental Figure S5.2). To examine this outcome more closely, we analyzed the growth data 
with GrowthCurver 220 to estimate intrinsic growth rate (r) as a proxy for bacterial fitness (Figure 
5.2 I). None of the resistant mutants had an r that was differed significantly from that of BW25113. 
These results suggested that there are no appreciable growth costs associated with bacterial 
evolution of resistance to phage T6, phage U115 and albicidin. While resistance to any of the 
antibacterials did not affect bacterial fitness under the tested conditions, we could not eliminate 
the possibility that our growth assays failed to detect minor fitness differences.  
Thus, we conducted additional experiments, in an attempt to measure more subtle fitness 




(see Chapter 5 Methods) for each test strain to gauge its fitness relative to a genetically-marked 
wild-type strain (BW25113∆icdC) under normal growth conditions. Competitive indexes were 
calculated as the ratio of resistant-mutant colony forming units (CFU) to CFU of the common 
competitor strain, BW25113∆icdC, to the ratio of BW25113∆icdC CFU to wild-type, BW25113, 
CFU. Each ratio was normalized by the starting ratio each competing strain. Results showed no 
significant differences in competitive indexes of the resistant mutants as compared to the common 
competitor (Figure 5.3). Therefore, it appeared that all T6-resistant, U115-resistant and albicidin-
resistant mutants suffered no fitness deficits, compared to non-resistant bacteria under normal 
growth conditions. 
All phage-resistant and albicidin-resistant mutants have mutations in tsx 
Owing to the importance of the Tsx porin in the interactions of all three antibacterials with cells, 
evolution of E. coli cross-resistance suggested that genetic changes in the tsx gene were likely 
involved. To examine this idea, we conducted whole genome sequencing (WGS) of all 29 strains. 
While some strains showed some single nucleotide variants (SNVs) and short insertions or 
deletions (indels) in tsx, many strains had no observable mutations in any genes using multiple 
variant calling pipelines including GATK 174 and breseq 221. While WGS and  variant calling 
pipelines are amenable for detecting SNVs and short indels, structural variants (SVs), including 
movement of transposable elements, are not easily detected 222.   Therefore, we conducted targeted 
Sanger sequencing of tsx in all 29 resistant mutants. As expected, results for the wild-type showed 
no mutations in tsx; however, mutations in tsx were identified in all 29 resistant mutants. For the 
10 T6-resistant strains we observed the following mutations in the tsx gene: 3 insertion sequence 
(IS) elements, 3 deletions, 3 nonsense mutations and 1 missense mutation (Figure 5.4 A, 




4 IS elements, 2 deletions, 1 insertion, 2 missense mutations, and 2 nonsense mutations (Figure 
5.4 A, Supplemental Table S5.2). Interestingly, of the 10 pairs of phage-resistant mutants isolated 
from the same parent culture, only 3 pairs (T6R4/U115R4; T6R8/U115R8; T6R10/U115R10) 
showed identical mutations in tsx (Figure 5.4 B, Supplemental Table S5.2). For the 9 albicidin-
resistant mutants we observed 6 IS elements, 2 deletions, and 1 missense mutation in tsx (Figure 
5.4 A). In addition, our data showed that eight of the 29 mutations in tsx clustered within the region 
spanning base pairs 375 to 435 (Figure 5.4 B). While it is likely that these mutations are conferring 
resistance to phage T6, phage U115 and albicidin, this was not experimentally confirmed via 
recombinant genetics because the work fell outside the scope of the current study. 
Discussion and Conclusion 
The phage life cycle relies on surface-exposed molecules to initiate infection and bacterial 
metabolism to replicate inside cells. Since phages T6 and U115 both require Tsx as a primary 
receptor, it is not surprising that spontaneous mutants to one phage confer resistance to the other 
phage 215. However, it is interesting that all 20 phage-resistant mutants are also cross-resistant to 
albicidin and that all 9 albicidin resistant mutants are cross-resistant to both phages. It was 
previously observed that T6-resistant mutants maintained their sensitivity to colicin-K, another 
antibiotic that enters via the Tsx porin 106. While all three antibacterials used in the current study 
require Tsx as a receptor, it is unclear whether replication of phages T6 and U115 and the 
mechanism of action of albicidin also converge on the same gene to confer resistance. Albicidin 
is a DNA gyrase inhibitor that blocks topoisomerase II, an enzyme which cleaves both strands of 
DNA to modulate supercoiling during DNA replication, gene regulation, and transcription 218.  
Phages require the DNA replication machinery of the host bacterial cell to make viral progeny 




Furthermore, the minimum inhibitory concentrations (MICs) of ciprofloxacin (another DNA 
gyrase inhibitor) and ampicillin for wild-type BW25113 bacteria and for each of the 29 resistant 
mutants did not differ statistically (Supplemental Table S5.3). These observations of unchanged 
phenotypes imply that selection by phage T6, phage U115, and albicidin seems to evolutionarily 
converge on the tsx locus, rather than involving changes at other loci. Indeed, the results of the 
targeted sequencing indicated this possibility, because each mutant was observed to undergo a 
change in the tsx gene (i.e., as opposed to no mutation at this locus, suggesting resistance occurred 
via a different mechanism). While the identified mutations were not validated as the causative 
mutations of resistance, it seems likely that the 29 different mutations found in tsx were conferring 
resistance to phage T6, phage U115, and albicidin. The combination of tsx mutations observed in 
all 29 resistant mutants and the lack of detectable fitness defects in these strains indicate that Tsx 
may be superfluous for E. coli in the laboratory environment.  
The 29 observed mutations in tsx fall within the promoter region, as well as various other 
locations along the gene. However, there seems to be a cluster of ‘hotspots’ for mutational changes 
in the region spanning 332 to 435 base pairs. These residues make up a surface exposed alpha helix 
and a beta sheet that spans the outer membrane of the bacteria. All of the mutations in this region 
were observed in phage-resistant strains, indicating that perhaps amino acid residues 88 through 
123 are important for phage binding, but not albicidin entry.  
Moreover, of the 10 “paired” phage-resistant mutants, only 3 of the pairs (T6R4/U115R4; 
T6R8/U115R8; T6R10/U115R10) showed the same tsx mutation. This means that even in a clonal 
population of E. coli, there are often multiple spontaneous mutants with different changes in tsx. 




assays cannot be used to compute a rate of spontaneous mutation; instead, these data should only 
be used to calculate a rate of spontaneous phenotypic resistance. 
It is also interesting that the profile of tsx mutations was different for the phage-selected 
resistant mutants, compared with the antibiotic-selected resistant mutants. There were 6 albicidin-
resistant mutants with an IS element inserted in tsx, while 3 of each of the phage-resistant mutants 
showed IS-element changes in tsx. This observation could be due either to a difference in selection 
pressures of phages versus antibiotics, or to a difference in the method of selection to amass these 
mutants. Underlying these possibilities are two opposing ideas. It has been previously assumed 
that insertion and excision of IS elements are stochastic events. However, recent evidence suggests 
that IS movement may actually be a form of directed mutagenesis in which IS elements target 
specific chromosomal loci to reduce stress under certain environmental conditions 224. The 
isolation of phage-resistant mutants in this study relied on spontaneous mutations accumulated in 
an overnight culture, while the isolation of antibiotic-resistant mutants allowed for both selection 
of spontaneous resistant mutants as well as evolution in the presence of albicidin. This difference 
suggests that the larger proportion of IS element insertions in tsx found in the set of albicidin-
resistant mutants might be caused by direct targeting of tsx by IS elements under stressful 
conditions. Without further experiments that use the same method to select for spontaneous phage 
and albicidin resistant mutants, we cannot rule out that a difference in selection pressures between 
phages and the antibiotic resulted in the skew of IS-element-insertion changes in tsx found in the 
albicidin-resistant mutants. 
Finally, it is worth noting that all 29 resistant mutants have gained fitness relative to wild-
type in the presence of albicidin or phage, with no appreciable fitness cost in an ordinary 




single antibiotic can also result in evolution of multi-drug resistance. Here, we showed that phage 
resistance can result in antibiotic resistance, and vice versa, at no fitness cost. This highlights a 
potential pitfall of the future therapeutic use of any antimicrobial whether it be phage or antibiotics. 
Without a clear understanding of the evolutionary implications of treatment, antimicrobial 
selection can result in both resistance and cross-resistance at no fitness cost to the bacteria. 
Materials and Methods 
Strains and culture conditions 
Strains in this study are listed in Supplemental Table S5.4. E. coli strains were cultured for 24 
hours with shaking incubation at 37ºC in lysogeny broth 16. The Tsx knockout, BW25113∆tsx, was 
used as a negative control in many experiments. A pseudogene knockout, BW25113∆icdC, was 
used as a control for the KanR cassette and as a marked competitor in the competition assays. 
Where appropriate, LB was supplemented with kanamycin at 30 µg/mL (LB Kan30). X. 
albilineans strains (provided by D. Gabriel, U Florida) were cultured for 48 hours with shaking at 
30ºC in Modified Wilbrinks (MW) medium 225. Lysates of phages T6 and U115 were obtained by 
mixing each phage with E. coli strain BW25113 in LB medium and culturing for 24 hours at 37ºC, 
followed by filtration (0.22 µm) to remove bacteria. 
Isolation of phage-resistant bacterial mutants 
Ten cultures of E. coli strain BW25113 were grown independently as described above, and diluted 
samples were spread on LB agar (1.5% agar) plates, pre-saturated with either phage T6 or phage 
U115. After overnight incubation at 37ºC, one colony was chosen randomly from each plate and 
colony-purified three times. For each of the 20 isolated mutants, phage resistance was confirmed 
via efficiency of plaquing (EOP) assays, which compared plaquing ability of phage T6 or U115 




Isolation of antibiotic-resistant bacterial mutants 
X. albilineans strain XA23 was cultured as described above, and a 10 µL sample was spotted onto 
each of ten Sucrose Peptone agar (SPA) plates that were incubated for 5 days at 30ºC 226. A sample 
from each of ten independently-grown cultures of BW25113 was then overlaid on one of the SPA 
plates, and incubated overnight at 37ºC. Colonies that appeared in the zone of growth inhibition 
around the XA23 spot represented spontaneous E. coli mutants that were resistant to albicidin. One 
plate was lost due to contamination; from each of the remaining 9 plates, one colony was randomly 
chosen and colony-purified three times. Albicidin resistance of each mutant was verified by plating 
a sample of a grown-up culture of the isolate on an XA23 spot, as described above. 
Antibiotic-resistance assays 
X. albilineans strains XA23 and LS126 were each cultured for 48 hours at 30ºC, and their optical 
densities at wavelength l = 600 nm (OD600) were estimated via spectrophotometry. Each culture 
was then diluted in MW medium, to obtain OD600 = 0.25. Then, a 10 µL sample of each diluted 
culture was spotted on a SPA plate, allowed to dry completely and then incubated for 5 days at 
30ºC. SPA plates were overlaid with 4 mL of LB top agar (0.75%) with 1 mL of a test E. coli strain 
at OD600 = 0.25, and incubated overnight at 37ºC. The next day, plates were imaged. Images were 
quantified using ImageJ, by thresholding until either the X. albilineans spots or E. coli clearings 
were outlined and the area within the outline was quantified. The ratio of the area of the zone of 
clearing to the area of the X. albilineans spot was used to define albicidin sensitivity: a ratio of 
greater than 1.0 indicates albicidin sensitivity, while a ratio of 1.0 indicates albicidin resistance.  
Minimum inhibitory concentrations (MICs) of ampicillin and ciprofloxacin were determined using 




Bacterial growth curves 
E. coli bacteria were cultured overnight as described above. Dilutions of a test strain in LB medium 
were placed in wells of a flat-bottomed 96-well plate, in the absence of phage or mixed with phage 
at a multiplicity-of-infection (MOI; ratio of phage particles to host cells) of ~10. Plates were 
incubated with shaking for 18 hours in an automated spectrophotometer at 37ºC, and OD600 
measurements were obtained every 10 minutes. Growth curve data were fit to a logarithmic curve 
using GrowthCurver and growth parameters were extracted 220. All growth curve data will be 
deposited on Dryad (doi:10.5061/dryad.ghx3ffbmn). 
Bacterial competition assays 
Replicated (n = 3) competition assays were conducted in LB medium by mixing two bacterial 
strains at a 1:1 initial ratio, and serially passaging (1:100 dilution) every 24 hours for 72 hours 
total. At the end, a diluted sample of each competition was plated on LB agar to measure viable 
bacterial density (colony-forming units; CFU), and on LB Kan30 agar to estimate the CFU of a 
KanR competitor; the density of the KanS competitor was estimated by subtraction. Competitive 
indexes were calculated as the ratio of resistant-mutant CFU to the CFU of BW25113∆icdC 
divided by the ratio of BW25113∆icdC CFU to BW25113 CFU. Each ratio was normalized by the 
starting ratio each competing strain. 
Sequencing 
Sequencing libraries were prepared using Illumina’s Nextera prep kit. Whole genome sequencing 
was done using paired-end 150bp reads on the Illumina NextSeq platform or paired-end 300bp 
reads on the Illumina HiSeq platform. For targeted sequencing, primers (5’-
CTGTGAAACGAAACATATTTTTG-3’ and 5’-CGTGCTTTTGTTGGC-3’) were designed 




resistant mutant and the ancestral BW25113 strain. Amplicons were Sanger sequenced at the Yale 
DNA Analysis Facility on Science Hill. Mutations were identified by comparing sequencing reads 




Chapter 5 Figures & Tables 
Figure 5.1 Tests of albicidin resistance 
 
Tests of albicidin resistance for representative spontaneous mutants of E. coli, selected for resistance to phage T6, 
phage U115, or albicidin. Wild-type BW25113 and the positive-control BW25113DicdC showed inhibited growth on 
agar plates with albicidin-producing X. albilineans (XA23), and normal growth on the non-producer, LS126. In 
contrast, mutants (T6R1, T6R2, U115R5, U115R6, albR4, albR7) and negative-control BW25113Dtsx grew equally 






Figure 5.2 Growth dynamics of representative E. coli mutants 
 
Growth dynamics of representative E. coli mutants selected for resistance to phage T6, phage U115, or albicidin, in 
environments with and without each phage. A-B Wild-type BW25113 bacteria grew only in phage absence (solid 
line), whereas Tsx knockout strain BW25113Dtsx grew similarly in phage-free as well as T6 (dashed line) and U115 
(dotted line) environments. C-H Each of the representative resistant mutants grew similarly in the presence/absence 
of phages T6 and U115, regardless of their prior selection for phage or albicidin resistance. I Intrinsic growth rate (r; 
proxy for fitness) estimates from growth-curve data (A-H and Supplemental Figure S5.2) showed that each strain 





Figure 5.3 Competition assays 
 
Competition assays showed that E. coli mutants resistant to phage T6 A phage U115 B or albicidin C did not 
measurably differ in fitness, relative to a non-resistant wild-type strain. Each point represents results from independent 
competition assays (n = 3), and statistical significance was determined using a t-test comparing competitive index of 





Figure 5.4 Mutations in tsx 
 
Mutations in tsx A Proportions of tsx mutations observed in sets of E. coli strains, selected for spontaneous resistance 
to either phage T6, phage U115 or albicidin. Mutations were due to insertion sequence elements (blue), deletions (red), 
insertions (yellow), missense mutations (purple) and nonsense mutations (orange). B Locations of tsx mutations for 




Chapter 5 Appendix 
Supplemental Figure S5.1 Tests of albicidin resistance for spontaneous mutants of E. coli 
 
Tests of albicidin resistance for spontaneous mutants of E. coli not described in main text, selected for resistance to 
phage T6, phage U115 or albicidin antibiotic. A Quantification of albicidin resistance (ratio of cleared zone to area 
of X. albilineans growth) showed that each mutant and the Tsx-knockout strain, BW25113Dtsx, were albicidin-
resistant (ratio = 1.0), whereas wild-type BW25113 and positive-control BW25113DicdC bacteria were albicidin-
sensitive (ratio > 1.0). B In all cases, mutant growth on agar plates was not inhibited by albicidin-producing X. 




Supplemental Figure S5.2 Growth dynamics of E. coli mutants 
 
Growth dynamics of E. coli mutants selected for resistance to phage T6, phage U115, or albicidin, in environments 
with phage T6 (dashed line), with phage U115 (dotted line), and without phages (solid line). A-X In all cases, mutants 





Supplemental Table S5.1 Efficiency of plaquing 
 
Efficiency of plaquing (EOP) for phages T6 and U115 on challenge strains of E. coli, selected for spontaneous 
resistance to each phage or to albicidin. EOP is defined as phage titer (PFU/mL) on the test strain divided by that on 
wild-type BW25113; EOP = 0 indicates phage growth on the challenge is below the limit of detection (<100 PFU/mL). 
Positive (BW25113DicdC) and negative (BW25113Dtsx) controls confirm expected susceptibility and resistance to 
each phage in replicate (n = 3) assays, whereas, all 29 mutants show cross-resistance to phage infection. Statistical 
significance (*; P < 0.05) indicates result of an unpaired t-test comparing three replicate measures to the EOP on 
BW25113DicdC. The ‘^’ indicates a phage with observable turbid clearing of the challenge-bacteria lawn, without 
making visible plaques.  
Phage T6 Phage U115
BW25113 ∆icdC 1.11 ± 0.55 1.32 ± 0.16
BW25113 ∆tsx 0* 0*
T6 R1 0* 0*
T6 R2 0* 0*
T6 R3 0* 0*
T6 R4 0* 0*
T6 R5 0* ^ 0*
T6 R6 0* 0*
T6 R7 0* 0*
T6 R8 0* 0*
T6 R9 0* 0*
T6 R10 0* 0*
U115 R1 0* 0*
U115 R2 0* 0*
U115 R3 0* 0*
U115 R4 0* 0*
U115 R5 0* 0*
U115 R6 0* 0*
U115 R7 0* 0*
U115 R8 0* 0*
U115 R9 0* 0*
U115 R10 0* 0*
alb R1 0* 0*
alb R2 0* 0*
alb R3 0* 0*
alb R4 0* 0*
alb R5 0* 0*
alb R6 0* 0*
alb R7 0* 0*
alb R8 0* 0*





Supplemental Table S5.2 Mutations in tsx 
 
Putative resistance mutations in the tsx gene, for each E. coli mutant selected for spontaneous resistance to either 
phage T6, phage U115, or albicidin. 
  
Strain Mutation Type Position Notes
T6 R1 Deletion 291-321 31 base pair deletion, new stop codon at residue 101
T6 R2 Insertional Element -75 IS2 with sequence [AGGCTCCTC] repeated
T6 R3 Deletion 402-733 332 base pair deletion
T6 R4 Nonsense 773 * G773A (W258Stop)
T6 R5 Insertional Element 403 IS2 with sequence [GGTCGTA] repeated
T6 R6 Nonsense 435 G435A (W146Stop)
T6 R7 Insertional Element 165 IS2 with sequence [GGAAC] repeated
T6 R8 Missense 725 * T725G (L242R)
T6 R9 Nonsense 535 G535T (E179Stop)
T6 R10 Deletion 410-420 * 11 base air deletion, new stop codon at residue 24
U115 R1 Insertional Element 400 IS3 with sequence [ATG] repeated
U115 R2 Insertion 53 1 base pair insertion at position 53, new stop codon at residue 24
U115 R3 Insertional Element 774 IS1 with sequence [GACAGCGGT] repeated
U115 R4 Nonsense 773 * G773A (W258Stop)
U115 R5 Missense 31 T31A (V11E)
U115 R6 Insertional Element 161 IS2 with sequence [GCAAC] repeated
U115 R7 Nonsense 375 C375G (Y125Stop)
U115 R8 Missense 725 * T725G (L242R)
U115 R9 Deletion 429-435 7 base pair deletion, new stop codon at residue 157
U115 R10 Deletion 410-420 * 11 base air deletion, new stop codon at residue 24
alb R1 Insertional Element -3 IS1 with sequence [CATATGAAA] repeated
alb R2 Insertional Element 344 IS1 with sequence [ACCTTAGCTTCGGT] repeated
alb R3 Deletion 64 1 base pair deletion, new stop codon at residue 111
alb R4 Insertional Element 116 IS5 with sequence [TTAA] repeated
alb R5 Insertional Element 665 IS2 with sequence [GTAAC] repeated
alb R6 Insertional Element 692 IS1 with sequence [TAAGACCCG] repeated
alb R7 Insertional Element -16 IS1 with sequence [GGGATTTC] repeated
alb R8 Missense 161 G161C (R54P)
alb R9 Deletion 4 1 base pair deletion, new stop codon at residue 111













20 ± 0               
20 ± 0               
20 ± 0
11.67 ± 7.64 
11.67 ± 7.64 
13.33 ± 5.77
BW25113 ∆icdC 20 ± 0 13.33 ± 5.77
BW25113 ∆tsx 20 ± 0          
26.67 ± 11.55
6.67 ± 2.89      
10 ± 0
T6 R1 20 ± 0 6.67 ± 2.89
T6 R2 20 ± 0 10 ± 0
T6 R3 20 ± 0 8.33 ± 2.89
T6 R4 20 ± 0 8.33 ± 2.89
T6 R5 20 ± 0 10 ± 0
T6 R6 20 ± 0 8.33 ± 2.89
T6 R7 20 ± 0 11.67 ± 7.64
T6 R8 20 ± 0 8.33 ± 2.89
T6 R9 20 ± 0 13.33 ± 5.77
T6 R10 20 ± 0 13.33 ± 5.77
U115 R1 20 ± 0 10 ± 0
U115 R2 20 ± 0 10 ± 0
U115 R3 20 ± 0 10 ± 0
U115 R4 20 ± 0 8.33 ± 2.89
U115 R5 20 ± 0 8.33 ± 2.89
U115 R6 20 ± 0 6.67 ± 2.89
U115 R7 20 ± 0 8.33 ± 2.89
U115 R8  10 ± 0 8.33 ± 2.89
U115 R9 20 ± 0 11.67 ± 7.64
U115 R10 20 ± 0 8.33 ± 2.89
alb R1 20 ± 0 11.67 ± 7.64
alb R2 20 ± 0 13.33 ± 5.77
alb R3 20 ± 0 13.33 ± 5.77
alb R4 20 ± 0 13.33 ± 5.77
alb R5 20 ± 0 8.33 ± 2.89
alb R6 20 ± 0 8.33 ± 2.89
alb R7 20 ± 0 8.33 ± 2.89
alb R8 20 ± 0 13.33 ± 5.77











BW25113 E. coli - CGSC
BW25113 ∆icdC E. coli KanR CGSC
BW25113 ∆tsx E. coli KanR CGSC
T6 R1 E. coli - This study
T6 R2 E. coli - This study
T6 R3 E. coli - This study
T6 R4 E. coli - This study
T6 R5 E. coli - This study
T6 R6 E. coli - This study
T6 R7 E. coli - This study
T6 R8 E. coli - This study
T6 R9 E. coli - This study
T6 R10 E. coli - This study
U115 R1 E. coli - This study
U115 R2 E. coli - This study
U115 R3 E. coli - This study
U115 R4 E. coli - This study
U115 R5 E. coli - This study
U115 R6 E. coli - This study
U115 R7 E. coli - This study
U115 R8 E. coli - This study
U115 R9 E. coli - This study
U115 R10 E. coli - This study
alb R1 E. coli - This study
alb R2 E. coli - This study
alb R3 E. coli - This study
alb R4 E. coli - This study
alb R5 E. coli - This study
alb R6 E. coli - This study
alb R7 E. coli - This study
alb R8 E. coli - This study
alb R9 E. coli - This study
XA23 X. albilineans - 219
LS126 X. albilineans KanR, StR 219
Phage Reference or Source
T6 J. Wertz (Yale U)
U115 215
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